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Abstract
Although once thought to have no beneficial medicinal value due to its historic reputation
as being a ‘silent killer’, recent investigations into the therapeutic applications of carbon
monoxide (CO) on mammalian physiology have sparked a growing interest in designing
metal-based carbonyl complexes to act as pro-drugs. Thoughtful design of transition
metal carbonyl complexes result in controllable and tunable CO release triggered by
photochemical labilization from the metal centre. The work contained in this thesis
focuses on the design, synthesis and CO release capabilities of a series of photoactive iron-
based carbon monoxide releasing molecules (photoCORMs). This work is complimented
with studies of analogous ruthenium complexes.
PhotoCORMs are able to impart spatial and temporal control over CO delivery following
site specific irradiation with an appropriate wavelength. High energy ultra-violet light
has poor tissue penetration and causes damage to the skin. Here, a series of iron
carbonyl complexes were synthesised. Extension of the ligand conjugation system
and addition of a nitrogen donor group proved to shift the absorption spectrum in a
bathochromic fashion. Examination of photoCORM capabilities reveal the iron carbonyl
complexes release CO following visible light irradiation.
The number of developed CORMs which satisfy the required pharmaceutical char-
acteristics is relatively small. Essential characteristics include water solubility and
biocompatibility. We expand on the design of our complexes by incorporating thiolated
saccharide ligands into the coordination sphere. The resulting dimeric carbonyl com-
plexes display significantly enhanced water solubility as well as a major change in CO
release behaviour.
The anti-inflammatory properties of the photoCORM systems were investigated in vitro.
Production of LPS-induced pro-inflammatory cytokine, TNF-α was markedly decreased
following CORM administration. Surprisingly, CORM potency was greatest when cells
were kept in the dark.
Designing two photon up-converter systems is a leading strategy to enhanced the light
harvesting ability of metal complexes. Here, the design of such attachable systems is
discussed.
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Chapter 1
Introduction
1.1 Carbon Monoxide: An Overview
The use of carbon monoxide (CO) as a therapeutic agent may come as a surprise if one
considers its historic reputation as being a ‘silent killer’. Indeed, the toxicity of this
colourless, odourless and tasteless gas has been well known since Greek and Roman
times.1
Despite its notoriety, the beneficial role of CO began to emerge during the 20th century
when Swedish physician Torgny Sjöstrand demonstrated that human beings constantly
exhale CO, even when all external sources of the gas were removed.2 The endogenously
produced CO was found to be a by-product of the oxidative decarboxylation of haem,
which is catalysed by a family of enzymes called haem oxygenases.3 Sjöstrand noted
that diseased patients produced significantly greater quantities of CO compared to
healthy patients.2 This surprising and unexpected observation led to a surge of studies
on the biological relevance of gaseous molecules.
Carbon monoxide, along side other biologically relevant gases, namely nitric oxide (NO)
and hydrogen sulfide (H2S), has been shown to play a pivotal role as a signalling molecule
in mammals.4 CO has been established as being anti-inflammatory,5,6 vasodilatory,7,8
anti-apoptotic9 and plays a crucial role in a number of immune-related disorders.10
The use of carbon monoxide as a therapeutic agent has sparked a number of questions.
1
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There are major concerns over administrative methods of gaseous CO. These include
the possibility of CO poisoning and what constitutes an effective dose, as well as
fundamental questions regarding its target sites and mechanism(s) of activity.
Pharmacological chemists are interested in the development of so-called carbon monoxide
releasing molecules (CORMs). These molecules act as inert molecular vehicles capable
of carrying bound CO through the blood stream and only releasing their load when
subjected to do so by a specific trigger at defined tissues. The advantage of using
CORMs include the possibility of carefully designing drugs so that properties such as
tissue specificity and CO release capability can be meticulously controlled.
1.2 Bioactivity of CO
1.2.1 Action of Haem Oxygenase
The majority of CO generated in mammalian organisms derives from the catabolism
of haemoglobin from red blood cells by the haem oxygenase (HO) enzymes. HO was
originally characterised by Tenhunen et al. in 1969,11 who uncovered the enzymatic
mechanism responsible for the oxidative degradation of haem to yield bilirubin, CO
and ferrous iron (Scheme 1). The conversion requires the presence of molecular oxygen,
nicotinamide adenine dinucleotide phosphate (NADPH), and the concerted action of
cytochrome P450 reductase.12
HO catalyses the oxidative degradation of haem by oxidising the α-methene bridge of
the protoporphyrin ring to form the green bile pigment and antioxidant, biliverdin.
Subsequently, involvement of NADPH and biliverdin reductase reduces the biliverdin
to form the yellow bile pigment and antioxidant, bilirubin.11 In this pathway HO is
rate-limiting.
2
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Scheme 1: Catabolism of haem by haem oxygenase
The roles of HO act to protect the organism. Free haem molecules are toxic to the
cellular environment, leading to lipid peroxidation and generation of reactive oxygen
species (ROS).13 The biliverdin and bilirubin produced are antioxidants and are capable
of performing an array of important cellular functions.14 The free ferrous iron generated
is reutilized, being taken up by ferritin and either excreted by the cell or recycled for
haem synthesis. The generated CO has been associated with a variety of beneficial effects
which include reducing cellular stress by inhibiting the production of pro-inflammatory
cytokines, thus suppressing the expression of pro-inflammatory enzymes.15
There are three isoforms of the HO enzyme: HO-1, -2 and -3, although only HO-1 and
HO-2 appear to be active enzymes.1 The HO-2 and -3 isoforms are constantly expressed
and act to regulate the basal level of free haem. HO-2 is a non-inducible isoform which
serves to maintain regulatory functions in the nervous system and is commonly found in
the brain, testis, liver and endothelium. HO-3 is structurally similar to HO-2 but with
3
CHAPTER 1. INTRODUCTION
a lower enzymatic activity.16 HO-1 is an inducible isoform that can be up-regulated by
a vast array of stimuli17 including substrate (haem), oxidants, heavy metals, cytokines
and radiation.12 This suggests that HO-1 is not only in the business of haem degradation
and iron homoeostasis, but represents a fundamental defence against stressful insults to
the organism.18,19 HO-1 has been explicitly shown to impart cellular protection against
a variety of injuries.5,15,20 Examples include protection against vascular diseases such as
atherosclerosis and hypertension12 as well as the suppression of endothelial cell apoptosis.21
HO-1 is critical for survival, with HO-1 deficiencies in mice and humans linked with
short lifespans. In contrast, HO-2 deficient mice can survive through their expected
lifespan. Mice treated with high doses of HO inhibitors or with a HO-1 deficiency
showed greater susceptibility to lipopolysaccharide (LPS) induced endotoxic shock.22
Genetic deficiency or inhibition of HO-1 activity has also been associated with oxidative
tissue damage18 and chronic inflammation in human and mice models. Up-regulation
or over-expression of HO-1 has been shown to improve vascular dysfunction and inhibit
chronic rejection.23 Interestingly, administration of gaseous CO to HO-1 deficient mice
acted to reduce the LPS-induced inflammation. Indeed, targeting HO-1 is an attractive
pathway for the therapeutic relief of a number of ailments such as inflammation and
reperfusion injury.
Although the functional importance of the HO system in providing an essential de-
fence for the organism has been well established, the precise mechanism(s) by which
HO-1 elicits this protective response remains unclear. The ability of CO to provide
cytoprotection mimics that of HO-1 in rodent models. Extensive research into the in
vivo application of CO has established a number of important beneficial functions in
response to various physiological and pathophysiological conditions.
1.2.2 Gaseous Mediations
The vital protective action of the HO system and its by-products led to the postulation
that CO acted as a biological gaseotransmitter. Indeed, it was discovered that CO
displayed similar protective properties observed for nitric oxide (NO). Studies on the
vessel relaxation properties of NO and CO commenced at the same time.
4
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From such studies the biomedical potential of NO rapidly emerged as a versatile molecule
capable of important physiological and pathophysiological effects. Ironically CO was
dismissed, its relaxation functions were viewed as being merely circumstantial and
were disregarded.17 To justify this action one must consider that at the time much
more information about NO had been collected as it was already recognised as being a
signalling molecule. NO is a reactive molecule capable of initiating a range of versatile
chemistry on biological targets. This is in contrast to CO, where only reactivity towards
haem moieties was known. Although the endogenous generation of CO was known well
before NO was recognised as a biological mediation, it was initially believed that the
physiological effects of NO and CO operated independently of each other. This was
later found not to be the case when NO donor molecules were shown to activate HO-1
and increase CO production.17
Nitric oxide is generated endogenously in mammalian organisms through the oxidative
conversion of l-arginine to l-citrulline. This reaction is catalysed by NO synthase (NOS),
of which there are three active isozymes: neuronal, endotherlial and inducible NOS. The
NO molecule is redox active, forming [NO]+ or [NO]– following a one electron oxidation
or reduction, respectively. The redox state of the diatomic molecule is responsible for
the physiological benefit it generates. NO acts as a superoxide scavenger, leading to
the formation of peroxynitrile ([O NOO]–). This is rapidly excreted from the body by
decomposing to NO2 and [NO3]– and exhaled.24
1.3 CO Target Sites
1.3.1 Soluble Guanylyl Cyclase
Soluble guanylyl cyclase (sGC) is a heterodimeric (α/β) haem protein found in a variety
of mammalian cells which sense cellular signalling molecules including NO and CO.
The catalytic reaction involves the conversion of GTP to cGMP, a cyclic nucleotide
which plays a role in a number of physiological processes including vasodilatation.25
Guanylyl cyclase contains two catalytic domains, an α and β domain. The β domain
5
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contains a 5-coordinate haem moiety. NO coordinates to the iron metal centre and
in doing so fully displaces a bound histidine. This results in a large conformational
change which activates the enzyme. On the other hand, CO coordinates with a lower
binding constant compared to NO. As a result, the histidine remains bound and iron
becomes 6-coordinate.26 It is thought that an intracellular molecule interacts with
the α domain which leads to the dissociation of the bound histidine to activate the
enzyme.24 Consequently, the extent at which CO activates sGC is much lower compared
to the activity achieved by NO. However in the presence of YC-1 (1, Figure 1), a small
synthetic molecule which activates sGC, an increase in the production of cGMP is
reported.
O
HO N N
Ph
1
Figure 1: sGC activator, YC-1
Recent studies have shown CO promotes the relaxation of vascular smooth muscles,
a response which has been attributed to the action of activated sGC.8 Motterlini and
co-workers investigated the effect CO has on aortic rings precontracted with phenylphrine,
and found CO activity is at least partially cGMP dependent. A study by Fan et al.
demonstrated that CO also had the ability to increase cellular ATP (adenosine triphos-
phate) in an sGC associated mechanism. The levels of ATP generated in vitro was
reduced in the presence of ODQ (1H -[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one), which
acts as a sGC inhibitor.27
1.3.2 Mitogen-Activated Protein Kinases
Mitogen-activated protein kinases (MAPKs) are a family of proteins which regulate a
number of cellular functions, including regulating the expression for pro-inflammatory
cytokines28 such as TNF-α (tumor necrosis factor) and IL-1 (interleukin-1). They are
activated by a variety of extracellular stimuli including UV light, heat, osmotic shock,
6
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inflammatory cytokines and growth factors.29 MAPKs consist of a serine-threonine
domain and achieve cellular signalling following phosphorylation. There are three
types of MAPK, namely, extracellular signaling-regulated kinase (ERK1/2), c-Jun
(N)-terminal kinase (JNK1/2/3) and p38 isoforms.
Activation of MAPK by endotoxin lipopolysaccharide (LPS) leads to a rapid increase
in the production of pro-inflammatory mediators and the down-regulation of anti-
inflammatory cytokines. Upon CO targeting of MAPKs, inhibition of the expression
of the pro-inflammatory cytokines and up-regulation of the production of the anti-
inflammatory cytokine IL-10 occurs. In vivo studies using mice models administrated
with LPS in the presence of CO displayed significantly reduced quantities of the
pro-inflammatory cytokine TNF-α. Choi and co-workers further demonstrated that
CO mediated this anti-inflammatory action via activation of p38, ERK1/2 and JNK
pathways in a concentration-dependent manner.5 Pathway p38 activation was achievable
at lower concentrations of CO (250 ppm) whilst ERK1/2 and JNK remain unaffected
at this dosage. Furthermore, dominant negative mutant mice models (Mkk−/−) showed
considerable increase in TNF-α production following LPS administration compared
to the Mkk+/+ mice. In the presence of CO, there was a significant up-regulation
of the production of the anti-inflammatory cytokine IL-10 in the Mkk+/+ specimens.
Mkk−/− mice in a CO-enriched atmosphere produced slightly greater amounts of IL-10
compared to specimens in a CO-absent atmosphere, which indicates CO achieves its
anti-inflammatory effects by targeting the MAPK pathway.5,28,30
It is unclear exactly how CO modulates MAPK-related pathways as the kinases do
not contain a haem residue. One potential candidate is the Mn(II) containing protein
phosphatase C2 (PP2C), which acts as a serine/threonine phosphatase involved in
responding to cellular stress.31 This offers a potential direct pathway in which CO could
modulate MAPK, where coordination onto the transition metal active site brings about a
fundamental change in the phosphorylation-dephosphorylation process. Conversely, CO
could modulate MAPK via an indirect pathway. In a study on lung ischemia-reperfusion
in rat models, Mishra et al. showed that CO suppressed ERK activation, which in turn
reduced early growth response 1 (Egr-1, a transcriptional activator of inflammatory
cascades) expression.32 Their findings highlight a cGMP dependent pathway, as the
7
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suppression of ERK was reversed in the presence of a sGC inhibitor.
1.3.3 BKCa channels
So-called ‘big conductance’ KCa channels are present in many types of vascular smooth
muscle cells and are considered to have two main physiological functions: determining
membrane potential and regulating electrical activity within the cell. The structure
of BKCa channels consists of two subunits comprised of tetramers: a pore-forming α-
subunit and an accessory β-subunit. The channels allow the influx of Ca(II) ions through
the membrane and an eflux of K+ ions, resulting in cell membrane hyperpolarization
and reducing cellular excitability. There are three types of BKCa channels: small,
intermittent and large conductance. The physiological role of BKCa channels include
neuronal excitability and smooth muscle contractility, which in turn affects vascular
activity.33
Mitochondrial produced reactive oxygen species (ROS) have been shown to activate BKCa
by increasing Ca(II) spark frequency along with increasing the effective coupling of Ca(II)
to K+ channels.34 As CO has been shown to promote ROS production in mitochondria,
this suggests an indirect mechanism by which CO could effect vascular activity.35 In
addition, evidence has emerged which suggests BKCa channels enhance cGMP-induced
relaxation of smooth muscles.36 The two systems are thought to be linked, as particular
substances which increase cGMP concentration also cause membrane hyperpolarization
in smooth muscle cells. It is hypothesised that this leads to vasorelaxation.37
Direct interaction of CO with K+ channels was originally met with scepticism as the
channels lack a transition metal (TM) centre for CO to react. Further investigation
showed that the haem containing complex, iron protoporphyrin IX, is involved in the
covalent bonding of calcium in Ca(II)-sensitive K+ channels. Wu et al. demonstrated
the vasodilatory action of artery smooth muscle cells in rats tails was achieved by
CO in an concentration-dependent manner.38,39 The suggested mechanism involved
an interaction between CO and a histidine residue located on the α-subunit of BKCa
channels.
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Figure 2: Suspected pathways involved in CO signalling (ROS = reactive oxygen species,
TM = transition metal)5,8,24,26,31,38–40
1.4 CO as a Therapeutic Agent
In prokaryotic cells such as anaerobic bacteria, exogenous CO is extracted and used
as a source of carbon and energy. In eukaryote organisms, CO acts as a versatile
signalling molecule and has been shown to play pivotal roles in a wide range of
physiological and pathophysiological processes.8 The beneficial effects attributed to
CO includes, but are not limited to anti-inflammatory processes,5,6 vasodilatation,7,8
risk reduction in organ transplant,20 platelet aggregation inhibition,41 oxygen sensing,40
bacterial growth inhibition,42 cell proliferation,4 anti-apoptotic effects and cytoprotective
effects.9
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Employing CO as a therapeutic agent is based on studies on induction and gene transfer
of HO-1, inhalation of gaseous CO and administration of CORMs. The inducible isoform
of heam oxygenase (HO-1) is activated by a number of oxidative stress triggers and
represents an opportunity for therapeutic targeting. Up-regulation and over-expression
of HO-1 has demonstrated cytoprotective effects in vitro18,21 and in vivo.43–45 Gene
therapy also offers an opportunity for optimizing and targeting vectors involved in
activation of HO-1. This line of treatment would involve screening patients for the
HMOX1 gene promoter polymorphrisms to highlight individuals who present a higher
risk of developing treatable diseases.46
Gaseous CO has been implemented in a variety of clinical trials that show a range
of beneficial effects can be achieved at concentrations between 20–500 ppm. However
administration of CO through the lungs has a number of drawbacks which must be
addressed. Gaseous CO means rough concentration estimates and issues remain such
as no tissue specificity and administration requirement of specialist equipment and
facilities.1 A valid alternative to gaseous CO is the use of drugs which carry and deliver
CO to biological systems. These CORMs usually consist of transition metal carbonyls
that release CO when stimulated by a specific stimuli.
1.4.1 Sepsis and Inflammation
Inflammation is a biological consequence of tissue responding to a harmful stimulus
such as a bacterial infection. It is true that inflammation is a common condition
associated with a multitude of chronic pathologies including cardiovascular disorders,
diabetes, cancer and obesity.47 It has been successfully demonstrated in cell cultures
that the production of pro-inflammatory cytokines (TNF-α and IL-1β) induced by LPS
is significantly inhibited when exposed to CO. Not only this, but the production of
anti-inflammation cytokines (IL-10) is promoted.
The ability of CO to alleviate inflammation has been extensively demonstrated in
several animals models and there is a good amount of evidence to suggest its potential
therapeutic use for treatment of inflammatory related diseases. Mice treated with a
lethal dose of endotoxins to bring about the liver disease fulminant hepatitis showed a
10
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20–90 % recovery after inhalation of a CO-enriched atmosphere.27,46 Another animal
model study to note is treatment of CO from the ruthenium-based CORM ALF-492 (2,
Figure 3) to mice suffering with cerebral malaria (an inflammation to the brain). The
study found complete protection from malaria is CO dependent, with the CORM up-
regulating the expression of HO-1.48 In addition, Perrella and co-workers demonstrated
that addition of the CORM rescued HO-1 deficient mice from sepsis.45
Ru
Cl
COS
Cl CO
COO
OH
HO
OH
OH
2
Figure 3: In vivo studies demonstrates CORM ALF-492 protects mice against cerebral
malaria48
Therapeutic treatment of CO for inflammatory conditions such as human inflammat-
ory bowel disease, Crohn’s disease and ulcerative colitis have all received mounting
interest. Plevy and co-workers studied the therapeutic modality of chronic colitis in
mice models. Administration of gaseous CO was shown to improve chronic intestinal
inflammation in IL-10 deficient mice.44 Ford and co-workers established protective effects
of 1 h/day gaseous CO (250 ppm) for inflammatory disease necrotizing enterocolitis in
rat models.49
1.4.2 Cardiovascular Disease
Utilizing CO as a therapeutic agent for vascular disease seems the most plausible
condition to treat due to ease of administration of gaseous CO. In the event of a serious
vascular injury, such as myocardial infarction, revascularization therapy should be
applied immediately to minimize and prevent further myocardial damage. HO-1 activity
has been established to protect against hypoxia50,51 and ischemia-reperfusion injury.52,53
Exogenous CO diminishes vasoconstriction, leading to decreased blood pressure and
improved circulation.
A number of studies demonstrate that chronic inhalation of low levels of CO attenuate
11
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a variety of cardiovascular ailments. Otterbein et al. studied the suppression of
intimal hyperplasia and graft infiltration in mice and rat models. Continuous exposure
of CO (250 ppm) 1 hour before injury was shown to lessen the intimal hyperplasia
associated with carotid artery angioplasty injury.54 Nagai and co-workers reported
ischemia-reperfusion injury of rat models was mediated following pre-inhalation of
CO (1000 ppm, 24 h).55 Vandier and co-workers reported chronic inhalation of CO
attenuates hypoxic pulmonary artery hypertension (PAH).56 In addition, Zuckerbraun et
al. demonstrated gaseous administration of low concentrations of CO (250 ppm, 1 h/day)
not only reversed PAH, but also reduced right heart hypertrophy and improved the
general health of the animal models.
1.4.3 Organ Transplantation
Although organ transplantation has developed rapidly over the last few decades, the
longer term outcome of this surgical technique remains poor. Despite advances in
approach, specifically employment of new immunosuppression drugs and better post-
operative care, many scientists now view organ transplantation as requiring therapeutic
treatment to avoid organ rejection. CO offers a potential therapy for organ transplanta-
tion due to its ability to prevent ischemia/repurfusion injury and elicit cytoprotective
effects.16
An organ is stored in a preservation solution prior to transplantation. Enrichment of the
solution with CO not only increases the survival chances of the recipient and organ itself,
but also diminishes oxidative injury and improves renal function and reduces histological
injury well after the transplantation surgery.46 Gaseous CO and CORMs have been
successfully employed to deliver beneficial responses in various organ transplantations
including heart,16 lung,16 kindey,16 liver57 and pancreas.16 Direct administration of CO
has also been shown to reduce the risk of reperfusion injury as a result of rejection of
transplanted organ.58
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1.5 Principles of Carbonyl Complexes
1.5.1 Bonding of CO
The atomic orbitals of the carbon and oxygen atom each consist of one spherical 2s
orbital and three barbell-shaped 2p orbitals. The 2p orbitals point along the Cartesian
axes (2px, 2py and 2pz) and are orthogonal to each other. The lobes of the 2p atomic
orbitals are represented as different shades to indicate the different phases of the wave
function. Atomic orbitals are able to combine constructively due to overlapping of two
in-phase orbitals or destructively in an out-of-phase interaction.
C O
2s 2py
2pz 2px
z-axis
y-axis
x-axis
C
O
O
C
C O
Figure 4: Representation of the atomic orbitals of CO
A constructive interaction results in the build-up of electron density between two nuclei
and leads to the formation of a molecular orbital, which is of lower energy compared to
the atomic orbitals. Destructive interactions do not result in a new bond, but formation
of an anti-bonding molecular orbital, which lies at a higher energy than the atomic
orbitals.
The two types of bonds formed in CO include one σ bond and two pi bonds. The σ
bond, which has cylindrical symmetry between the carbon and oxygen nuclei, is formed
from the hybridization of the 2s and 2pz orbitals in order to achieve the optimum
shape for bonding. The σ* orbital is formed when the two atomic orbitals combine
in a destructive, out-of-phase manner. This anti-bonding molecular orbital is situated
predominantly on the carbon atom, and lies at a higher energy compared to the bonding
molecular orbitals. Saturation of the σ* orbital results in a lengthening of the carbon
13
CHAPTER 1. INTRODUCTION
oxygen bond. In the resulting hybridizated orbitals, a non-bonding orbital arises from
the pair of orbitals which point away from the C O bond.
The number of atomic orbitals (2s and 2pz on each nuclei) overlap to give an equal
number of molecular orbitals (σ bonding, two σ non-bonding and σ* orbitals). Com-
bination of the 2pz atomic orbitals occur in much the same way as the 2py and 2px,
resulting in the formation of a pi bond in the respective direction. The combination of
these orbitals out of phase result in anti-bonding pi orbital, which can participate in
back donation to a metal centre. The contribution of the atomic orbitals of carbon and
oxygen and the resulting molecular orbitals of CO are depicted in Figure 6.
C
C
OC
O
O
C O
Figure 5: σ and pi bond formation in CO
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Figure 6: Molecular orbital diagram for carbon monoxide
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1.5.2 Binding of CO to Transition Metal Centres
The majority of metal carbonyls exist as 18-electron species. This is a consequence of
the bonding between the CO ligand and metal centre being covalent. The strength of
the M CO bond is dictated by the delocalisation of bonding electrons in the molecular
orbitals formed between the metal and CO ligand. In carbonyl complexes, the CO
ligand is bound to the metal atom by two types of bonding interaction (Figure 7). The
lone pair of electrons situated on the carbon atom have the appropriate geometry to
overlap with the atomic orbitals of the metal to form a σ (M C) bond. The atomic
orbitals of the metal used in this type of bonding are usually a combination of the s, p,
dz2 and dx2−y2 atomic orbitals. The remaining filled dxy, dxz and/or dyz orbitals of the
metal are able to overlap with the empty pi* orbital of the CO, and in doing so donate
electron density back to the ligand (pi-backbonding). This results in a strengthening (and
therefore shortening) of the M CO bond. As a result of the carbon anti-bonding orbital
gaining electron density from the metal, the carbon-oxygen bond becomes weakened
and lengthens. Early transition metal do not commonly form stable carbonyl complexes
because they often exist in high oxidation states, and consequently do not contain filled
d orbitals. Going across the period of the transition metal series the metal d orbitals
become more electron rich. The increased electron density on the metal centre leads to
the d orbitals becoming smaller and consequently unavailable for bonding. Therefore
carbonyl complex become uncommon again towards the end of the transition metals
series.
C O
C OM
M
Figure 7: Carbon acts as a weak electron pair donor, forming a σ (M C) bond (top).
Empty pi* orbital on carbon acts as pi-acceptor, achieving pi bonding via
pi-backbonding (bottom)
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1.6 Development of Carbon Monoxide Releasing Mo-
lecules (CORMs)
1.6.1 Early CORMs
The investigation into using commercially available metal carbonyls as CO-releasing
molecules (CORMs) was initiated by Motterlini et al. in 2000. Initial transition metal
complexes screened for CORM viability (Figure 8) included iron pentacarbonyl (Fe(CO)5,
3), dimanganese decacarbonyl (Mn2(CO)10, 4) and tricarbonyldichlororuthenium(II)
dimer ([Ru(CO)3Cl2]2, 5). Direct addition of Fe(CO)5 or Mn2(CO)10 to a myoglobin
(Mb) solution did not display CO liberation via the conversion of Mb to carbonmonoxy-
myoglobin (MbCO). However both complexes released CO following exposure to light.
This is in contrast to [Ru(CO)3Cl2]2, which released CO spontaneously.
All of these early CORM models had problems. All are insoluble in aqueous media,
Fe(CO)5 and Mn2(CO)10 require photolysis to deliver CO and Fe(CO)5 exhibits high
toxicity issues. Further investigation into the CO release properties of [Ru(CO)3Cl2]2 in
DMSO revealed the complex dissociates into the tricarbonyl (fac-[RuCl2(CO)3(DMSO)])
and dicarbonyl (cis-cis-trans-[RuCl2(CO)2(DMSO)2]) species following CO liberation.
The amount of CO delivered was also low, liberating only 0.9 mol−1 CO per CORM. Nev-
ertheless, Motterlini et al. investigated the biochemical properties of both Mn2(CO)10
and [Ru(CO)3Cl2]2. Neither complex displayed worrying cytotoxicity profiles in con-
centrations ranging from 40–210µmol L−1, and both displayed vasorelaxation activity
operating via a cGMP-dependent pathway.7
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Figure 8: Early CORMs investigated by Motterlini et al.7,58
With the desire to design a water soluble CORM, Motterlini et al. coordinated the
biological ligand glycine to a ruthenium carbonyl metal centre. The glycinate ligand
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rendered the complex less toxic and more water soluble. Indeed, Ru(CO)3Cl(glycinate)
(referred to as ‘CORM-3’) was the first example of a pharmacologically-active water-
soluble CORM (6, Figure 8). CORM-3 has been effective in a number of in vitro,
ex vivo and in vivo biological models.8,26,58 However, there are issues associated with
the complex which derive from its reactivity with water. Due to its rich aqueous
chemistry, it is difficult to isolate in pure form. Infra-red (IR) analysis shows three
distinct carbonyl peaks consistent with the fac-Ru(CO)3 group at 2137, 2072 and
2058 cm−1. The presence of an additional peak at 1985 cm−1 was initially thought to
be a Ru(CO)2 by-product. However, this was later discovered to be the result of a
water-gas shift reaction of CORM-3, resulting from a deprotonation of the glycinate
ligand (yielding [Ru(CO)2(COOH)Cl(glycinate)]–). Liberation of the carboxylic proton
lowers the solution pH. Raising the pH results in the replacement of Ru Cl by Ru OH.
Further acidification of [Ru(CO)2(COOH)Cl(glycinate)]– results in liberation of the
glycine ligand, yielding [Ru(CO)3Cl3]–.4
1.6.2 Spontaneous CORMs
Spontaneous CO release usually proceeds via one of two possible mechanisms: thermal
dissociation of the CO ligand or substitution of the CO ligand by a molecule present in
the biological system. Thermal dissociation of CO involves the lengthening and breakage
of the M CO bond, creating a vacant site which can be occupied by a different ligand
(usually a solvent molecule). For such a mechanism to proceed, the CORM itself must be
relatively unstable to undergo thermal activation at biologically suitable temperatures
(37 ◦C). Indeed, CO donation capabilities of CORMs which are thermally activated
can be modulated via the trans effect. This observation was noted by Doctorvich
and co-workers who reported a series of tetrachlorocarbonyliridate(III) complexes (7,
Figure 9) harbouring nitrogen-based ligands trans to the CO.59 Rate of CO release
(rate of reaction) monitored under physiological conditions at 37 ◦C was observed to be
approximately 20 times greater when 2-dimethylaminopyridine (pi-acceptor) was trans
to CO compared to Cl– (weak σ-donor).
One CORM considered to release CO spontaneously as demonstrated in vitro and in
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Figure 9: Trans-effect on CO release investigated by Doctorvich and co-workers59
vivo is CORM-3 (6, Figure 8). Although the precise CO release mechanism is not
known, substitution of the chloride or glycinate ligand with an incoming electron-
withdrawing molecule seems plausible. Indeed, CO release from 6 has been shown to
be cysteine concentration dependant, suggesting an interaction between the CORM
and the amino acid which facilitates CO release.60 Of all the reported CORMs to
date, 6 has received the most attention in terms of studies verifying its therapeutic
actions. However, the ruthenium carbonyl complexes possesses a number of pitfalls
which have ultimately hindered its clinical development. Not only are there issues
regarding purification (mentioned above), but also its instability in aqueous solutions.
This is a crucial setback in terms of drug delivery, causing the administrated CORM
to release CO before reaching its medicinal target site. One strategy currently being
employed to enhance cellular delivery is the generation of macromolecule-incorporating
CORMs. Hubbell and co-workers60 utilized polymeric nanocarriers in the sub-hundred
nanometer range. The polymeric micelles comprised of a hydrophilic poly(ethylene
glycol) block, a poly[Ru(CO)3Cl(ornithinateacrylamide)] core responsible for CO release,
and a hydrophobic poly(n-butylacrylamide) block (8, Figure 10). Comparing the CO
release properties of 6 with the micelle-incorporated version found that the parent
complex released slightly more CO (0.9 eq vs 0.76 eq). Of course, the high CO-loading
capability of the micelle macromolecule means a significantly enhanced therapeutic
efficiency of the system. This has been demonstrated in vitro where the CO-releasing
micelle attributed significantly greater anti-inflammatory effects compared to 6 alone,
which was surprisingly shown to be ineffective in this particular assay.
In another interesting study concerned with the in vivo CO release of 6, Bernardes
and co-workers reported spontaneous release of CO from metalloproteins.61 Ruthenium
complexes of the general formula [Ru(CO)3L3]2+ are known to react with proteins
18
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Figure 10: Micelles incorporating Ru(CO)3Cl(amino acidate) structure reported by
Hubbell60
yielding mono- and dicarbonyl ruthenium(II) protein adducts.62 To this effect, Bern-
ardes coordinated the hen egg white protein lysozyme (HEWL) to a [Ru(CO)2]2+
moiety via metalation of a surface-exposed histidine (His) functionality to yield HEWL-
[Ru(II)(CO)2]. The complex is thought to undergo a water-gas shift reaction, in which
the released CO rapidly forms CO2. In order to authenticate CO release, a ‘turn on’
fluorescent probe was employed which exhibits a fluorescent response specifically to
CO. In developing metalloproteins which exhibit bio-selectively, reaction of [Ru(CO)2]2+
with bovine serum albumin (BSA) yielded BSA-[Ru(II)(CO)2], which was shown to
release CO spontaneously in aqueous solution during in vitro studies using cultured cells
and in vivo studies of mice models. Albumin has been shown to selectively accumulate
in tumour tissues and offers an advantageous pathway to bio-distribute CO to cancer
cells.
Romão and co-workers developed a series of CORMs of the general formula
[Mo(CO)nCNR6–n] with the aim of specifically protecting against acute liver fail-
ure. Previous work by Beck and co-workers examined the properties of a series of
Mo(CO)3CNCH2COOH complexes bearing different isocyanoacetate ligands.63 These
complexes were generally of low molecular size (an important consideration for drug
development to ensure adequate cellular uptake, MW < 500–600 g mol−1) and displayed
decent water solubility and stability under ambient conditions.
With this in mind, Romão explored the CO release properties of a series of molybdenum
carbonyl complexes which varied with respect to number and structure of isocyanoacetate
ligand, and consequently number of CO ligands (Figure 11).64 In vitro studies of these
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complexes revealed no uptake of the CORMs into the cultured cells. Biological activity
was therefore evaluated via in vivo studies on mice proceeding acetaminophen-induced
liver injury. Toxicity studies revealed complexes of the general formula Mo(CO)5L were
lethal, with lower CO containing analogues ALF-785 (9) and ALF-795 (10a, Figure 11)
producing no toxicity readings. CORMs 9 and 10a administered to mice models of
acetaminophen-induced liver injury resulted in a significant decrease in serum levels
of the liver enzyme, alanine aminotransferase, which is associated with liver injury.
Despite harbouring fewer CO ligands, 10a activity superseded that of 9. Following these
encouraging results, the group generated a series of isocyanoacetate ligand derivatives
to coordinate to a Mo(CO)3 moiety to further enhance liver targeting and biological
activity. One of the most influential factors demonstrated was the number of methyl
substituents present on the isocyanoacetate molecule, with two methyl groups (ALF794,
10b, Figure 11) producing the most desirable results.
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Figure 11: Molybdenum isocyanoacetate carbonyl complexes reported by Romão64
1.6.3 Enzymatic CORMs
Enzymatic activation of CORMs (so called ET-CORMs) represent a unique trigger
mechanism by which CO is only liberated from the CORM in the presence of a specific
enzyme. This strategy is particularly advantageous if an enzyme is overexpressed as
a result of tissue damage or disease. In this sense, the ET-CORM becomes inducible
(comparable to HO-1 activation) by responding to enzymatic changes in tissues to deliver
site-specific therapeutic action. Incorporation of an ancillary ligand which features a
functional group known to bind to a specific enzyme is likely to promote metabolic
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decomposition of the drug, thereby triggering CO release. However, in designing ET-
CORMs one must not only consider the enzyme’s mode of action (substrate target) and
location, but also its structure, in particular its active site. Enzymes which comprise of
a haem co-factor may be unsuitable activators as the unbound CO will likely bind to the
nearby haem, thereby inhibiting the therapeutic action of the ET-CORM. Furthermore,
enzymatic activation could be achieved by a variety of different enzymes which all bind
to the same substrate. Careful consideration of the ET-CORM coordination sphere
may offer specific enzymatic binding and generate truly site-specific CO release.
The first explicit use of enzyme-triggered CO release was reported by Schmalz and
co-workers, whom also coined the term ‘ET-CORM’.65 Earlier observation of the readily
labile nature of an dienol-Fe(CO)3 complex prompted the synthesis of a dienylester-
Fe(CO)3 precursor, which displayed greater stability under physiological conditions.
Once the dienylester-Fe(CO)3 precursor entered a cell it would be cleaved by intracellular
esterases, converting back to the dienol-Fe(CO)3 species which would then decompose,
yielding Fe(III), the dienol ligand and three equivalents of CO (Figure 12, top). Schmalz
put this concept into practise by investigating the esterase-triggered CO release of
acyloxydiene-iron tricarbonyl complexes 11a–11b, in addition to an diacetoxydiene-iron
tricarbonyl complex 11c and an esterase-insensitive control complex 11d (Figure 12,
bottom). ET-CORM activity was monitored via the myoglobin assay (Section 2.1.3) in
the presence of an esterase enzyme. Under such conditions, CO liberation occurred. In
the absence of any esterase, no CO release was detected.
Further to this work, Schmalz explored the structural influence of a series of acyloxy-
cyclohexadiene-Fe(CO)3 complexes on rate of CO release.66 In this study, two regioi-
somers were used: one with the ester functionality positioned on the inner position
of the diene ligand, and the other with the ester functionality at the outer position.
Schmalz also assessed the influence of an aliphatic ester chain on rate of reaction.
Their findings demonstrate that ester functionality at the outer position of the diene
released CO quicker compared to those positioned at the inner position. Although the
explanation for this remains unclear, it is thought the major influence stems from the
stability of the formed intermediates (mechanism mentioned in Figure 12). Lengthening
of the ester chain resulted in a significant decrease in rate of reaction. Indeed, in vitro
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Figure 12: Top: Proposed enzymatic CO release mechanism. Bottom: [Fe(CO)3]-based
complexes used by Schmalz to establish ET-CORM activity65
studies revealed enzymatic release of CO was fastest from acetate (R = Me) groups with
slower release from pivalates (R = tBu) and palmitates (C15H31). In a further study,
Schmalz and Yard67,68 evaluated the biological activities of known ET-CORMs (11a-
11b, Figure 13) with respect to toxicity, cytoprotective actions against hypothermic
preservation damage and ability to inhibit TNF-α-mediated vascular cell adhesion
molecule-1 (VCAM-1) expression. Similar to previous studies, the structure-activity
relationship of ET-CORMs revealed ester functionality and position is crucial in influen-
cing rate of reaction and biological response. Although none of the parent compounds
from which the ET-CORMs are derived exhibited any cytotoxicity behaviour, the
resulting ET-CORMs displayed significantly varying degrees of toxicity. Furthermore,
only ET-CORMs with the mother compound cyclohexen-2-one (11a and 11b series)
displayed any protective actions against hypothermic preservation damage, with acetate
ester functionality producing the greatest protection and palmitate the worst. All
complexes reported a decreased in TNF-α-mediated VCAM-1 expression.
1.6.4 Co-Drug Assisted Release CORMs
Many research groups have explored CORM activation via administration with a co-
drug. This strategy has been most successfully demonstrated in combination with
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Figure 13: ET-CORMs investigated by Schmalz and Yard67,68
metal-based CORMs. CO can be readily substituted via an associative mechanism by
an approaching ligand: the incoming ligand forms a new M L bond, increasing the
coordination number of the complex. This leads to the elongation and breakage of the
M CO bond. Activation of a pro-drug (CORM) through treatment with a co-drug will
inevitably result in the generation of intermediate species following liberation of CO.
One must ensure that not only the pro- and co-drugs are non-toxic, but any subsequent
intermediate(s) display minimal detrimental effects towards tissues.
Liu and co-workers reported the synthesis of a diiron hexacarbonyl species featuring a
bidentate thioglycerol bridge (12, Figure 14).69 The presence of four hydroxyl groups
on the bridging ligands arguments excellent water solubility. CO release was achieved
via substitution by co-drug, cysteamine (CysA). The use of thioglycol and CysA is
appropriate, with both having been used in medicinal applications, any emerging
intermediate species should exhibit little/no harmful effects. However, the traditional
myoglobin assay (Section 2.1.3) could not be employed here as the presence of the
excess reducing agent (sodium dithionite) prompted CO release from the diiron complex.
Spectroscopic analysis of the CO release behaviour revealed loss of one equivalent of CO
following substitution of CysA, with further loss of CO resulting in the formation of a
monoiron (Fe(II)(cis-CO)2) species. The parent diiron complex consists of an ‘Fe(I)Fe(I)’-
core, which indicates an oxidative mechanism to form the later intermediates. Since the
spectroscopic experiments were carried out in an inert atmosphere, Liu speculated the
most probable source of oxidation was the labile thiol proton of the CysA co-drug. This
idea was supported spectroscopically as the protonated and deprotonated forms were
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identified as intermediate species following CO release. Under an open atmosphere, Liu
reflected a similar first-step labilisation of CO by CysA would occur, followed by rapid
oxidative destruction caused by molecular oxygen.
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Figure 14: Diiron hexacarbonyl activated by CysA, reported by Liu and co-workers69
1.6.5 PhotoCORMs
An attractive and selective strategy is the photochemically-activated loss of CO from
photosensitive CORMs. PhotoCORMs are inherently stable in the dark, and only release
CO in response to stimulation by incident light of a specific wavelength. They have
obvious topical applications, such as treatment of skin diseases, transdermal delivery of
CO, or localised CO treatment to organs, tissues or tumours via photodynamic therapy
technologies. The wavelength (and therefore energy) of incident light required to break
the M CO bond is of significant importance in the development of photoCORMs. The
majority of carbonyl complexes will decompose following irradiation of ultra-violet (UV)
light, thereby releasing their load of CO. However activation by UV light is damaging
to the biological target and elicits poor tissue penetration depth. Excitation from
longer wavelengths of light are less biologically harmful and can penetrate deeper into
the skin, allowing the CORM to target sites deeper inside solid tissue.70 Preferably, a
photoCORM would be activated by near-infrared (near-IR) irradiation, as this region of
the electromagnetic spectrum allows for the greatest tissue penetration without causing
harm to tissues.71 The development of photoCORMs has recently been reviewed in
detail.72
The first explicit use of light to act as a trigger mechanism for CO release, and indeed the
first coined use of the term ‘CORM’ came from Motterlini et al. in 2002.7 As mentioned
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above, simple metal carbonyls Fe(CO)5 and Mn2(CO)10 were shown to only release CO
when irradiated with ‘cold light’ over approximately one hour. Of course, these systems
were not specifically designed to adhere photoCORM behaviour. Early photoCORMs
designed specifically to release CO in response to stimulation from light required high
energy, UV irradiation to liberate the bound CO. What constitutes a UV-activated or
visible light activated photoCORM is not straight-forward. Typically one would classify
the molecule as visible light activated if the absorption for the electronic transitions
lie above 400 nm. However, commonly these electronic transitions are broad and may
overlap between the UV and visible regions of the spectrum. For the purposes of this
thesis, photoCORMs are divided based on the light source used in practical applications
to release CO.
The first example of a CORM specifically designed to utilize light to release CO was
reported by Schatzschneider and co-workers in 2008.73 The reaction of Mn(CO)5Br
with tris(pyrazolyl)methane (tpm) yielded [Mn(CO)3(tpm)]+ (13, Figure 15). The
cationic manganese centre is water soluble and bears three CO ligands. The tpm
ligand framework was chosen due to its synthetic ease. Also, further functionality could
be introduced to the complex via substitution of the acidic methine proton. Upon
irradiation with UV light (365 nm), the complex releases approximately two equivalents
of CO and displayed promising anti-cancer properties against human colon cancer
cells. However, when the photo-triggered CO release was surveyed by ultrafast laser
spectroscopy, it was revealed that only one of the three CO ligands is photolabile. The
loss of subsequent CO ligands was thought to most likely be a consequence of manganese
oxidation.74,75 Functionalisation of the tpm ligand framework (14, Figure 15) offered a
gateway into achieving uptake by a specific type of cell. This type of targeted delivery
has obvious advantages, especially when developing anti-cancer treatments. With
this in mind, Schatzschneider successfully employed Pd-catalysed Sonogashira cross-
coupling and alkyl-azide click chemistry to coordinate peptides to the tpm-manganese(I)
tricarbonyl complex.76 The resulting peptide CORM was shown to have a similar CO
release profile to that of the parent complex. Using a similar approach, the group later
successfully attached the tpm-manganese(I) complex to azido-modified silicium dioxide
nanoparticles to act as a carrier. The resulting complex was shown to have similar CO
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release properties to that of the parent complex.77
With the aim of gaining an insight into the extent to which overall charge and ligand
sphere influenced CO release, Berends and Kurz performed a comparative study using the
cationic species [Mn(CO)3(tpm)]+ (13, Figure 15) synthesised by Schatzschneider, and
the neutral complex [Mn(CO)3(bpzaa)] (where bpzaa = bis-(pyrazolyl)acetic acid)(15,
Figure 15).75 Using a multi-analytical approach, incorporating IR, UV/Vis and electron
paramagnetic resonance (EPR) spectroscopies, the pair established a step-wise mechan-
ism by which CO ligands are replaced by solvato ligands. The absorption maxima for
each complex lies at 349 nm and 361 nm, respectively, with loss of two equivalents of CO
following UV (365 nm) irradiation. The postulated photoproducts undergo oxidation of
the manganese metal centre without loss of the ligand architecture (IR data indicate a
cis-Mn(I)(CO)2 species).
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Figure 15: First photoCORM (left) and subsequent functionalised derivatives (middle)
reported by Schatzschneider76,77 with the neutral comparison complex (right)
synthesised by Berends and Kurz75
The first documented use of the term ‘PhotoCORM’ came from Ford and co-workers in
2010.78 Ford reported an air- and water-soluble tungsten(0) carbonyl complex bearing
a tris(sulphonatophenyl)phosphine ligand (16, Figure 16). The complex comprised of
five CO ligands, but upon UV irradiation (305–405 nm) only released one equivalent of
CO. Following photolabilisation of CO, a water molecule coordinates to the vacant site.
The slow liberation of additional CO from this secondary species is thought not be to
photochemical, but a result of the oxidation of the tungsten metal centre.
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Figure 16: Tungsten-based photoCORM reported by Ford and co-workers78
Employing alkynyl chemistry, Lynam and co-workers successfully introduced a biologically-
compatible sugar ligand onto a molybdenum carbonyl complex, yielding 17 (Figure 17).79
The reported cyclopentadienyl-molybdenum photoCORM displayed excellent water
solubility and was shown to release CO slowly in aqueous media. However, rate of
reaction rapidly increased when the complex was irradiated with UV light (325 nm). In
both instances, approximately two equivalents of CO were lost.
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Figure 17: Mo-fructopyranose photoCORM reported by Lynam and co-workers79
The Spingler group developed a series of manganese and rhenium systems which
incorporated tripodal nitrogen ligands bearing a central phosphorus linking atom.80
The rhenium complexes displayed no absorption maxima greater than 320 nm and
exhibited no photoCORM activity. The manganese complexes were shown to be stable
in the dark whilst in the presence of myoglobin. Photoactivation at 365 nm showed
ligand-dependent loss of CO within 60 minutes. Complexes featuring the imidazol-2-
ylphosphane (18, Figure 18) ligand architecture liberated two equivalents of CO per
metal centre, whereas those featuring the imidazol-4-ylphosphine (19, Figure 18) ligand
framework only released one equivalent.
Extending on this work, Kunz synthesised two related 2-hydroxypropyl methacrylamide
(HPMA)-based polymers to coordinate to an Mn(CO)3 core.81 The idea behind incor-
porating large macromolecules is to hone the delivery capabilities of the system. This
is especially effective in the selective toxicity of cancer cells as such macromolecules
are known to accumulate in tumour tissues, as described by the enhanced permeability
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Figure 18: Manganese photoCORMs developed by Spingler80
and retention effect. The polymeric carrier coordinates to the manganese core via a
bis(pyridylmethyl)amine architecture. The corresponding Mn(CO)3–polymer conjugates
(20, Figure 19) displayed photolytic release of CO under UV conditions. However, due
to the polymer loading, turbidity of the solution may have influenced the myoglobin
assay data.82
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Figure 19: Polyermic bis(pyridylmethyl)amine-functionalised manganese complexes re-
ported by Kunz81
Kodanko and co-workers reported the synthesis of the Fe(II) dicationic photoCORM,
[Fe(CO)(N4Py)]2+ (21, Figure 20).83 The complex exhibits excellent water-solubility
and was shown to release CO in a triggered fashion following UV irradiation (365 nm).
Investigating the biological applications of the photoCORM revealed photoinduced
cytotoxicity behaviour against prostate cancer cell cultures. Further modification of the
transition metal motif by attaching a peptide molecule (Ac-Ala-Gly-OBn) was achieved,
although no CO release data, nor influence of the peptide on tissue- or cell-specific drug
uptake was included.
Extending their earlier work on Mn(CO)4(C∧N) systems (where C∧N= ortho-metallated
2-phenylpyridine or benzoquinoline), Fairlamb and co-workers explored the CO release
behaviour of a related Mn(CO)4(C∧N) complex (22, Figure 21).84 The UV-activated
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Figure 20: Monocarbonyl iron photoCORM reported by Kodanko and co-workers (R =
H, Ac-Ala-Gly-OBn)83
(365 nm) photoCORM is thermally stable in the dark and releases up to three equivalents
of CO. The photorelease behaviour was shown to operate via a step-wise process, by
which the liberation of CO could be switched ‘on and off’ simply by starting/stopping
the UV irradiation. Cell viability experiments pre- and post-irradiation revealed none
of the degradation species infer toxicity issues to the cell cultures.
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Figure 21: Manganese photoCORM reported by Fairlamb and co-workers84
Schatzschneider and co-workers furthered their photoCORM work on a range of
ruthenium based structures incorporating 2,2′-bipyridine (bpy) ligands and related
structures (23-25, Figure 22).85 The strong MLCT (metal-to-ligand charge trans-
fer) transitions make the ligand ideal for photoCORM development. Furthermore,
the ligand framework can be readily modified to introduce biologically compatible
functionalities. In this instance, attachment of a peptide nucleic acid (PNA) to the
2-(2′-pyridyl)pyrimidine complex yielded 23 (where X = N, R1 = H and R2 = PNA).
Illumination of all complexes at 365 nm resulted in the liberation of one equivalent of
CO. In the case of the PNA-derivative, the CO release behaviour remained identical to
that of the parent complex.
An interesting sawhorse type ruthenium complex bearing carboxylic and amino acid
molecules within the coordination sphere was developed by Zhang and co-workers.86
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Figure 22: Ruthenium bi- and ter-pyridine photoCORMs derivatives reported by
Schatzschneider and co-workers (Boc = tert-butyloxycarbonyl, Fmoc =
9-fluorenylmethyloxycarbonyl)85
The sawhorse complex, namely [Ru(µ2-carbonylato)(O(C O)R)2(CO)2]2 (26, Figure 23)
released CO when triggered by LED (light emitting diode) UV irradiation (365 nm).
rate of reaction was shown to be dependent on the nature of the bridging ligand, which
was varied from acetato- to arylcarbonxylato. Photolysis monitored by IR spectroscopy
revealed the growth a new peaks following disappearance of peaks in the carbonyl
region, which suggests the formation of a stable photoproduct. These intermediates
were further analysed by ESI-MS, which indicated the replacement of one labile axial
ligand with a solvent molecule.
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Figure 23: Sawhorse rutheium photoCORM reported by Zhang86
An essential feature of any given (photo)CORM is that its breakdown products
(‘iCORMs’) post CO release must be non-toxic and excretable. One of the lead-
ing strategies to generate inactive, isolatable iCORMs is to employ ligands which
incorporate more donor groups than there are labile CO ligands (Scheme 2). The idea
being that once one CO ligand has been release from the metal centre, the additional
donor group of the ligand, preferentially at the end of a pendant ‘arm’, will coordinate
to the metal centre.
Schatzschneider and co-workers developed such photoCORMs using the tetradentate
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Scheme 2: Scheme depicting (photo)CORMs ligand framework comprising of additional
pendant donor ‘arms’ which are able to coordinate to the metal centre
following CO release
ligand, tris(2-pyridylmethyl)amine (tpa). The resulting cationic manganese photoCORM
bears three labile CO ligands (27, Figure 24).87 The complex is stable in the presence
of myoglobin in the dark for up to 16 hours. Following UV illumination (365 nm)
approximately three equivalents of CO were released. However, when kept in the dark
for only 1 hour pre UV light activation, only two equivalents were photo-released. This
suggests that release of the third CO equivalent operates via a non-photochemical
mechanism. Of course, the developed tpa ligand only contains one pendent ‘arm’, which
limits the number of isolatable iCORMs as this particular species can lose up to three
CO equivalents. Schatzschneider reports that synthesis of a novel hexadentate ligand
with one pendant donor group per CO is currently under preparation in their laboratory.
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Figure 24: Manganese photoCORM with tetradentate ligand, including one pendent
‘arm’, reported by Schatzschneider and co-workers87
A series of photoactive tetracarbonyl manganese complexes (28, Figure 25) harbouring a
2-phenylpyridine ligand architecture have been developed by Fairlamb and co-workers.88
The 2-phenylpyridine ligands were generated using a Suzuki-Miyaura cross coupling
31
CHAPTER 1. INTRODUCTION
reaction. Varying the substituent on the 4-position of the phenyl ring led to modulation
of CO release properties. All complexes were shown to be stable in the absence of light,
and only released CO to myoglobin following irradiation using a TLC lamp (365 nm).
Investigations of photoCORM behaviours using an LED irradiation system operating
at 365 nm and 400 nm led to significant increases in CO release capabilities.
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Figure 25: Tetracarbonyl phenylpyridine manganese photoCORMs reported by Fairlamb
and co-workers88
The design of visible light activated photoCORMs has been at the forefront of field
development during the past few years. Transition metal carbonyl complexes which
partake in distinct metal-to-ligand charge transfer (MLCT) transitions have been shown
to facilitate CO labilisation from the metal centre.89 Indeed, the photoreactivity of a
given metal complex is indicative of the electronic transitions possible. Ligand field
transitions still occur, but are unlikely to cause photodissociation of CO due to the
relatively high energy of the M CO anti-bonding orbitals (Figure 26).
MLCT transitions, which are of high intensity and spectroscopically allowed, arise
from the excitation of electrons from orbitals predominantly of metal character to
orbitals predominantly of ligand character (Figure 27). This decrease in the electron
density of the metal t2g orbitals weakens the complex’s backbonding capabilities and
therefore facilitates CO loss. Complexes which are able to undertake such transitions
generally featuring electron rich d orbitals and possess ligands fostering low lying empty
pi* orbitals (such as pyridines or diimines).
The more successful candidates consist of d6 metal centres, including Mn(I), Re(I), Fe(II)
and Ru(II). Of course, success in designing visible light activated photoCORMs also
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Figure 27: Metal to ligand charge transfer (MLCT) of an octahedral d6 complex
revolves around the synthesis of photosenstive ligands suitable for coordination to metal
centres, which are able to facilitate MLCT transitions. The design principles which allow
for visible light driven CO release can be rationalised using DFT (density functional
theory) and TD-DFT (time-dependent density functional theory) calculations.90
Surveying the literature, the first demonstrated visible light activated release of CO
was reported by Westerhausen and co-workers in 2011.91 The previously known iron
complex, dicarbonylbis(cysteamine)iron(II) (so-called CORM-S1, 29, Figure 28) was
shown to release approximately two equivalents of CO following irradiation with visible
light (470 nm). The complex architecture consists of two cysteamine ligands, which
were purposely chosen due to their degradation to cysteine. Interestingly, the complex
bears no organic chromophore ligand framework, which limits the possibility of further
modification.
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Figure 28: CORM-S1, developed by Westerhausen and co-workers91
Inspiration for photoCORM development can originate in a number of different forms.
Ford and co-workers built theirs on the basis of fac-Re(bpy)(CO)3(X)+ (bpy = 2,2′-
bipyridine, X = halide) complexes, which are well-known CO oxidation catalysts and
exhibit luminescent properties.92 Probing the CO release behaviour of these complexes
revealed photodissociation (405 nm) of one equivalent of CO. It is important to note that
the quantum yield (Section 2.2.1) in the UV-region (365 nm, 0.21) is greater than the
visible range (405 nm, 0.11). Due to the complexes exhibiting poor water solubility, Ford
incorporated the hydroxylated ligand P(CH2OH)3 to solubilse the complex. Scheme 3
shows the active photoCORM (30) and photoproduct (31). Notably, photolysis of
the rhenium complex leads to a detectable shift in the luminescent band. In aqueous
solution a strong emission band at 515 nm is observed, which red-shifts to 585 nm for
the photoproduct. This provides a crucial insight into the cellular uptake behaviour of
the photoCORM in vitro.
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Scheme 3: Luminescent rhenium photoCORM reported by Ford and co-workers92
Photorelease of CO from the hydrogenase-inspired Na2[(µ-SCH2CH2COO)Fe(CO)3]2
was reported by Fan and co-workers.93 This diiron system consists of six labile CO
ligands and a water solubilizing dithiolate bridge containing carboxylate end groups
(32, Figure 29). When shielded from light, the complex is both air- and water stable.
In the presence of strong donor molecules (such as PMe3), the complex releases CO via
a nucleophilic substitution reaction. Photochemical liberation of all six CO ligands was
achieved within 30 minutes following broadband visible light irradiation. Quantification
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of CO release behaviour was reported following irradiation at 390 nm.
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Figure 29: Anionic diiron-based photoCORM reported by Fan and co-workers93
Quantification of breakdown products post CO release, in terms of structure, toxicity and
biological activity, is an integral part of understanding CORM behaviour. One leading
strategy to contain any subsequent photoproducts is to bind the metal-ligand moiety to
a macromolecular carrier. This methodology was utilised by Smith and co-workers, who
developed a number of dendrimer macromolecules bound to an Mn(CO)3-core.94 Smith
reported two metallodendrimers: a tetranuclear and octanuclear Mn(CO)3 functionalised
system (33). In addition, a mononuclear analogue (34) was synthesised in order to
quantify the scaling effect of additional metal centres (Figure 30). Photochemical
activation at 410 nm liberated two out of the possible three CO ligands per metal centre,
with the dendrimers taking approximately twice as long to release CO compared to the
monomeric system.
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Figure 30: Manganese-based matallodendrimers and monomeric analogue reported by
Smith and co-workers94
Development of photoCORMs which incorporate the biocompatable scaffold vitamin
B12 was originally examined by Bogdanova and co-workers in 2012.95 Reaction of
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[Re(CO)2Br4][Et4N]2 with cyanocobalamin (vitamin B12) resulted in the formation of
a 17-electron rhenium dicarbonyl species (so-called ‘Re-B12CORM’, 35, Figure 31).
Such systems exhibit superior water solubility and biocompatability compared to the
parent metal complex. Furthermore, the Re-B12CORM derivatives display improved
stability in aqueous aerobic media as well as cytoprotective actions against ischemia-
reperfusion injury. The complex does release CO, but not under photoillumination.
More recently, Bogdanova and co-workers revealed cellular uptake problems with the
Re-based system.96 Development of a vitamin B12 scaffold capable of intracellular uptake
of an inorganic motif was achieved by complexation of a Mn(CO)3-core with the vitamin
B12 molecule via the ribose sugar moiety (so-called ‘Mn-B12CORM’, 36, Figure 31).
Photoinduced CO release from Mn-B12CORM was firstly probed via IR spectroscopy.
When shielded from light, no observable changes occurred. Exposure to blue LED
(470 nm) illumination resulted in a steady decrease of all carbonyl peaks over three
hours. Furthermore, exposure to green (496 nm) Ar laser irradiation resulted in slower
labilisation of the three CO ligands. In order to verify the cellular uptake issue with
Re-B12CORM had been addressed, the cytoprotective actions of Mn-B12CORM were
demonstrated on a cell culture of fibroblasts.
Bengali and co-workers examined the photorelease properties of a Mn(CO)3 fragment
supported by the sterically hindered DAB (1,4-diaza-1,3-butadiene).97 The complex in
question, namely fac-[Mn(CO)3(iPr2Ph DAB)] (37, Figure 32) (where iPr2Ph − DAB
= N,N ′-bis(2,6-diisopropylphenyl)-1,4-diaza-1,3-butadiene) is unstable when exposed
to ambient light. In such conditions, a thermal reaction occurs which results in the
separation of the diimine ligand with formation of Mn(CO)4Br. The complex has
an absorption maxima at 582 nm, and CO release behaviour was monitored via IR
spectroscopy following visible light (560 nm) illumination. The IR spectrum showed a
gradual decrease in all carbonyl peaks, with no evidence of intermediate photoproducts
forming. Bengali speculates the photolytic cleavage of CO is driven by a MLCT
transition originating from a combination of the Mn CO pi and bromide p orbitals
to the pi* orbitals of the diimine ligand. The outcome of which reduces the extent of
back-bonding to the CO ligand which facilitates CO loss. Extraction of the bromide
by TlPF6 in a CO atmosphere yielded the cationic species, [Mn(CO)4(iPr2Ph-DAB)]+
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Figure 31: Left: Re-vitamin B12 CORM attached via a C≡N linkage.95 Right: Mn-
vitamin B12 PhotoCORM ligated via the ribose moiety96
(38, Figure 32). Dissolution results in loss of the axial CO by the solvent molecule.
Furthermore, the cationic analogue displays enhanced thermal reactivity resulting in
loss of CO. However, due to the loss of the halide, the ligand does not dissociate from
the complex in ambient light. With respect to its photolytic CO release, the latter
complex releases CO at a decreased rate compared to the parent complex.
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Figure 32: Left: Neutral manganese tricarbonyl complex including the sterically bulky
DAB ligand. Right: Related cationic manganese tetracarbonyl complex
Work done by Mascharak and co-workers established absorptivity of carbonyl complexes
can be systematically increased by extending the conjugation system of the ligand
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framework (Figure 33).98 Using a variety of structurally similar ligands featuring
a pyridine and quinoline moiety, as well as conjugated aromatic nitrogen donors,
Mascharak synthesised a series of manganese(I) carbonyl complexes which progressively
displayed a red shift of the absorption band. These ligands all coordinated to the
manganese(I) metal centre in a bidentate fashion, with the sulfur containing ligand
(qmtpm) eliciting the most substantial shift furthest into the visible. A key observation
of this work is the significant red shift observed when comparing complexes bearing
halide ligands and those featuring other donors. For example, the electronic transition
of fac-[Mn(qmtpm)(CO)3(MeCN)][ClO4] at 435 nm is significantly shifted to 535 nm in
fac-[Mn(qmtpm)(CO)3Br].
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Figure 33: Bidentate ligands containing coordinating nitrogen donors synthesised by
Mascharak98
Mascharak later synthesised ruthenium analogues featuring the qmtpm ligand, which
coordinated in a meridional fashion (Figure 34).99 In contrast to the manganese species
(where the ligand binds in a bidentate fashion), in the ruthenium complexes the ligand
coordinates in a tridentate fashion. This particular study focused on the photoactivity of
two complexes, [Ru(Cl)(CO)(qmtpm)(PPh3)]+ (39) and [Ru(Cl)(CO)2(qmtpm)]+ (40)
following irradiation in the 300–450 nm wavelength range. The CO release behaviour of
both complexes was examined in acetonitrile. In the case of 39, small spectral changes
were observed when the complexes was kept in the dark in the presence of myoglobin.
Slow release of CO was thought to facilitate through the strong trans-effect of the PPh3
ligand. Indeed 40, which contains no PPh3 ligand is fully stable in such conditions.
rate of reaction was shown to be dependent on the illumination wavelength. Moreover,
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visible light activated CO release was only achievable with the PPh3-containing complex.
Irradiating with a light cut-off at 380 nm yielded a significantly enhanced rate of reaction
compared to a cut-off filter at 440 nm.
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Figure 34: Ruthenium-based photoCORMs reported by Mascharak99
Following this work, Mascharak described the photorelease behaviour of two complexes
featuring the bidentate ligand 2-phenylazopyridine (azpy), namely, fac-[MnBr(azpy)(CO)3]
(41) and fac-[Mn(azpy)(CO)3(PPh3)]+ (42, Figure 35). The azpy ligand was specifically
implemented into the coordination sphere due to its strong pi-acidity in order to enhance
MLCT transitions in the visible region. In this study, substitution of a halide ligand
with PPh3 resulted in a blue-shift in the absorption spectrum, along with a decrease in
rate of reaction. This observation is consistent with the expected behaviour of systems
which utilise pi-acceptor ligands, which are known to stabilise low-lying orbitals by
withdrawing electron density from the metal centre, resulting in an increase in the
energy required for MLCT transitions. Photorelease of CO from 41 upon exposure
to visible light (with a 520 nm cut-off filter) showed quick CO release within minutes.
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Figure 35: fac-[MnBr(azpy)(CO)3] and fac-[Mn(azpy)(CO)3(PPh3)]+ reported by
Mascharak100
More recently, Mascharak made use of the benzothiozole-derivative ligand, 2-(2-pyridyl)-
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benzothiazole (pbt).101 Like other benzothiozole ligands, pbt exhibits strong anti-tumour
activities and acts as a stable fluorophore. By complementing these two characteristics
of the ligand architecture, Mascharak developed the biologically trackable, anti-cancer
photoCORM, fac-[MnBr(CO)3(pbt)] (43, Figure 36). This complex displays a ‘turn-on’
fluorescent nature following labilisation of CO. Illumination with broadband visible light
causes dissociation of the pbt ligand, which in turn is responsible for the fluorescence
observed. This phenomenon provides a pathway to quantify uptake of the drug to target
cells. Fluorescence imagining studies with human breast cancer cell lines revealed loss
of the pbt ligand from the metal centre, along with a 50 % reduction in cell viability
following visible light irradiation.
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Figure 36: Fluorescent manganese photoCORMs reported by Mascharak101
Delving into the rational design principles for visible light activated CORMs developed
by Mascharak, Zobi and co-workers analysed the absorption shift of fac-Mn(CO)3
complexes featuring 2,2′-azopyridine ligands modified with either an electron-donating
or electron-withdrawing substituent (44, Figure 37).102 As mentioned above, Mascharak
reasoned visible light activation of manganese carbonyl complexes is based on two
fundamental strategies: increasing the conjugation of aromatic ligand framework, which
results in the stabilisation of the LUMO orbital associated with MLCT transitions,
and substitution of pi-acid ancillary ligands with ligands containing σ-donors or pi-basic
functionality, leading to an decrease in the HOMO–LUMO gap. Methodical substitution
of ligand functionality from weakly electron-donating groups (CH3) to weakly electron-
withdrawing (Br) and strongly electron withdrawing groups (CF3) resulted in an red
shift of absorption maxima between 330–693 nm. TD-DFT calculations and UV/Vis
spectroscopy data indicated that presence of an electron-withdrawing group caused a
decrease the HOMO–LUMO gap with a subsequent bathochromic shift of the absorption
band. In the presence of an electron-donating substitutent, the HUMO–LUMO gap
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increases, resulting in an hypsochromic shift of the absorption band.
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Figure 37: Systematic introduction of electron-donating to electron-withdrawing sub-
stituents, and their influence of absorption maxima102
1.6.6 Non-Organometallic CORMs
The vast majority of reported CORMs contain a transition metal centre with bound CO
ligands. Beside organometallic compounds, there are a handful of non-organometallic
compounds that are able to release CO. Included in these is the boroncarboxylate
compound, Na[H3BCO2] (termed ‘CORM-A1’). This water soluble CORM has been
shown to release CO at a significantly slow rate under physiological conditions. Its CO
release is pH-dependent, with rate of reaction from CORM-A1 gradually increasing as
pH decreases from 7.0 to 5.5. Motterlini et al. characterised its therapeutic potential
by adding the CORM to aortic rings which had been precontracted with phenylephrine.
Vasorelaxation was observed 33 minutes after addition. After liberation of the CO
equivalent, which originates from the carboxyl group, the compound is rendered inactive
(termed ‘iCORM-A1’), and vasorelaxation properties cease. The ability of CORM-1A
to induce vasorelaxation was partially inhibited by a sGC inhibitor, and unaffected by
an inhibitor of KATP potassium channels. The vasodilatation elicited by CORM-A1
was markedly increased in the presence of sGC activator YC-1, suggesting a direct
cGMP-dependent pathway.103
Liao and co-workers developed the visible light activated unsaturated cyclic α-diketone,
45 (Scheme 4).104 Synthesis of the organic molecule occurs via a Diels–Alder reaction.
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Illumination with visible light (470 nm) resulted in release of two equivalents of CO.
However, in water the ketone functional groups form an equilibrium with the correspond-
ing hydrate. CO release from the α-diketone system involves activation of one carbonyl
group by the other. Therefore to prevent hydration of the α-diketone system, Liao
encapsulated the anthracene molecule in a hydrophobic micelles (the inner, hydrophobic
micelle prevented hydration). The fluorescent nature of the anthracene molecule allowed
for the trackable delivery of CO to biological targets. Micelles encapsulated with the
organic photoCORM were incubated with leukemia cells. Photochemical activation
of the molecule was studied by fluorescence microscopy, which detected a bright blue
fluorescence corresponding to anthracene derivatives following CO release.
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Scheme 4: Visible-light activated unsaturated cyclic α-diketone reported by Liao and
co-workers104
The strategy of incorporating a chromophore into organic-based photoCORMs has
also been utilized by Klán and co-workers, who reported a series of meso-carboxy
BODIPY (COR-BDP) derived compounds (46, Figure 38).105 Previous studies of the
frontier orbitals of various chromophores identified the boron-dipyrromethene (BODIPY)
molecule as being suitable for visible light driven CO release.106 The reported compounds
are soluble in aqueous solutions and exhibit no cytotoxicity. The absorption maxima
(where R1 = H and R2 = Me) lies at 502 nm with complete decomposition of the
molecule following illumination at 500 nm. By comparison, the COR-BDP molecule
bearing the 3,5-distyryl groups caused a bathochromical shift in the absorption spectrum
to 652 nm, which trailed to approximately 750 nm. This red shift is consistent with the
addition of further pi-conjugation into the chromophore structure. Both compounds
released CO in a controllable manner, with liberation of CO ceasing once irradiation
was halted.
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Figure 38: Visible to near-IR activated meso-carboxy BODIPY (COR-BDP) derived
compounds reported by Klán and co-workers105
1.7 Design Principles for the Ideal (Photo)CORM
The development of metal carbonyl complexes to act as CORMs is extremely challenging.
Just like any other pharmaceutical drug, CORMs must adhere to a stringent set of
requirements. Far removed from the traditional settings of dried organic solvents
and oxygen-free conditions, CORMs should exhibit stability and solubility in aerobic
aqueous media. Crucially, the ideal CORM would satisfy the appropriate pharmaceutical
characteristics (ADME: administration, distribution, metabolism, excretion). The
administrated CORM must remain intact in the circulation system and only become
active once the targeted tissues have been reached. Liberation of CO must be tightly
controlled, with subsequent intermediate breakdown products exhibiting a non-toxic
response before being efficiently excreted.
The challenge for synthetic chemists is to incorporate intelligent and rational design
principles into the CORM ‘drug sphere’ in order to generate complexes with the
appropriate pharmaceutical properties. Metal-based CORM design can be broken down
into three fundamental levels; the transition metal, the coordination sphere and the drug
sphere (Figure 39). Although CORMs are not restricted to being transition metal based,
for metal-based CORMs the choice of which metal to utilize is critical. The majority of
metal carbonyl complexes employ metals from groups 6, 7 and 8 (Cr, Mo, Mn, Re, Fe
and Ru) due to their tendency to form stable 18-electron complexes. Metals from groups
3, 4 and 5 (Sc, Ti and V triads) are generally avoided due to their oxygen sensitivity,
so too are metal from groups 9 and 10, which are characterised by electronically
unsaturated 16-electron complexes. Surveying the literature, the most popular choice of
transition metal include manganese, iron and ruthenium. Mn(I) carbonyl complexes are
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generally oxidatively stable and are able to incorporate a wide variety of ancillary ligands.
However, concerns have been raised regarding manganese flux across the blood-brain
barrier causing neurotoxicity.107 Iron is readily used in organisms, and although excess
iron can be damaging, Fe-based CORMs offer a promising platform for the development
of CORMs. So too does ruthenium, which has already been incorporated into leading
CORMs such as CORM-3.
Careful consideration of the ancillary ligands in the CORM coordination sphere means
pharmacological parameters such as water-solubility, biocompatability, biodistrubution
and breakdown product profile can be meticulous tuned in the drug sphere. Of course,
the coordination sphere must contain at least one M CO bond. Reactivity of which can
be influenced not only by the nature of the metal centre, but also by the ancillary ligands
present. The composition of the coordination sphere will represent the fundamental
properties exhibited by the CORM, namely responding to trigger mechanisms to
release CO, accelerating CO substitution or providing stability following CO release.
Coordinating ancillary ligands/biomolecules harbouring desirable functionality at their
distal sites allows for the development of a drug sphere which adheres to the appropriate
ADME and targeting behaviours.
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Figure 39: Depiction of CORM drug sphere, where L1 harbours a targeting vector
controlling biodistrubution, L2 bears a CO-release probe, L3, L4 and L5
represent CO, halide or co-ligand and L6 imparts water solubility
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1.8 Direction of Research
The field of carbon monoxide releasing molecules is still in its infancy. With the
enormous variety of transition metal carbonyl complex possible, the field is rapidly
expanding with novel CORMs being reported each year. Of particular interest is the
development of photoactivated CORMs (photoCORMs) which offer advanced spatial
and temporal control over CO release. While the mechanism of light-induced CO release
is well established, activation via damaging UV irradiation still dominate the literature.
Development of visible-to-near IR activated CORMs offer maximal tissue penetration
and minimal irradiation damage to tissue.
Taking inspiration from the [Fe]-hydrogenase active site,108,109 we have identified a
family of group 8 carbonyl complexes with the potential to act as photoCORMs. These
complexes comprise of a unique 5-membered ferracyclic ring, featuring a low spin Fe(II)
metal centre harbouring two cis-CO ligands, with a potential third CO functionality
‘hidden’ in the carbamoyl metallocycle. We recognised that such a CO-rich metal centre
comprising a pyridyl chromaphore could provide a platform on which to build accessible
photoCORMs activated by visible light. Not only does the pyridyl ligand offer flexible
functionality modification, but also the possibility to extend the chromaphore pi-system
to shift the absorption band of the complex. Substitution of a halide ligand for thiolated
saccharide molecules results in the formation of water-soluble dimeric species which
are also visible light activated. Analogous ruthenium carbonyl complexes are also
reported and the synthesis of florescence derivatized chromophores are investigated.
PhotoCORM behaviour is assessed using IR spectroscopy and the myoglobin assay.
Beyond chemical synthesis, in vitro studies into the anti-inflammatory properties of
these novel iron-based complexes have been carried out on THP-1 cells administrated
with the endotoxin, lipopolysaccharides (LPS).
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Assessing CORM Activity
2.1 Detection of CO release
The clinical development of leading CORMs require precise quantification of their
CO release capabilities. Analytical methods can be employed to fully define the
fundamental CO release properties for a given CORM, providing data verifying important
parameters including molar equivalents of CO released per mole of active CORM, rate
and mechanism of CO release and identification of potential intermediate species.
However, monitoring a compounds CO release is not always straightforward as a large
number of variables need to be tightly controlled. For instance, factors such as assay
solution, temperature and presence of potential activators such as oxygen, light or
assay-dependent molecules can all impact CO release behaviour and thereby results in
unreliable data. In this section, the analytical techniques used to monitor CO release
are discussed.
2.1.1 Infra-Red Spectroscopy
Perhaps the most obvious and easily accessible technique available to follow CO release
is infra-red (IR) spectroscopy. Signature vibrational bands for metal-bound carbonyls
typically appear in the 1800–2100 cm−1 region. The exact position of each band
depends on the extent of backbonding exhibited by the metal d orbitals towards each
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carbonyl ligand present: increased electron density into the pi* orbital of the carbon
atom strengthens the M C bond whilst weakening the carbon-oxygen bond, which
corresponds to a lowering of the wavenumber (energy) at which the carbonyl bond
vibrates (as seen in the IR spectrum). It is on this basis that ligation influences
of other ligands within the drug sphere can be assessed. Monitoring CO release is
straightforward: the intensity of the carbonyl vibration decreases following a trigger
stimuli. However, this method is limited to behaviour exhibited in pure organic solvents
or deuterium oxide (D2O), as transmittance in aqueous solution is poor.
IR spectroscopy is a powerful tool when it comes to identifying intermediate (iCORM)
species. New vibrational bands which appear at a similar rate to the disappearance
of the carbonyl band(s) is indicative of the formation of an intermediate species. A
particularly helpful insight is whether or not the ligand architecture of the active
CORM detaches from the metal centre following CO liberation. This is of fundamental
importance as the freed ligand could have profound biological implications in vitro and
in vivo. It should also be noted that gaseous by-products dissolved in solution can be
detected and quantified.
One advantage of monitoring CO release via IR spectroscopy is the procedure requires
no technique-dependent species which would influence CORM activity. Indeed, the CO
release capability of the diiron complex reported by Liu and co-workers could not be
analysed by the traditional myoglobin assay (section 2.1.3) as the reducing agent present
influenced CO liberation.69 Therefore a combination strategy was employed, where IR
monitoring of the solution every 10 minutes was correlated with the spectral decay
observed via UV/Vis spectroscopy. IR monitoring can also be employed for substances
requiring light activation. Depending on the time scale of the reaction, activity can be
monitored on an interval time frame using solution aliquots. Alternatively, an IR probe
can be incorporated into the set-up design, and time-resolved CO loss can be measured
in situ by directly irradiating the solution cell.
Furthermore, IR spectroscopy is not limited to solution-based analysis. Gas phase
IR spectroscopy takes measurements from the head-space above the solution where
the intensity of gaseous CO can be recorded. To quantify the amount of CO in the
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head-space, a calibration curve is obtained using known CO quantities.
2.1.2 UV/Vis Spectroscopy
UV/Vis spectroscopy provides an insight to the types of electronic transitions taking
place. This is particularly helpful for the practical application of photoCORMs, as
it allows for the refinement of the irradiation wavelength used to trigger CO release.
Furthermore, liberation of CO is often accompanied by distinct spectral changes as
an intermediate (iCORM) species forms. Combining this detection method with
IR spectroscopy could provide mechanistic information such as whether the ligand
architecture has altered, or detached from the transition metal centre. Moreover,
addition of a CORM to an aqueous, aerobic environment could fundamentally alter
its CO release profile. This was the case for the diketone photoCORM developed
by Liao and co-workers, where the active species underwent a hydration reaction in
the presence of water.104 UV/Vis spectroscopy revealed this hydrated species did not
possess the absorption transition responsible for visible light triggered CO liberation.
UV/Vis spectroscopy is also a useful means to investigated CO loss from an aerobic
aqueous solution. Ford and co-workers reported a trianionic tunsten photoCORM
capable of releasing CO in aerated media.78 The photo-induced liberation of CO was
characterised by an increase in the absorption spectrum at 410 nm. Interestingly, the
complex underwent a ‘back reaction’ (in a CO atmosphere) in which the observed
spectral changes reversed, yielding a final spectrum similar to that of the initial
photoCORM.
2.1.3 Myoglobin Assay
The most widely used detection method of CO release is the myoglobin (Mb) assay.
This method relies on UV/Vis-spectroscopic changes as the newly liberated CO converts
dexoymyoglobin (deoxy-Mb) to carboxymyoglobin (MbCO). The UV/Vis spectroscopy
profile of deoxy-Mb is an intense, single-hump band at 557 nm, which shifts to the
double-hump profile of MbCO, with peaks at 540 nm and 577 nm (Figure 40). The
48
CHAPTER 2. ASSESSING CORM ACTIVITY
assay is conducted in a phosphate buffer saline (PBS) solution at physiological pH 7.4
and a temperature of 37 ◦C.
500 520 540 560 580 600
510
585
550
570
λ/nm
Figure 40: An example spectra of the conversion of deoxy-Mb (blue) to MbCO (red)
elicited via CORM activity (MbCOmax in black, isosbestic points labelled)
For this experiment to be valid, the amount of deoxy-Mb present in the assay must
exceed the potential CO release capabilities of the CORM in order to prevent premature
saturation of the deoxy-Mb solution. Once the spectral changes have plateaued, the
amount of CO released can be determined. The solution is then saturated with gaseous
CO to give the total MbCO (MbCOmax) reading.
Although the myoglobin assay represents the principle method for reporting CORM
behaviour, the assay suffers from a number of issues.82 Firstly, the myoglobin solution
is only stable for a short period of time, so fresh solutions must be prepared prior to
each experiment. Furthermore, the assay must be completed under an inert atmosphere
to prevent the formation of oxymyoglobin. This limitation is particularly pronounced
for CORMs which require oxidation to fully complete CO liberation, as is the case of
the ET-CORMs reported by Schmalz and co-workers.65,66 In fact, the assay requires
an excess of reducing agent, sodium dithionite, to convert the myoglobin to the CO-
scavenging deoxy-Mb. The CO release capability of the diiron CORM developed by Liu
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and co-workers was shown to be influenced by this reducing agent, therefore a reliable
profile of CO release could not be obtained via the Mb assay.69 More recently, evidence
has immersed to suggest CO release from CORM-2 and CORM-3 (5 and 6, respectively,
Figure 8) is modulated in the presence of sodium dithionite.110 In fact, no liberation of
CO was detected from either complex using CO electrodes (Section 2.1.6), presumably
due to the lack of sodium dithionite.42
Additionally, the source of reducing agent is important, as commercially available dith-
ionite is often not pure enough for such experiments. Turbidity, which is especially likely
in CORMs incorporating macromolecules, can effect the accuracy of the data collected.
Another factor to consider is the UV/Vis absorption profile of the CORM itself. This is
particularly relevant for highly coloured metal complexes (often photoCORMs) which
exhibit absorbance bands which overlap with the absorption bands of the myoglobin.
Species with strong bands in the 500–600 nm region are likely to affect the spectra.
However, one can get around this issue by using internal reference points known as
isosbestic points. Isosbestic points are points in a spectra where two interconverting
species (deoxyMb MbCO) overlap. They act as an internal references because
the points are constant and unchanging throughout the conversion. Therefore any
deviation from the isobestic points can be corrected for. The myoglobin assay contains
four isobestic points at 510, 550, 570 and 585 nm. Typically data treatments ensure the
spectra intersect at isosbestic point 510 nm, which could possibly lead to non-aligned
spectra at the remaining isosbestic points.
The amount of MbCO formed via CORM activity is based on the assumption that 0 %
MbCO is present in the deoxyMb spectra. Therefore the absorption reading at 540 nm
at this point represents 0µm MbCO. Before calculating the amount of MbCO formed
during the assay, the total amount of MbCO formed following gaseous CO saturation
(MbCOmax) is calculated (Equation 1, 540 = 15.4 mm−1 cm−1).
MbCOmax =
OD540
540
× 1000 (1)
Using the MbCOmax value, a new extinction coefficient (2) value can be calculated
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(Equation 2) in order to account for the growing absorbance at 540 nm (∆OD540). For
this calculation, the isobestic point at 510 nm is traditional employed (ODISO-510).
2 =
∆OD540 −∆ODISO-510 × 1000
MbCOmax
 (2)
Using the newly calculated 2, the concentration of MbCO converted from deoxyMb
via CORM CO release can be determined (Equation 3).
MbCO =
∆OD540 −∆ODISO-510
2
× 1000 (3)
The myoglobin assays allows a rate of MbCO formation to be determined, which offers
a means to quantify the rate of CO released from the active CORM species. However,
one must be careful when deriving kinetic parameters by this method. The majority
of reported CORMs possess more than one labile CO ligand. This adds a degree of
complexity to calculating rate constants: each intermediate will have its own kinetic
profile, which would ideally be determined independently.82
2.1.4 Gas Chromatography
Gas chromatography represents a method of quantifying the amount of gaseous sub-
stances in a head-space of a particular volume. This strategy can be applied to monitor
the amount of CO released from a CORM. This detection method is independent of
solvent used, presenting an opportunity to monitor CO release from an aerobic aqueous
environment (due to the poor solubility of CO in water). Of course, solution factors
such as pH and presence of biological species (e.g. amino acids in media) could influence
CO release.
2.1.5 Florescent Probe
Detection of small signalling molecules including NO and H2S has been achieved via
the use of florescent probes.111,112 Chang et al. developed a florescent probe featuring a
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borondipyrromethene difluoride (BODIPY) core for the detection of CO.113 This first
generation carbon monoxide probe (COP-1, Figure 41) comprises a palladium(0) motif,
which quenches the compounds fluorescences. In a highly selective reaction involving
only CO (other biologically relevant signalling molecules such as NO and H2S eliciting
no reaction), COP-1 exhibits a ‘turn on’ fluorescence at 503 nm following coordination of
CO with liberation of palladium(0).114 In vitro studies have shown that cells incubated
with COP-1 displayed increased fluorescence following CORM administration compared
to cells without. Furthermore, cell viability studies revealed the compound elicits no
cytotoxicity issues.
As the fluorescence of COP-1 is triggered specifically by CO, it offers a unique platform
to monitor the cellular uptake and biodistribution of a given CORM. Schatzschneider
and co-workers successfully employed COP-1 to access the CO release capability of an
Mn(CO)3-based photoCORM.115 Incubation of the photoCORM with COP-1 in the
dark resulted in only very weak fluorescence, whilst strong fluorescence was observed
following irradiation at 365 nm. However, the florescence of the supernatant fraction
appeared to be much stronger than the fluorescence of the cell-containing fraction.
This demonstrated that the majority of the active CORM remained in the supernatant
fraction at the time of irradiation, illustrating the complexes poor cellular uptake
behaviour.
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Figure 41: ‘Turn-on’ fluorescence exhibited by COP-1 upon reaction with CO
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2.1.6 Electrodes
Electrodes have been utilized for the detection of signalling molecules, CO and NO.
One particular dual electrode system to mention is the two platinum microelectrode
system featuring an Ag/AgCl reference electron, all coated with an PTFE gas permeable
membrane. One of the platinum microelectrodes (250µm in diameter) is plated with tin.
The second platinum disk is much smaller at 25 µm in diameter. Surface modification as
well as size alterations between these two sensing disks results in an apparently separate
sensitivity ratios of NO and CO at each microelectrode. Indeed, CO oxidation occurs
more favourably at the tin-coated electrode than the platinum electrode. By employing
a calibration curves, simultaneous detection of CO and NO from either electrode allow
for the concentration of CO and NO to be determined.114,116
2.2 PhotoCORM Considerations
2.2.1 Quantum Yield
For a reaction to be classified as being photochemical, it must adhere to two fundamental
photochemical laws: the Grotthuss–Draper law states a photochemical reaction can
only take place following light absorption,117 and the Stark–Einstein law states one
photon will only activate one molecule for a subsequent reaction.118 This is known as the
‘photoequivalence law’. The quantum yield (Φ) of a reaction is a unitless measurement
of the efficiency of a photochemical process. By definition, quantum yield is the number
of moles of product produced per mole of monochromatic light absorbed (Equation 4).
A photochemical process in which all molecules absorb all photons will have a quantum
yield near 1.0. The exception to this is photopolymerization, where the moles of
activated monomers divided by the moles of photons absorbed is likely to exceed 1.0.
Deactivation of the excited state via a non-radiative return pathway (transitions without
photon emission), rather than through fluorescence processes will lower the quantum
yield measurement.
Φ = moles of product producedmoles of photons absorbed (4)
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Typically, the quantum yield is measured at a specific wavelength of irradiation. Meas-
urements obtained from broadband light sources will be less precise. One disadvantage
of quantum yield measurements is that they provide no insight into why a photochemical
process is efficient. Furthermore, the quantum yield value of a molecule is dependent on
any competing processes occurring. Therefore the fluorescence (and therefore quantum
yield value) of a molecule can be limited by these competing processes despite the
photochemical reaction efficiency being high.
2.2.2 Release Kinetics
The half-life, t1/2, of an drug can be defined as the time it takes for the active species to
lose half of its activity. The half-life is a constant and implies an exponential decay with
an intrinsic rate can be applied to the photochemical reaction, regardless of conditions.
However, this is not the case. There is no intrinsic rate constant (nor half-life) associated
with the photoliberation of CO. Moreover, the rate at which a CORM releases CO is
directly dependent on the experimental or biological environment in which the rate
is being measured, with absorbance of the solution being a critical parameter. The
latter will of course depend on the nature and concentration of the species in solution,
in particular any daughter products of initial CO release. For example, the kinetics
associated with the photochemical dissociation of CO from the photoCORM is likely
to be unique for that species, and each photoactive intermediate species would have a
separate kinetic profile. Quantum yield is therefore the preferred measure for comparing
the photochemical activation of photoCORMs.
2.3 In Vitro Activity Studies
Beyond quantifying CO release, the clinical development of CORM systems relies on
building a pharmacokinetic profile for the active species by collecting data from a number
of in vitro and in vivo biological studies. To date, the majority of reported CORMs lack
the prerequisites required for clinical development: display low toxicity pre- and post CO
release, have predictable biodistribution, exhibit a known therapeutic action and adhere
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to suitable ADME behaviour (which requires stability and solubility in aerobic aqueous
media). A pharmacokinetic profile for a given CORM may include biodistribution
studies,119 cell viability studies,84,93 cytoprotection assays83,95 and anti-inflammatory
assays.60
2.3.1 Cytotoxicity
Traditionally, the primary in vitro biological study preformed measures the cytotoxicity
profile of the CORM system. This information is essential, as further therapeutic
studies would be redundant if the complex displays unsatisfactory toxicity. Furthermore,
metal-containing CORMs often form intermediate species following CO release, which
could produce toxicity issues.
Cell viability can be studied using a number of assays, the most common of which
is the alamar blue assay120 and the MTS cell proliferation assay.121 Both represent
colourimetric sensitive assays for the quantification of viable (living) cells. The alamar
blue assay contains the active ingrediant resazurin (blue, non-fluorescent) which is
continuously reduced to resorufin (red, highly fluorescent) in cells. During the MTS cell
proliferation assay, viable cells within a cell culture are treated with a MTS tetrazolium
compound, which is reduced via NADPH-dependent dehydrogenase enzymes present
in metabolically active cells. The reduced tetrazolium compound forms a formazan
dye, which has an absorbance at 490–500 nm. In both assays, spectrophotometric
measurement of the formation of resorufin (in the alamar blue assay) and formazan dye
(in the MTS assay) act to quantify the number of viable cells present in each assay.
The above assays both respond to the cellular metabolism of viable cells. The lactate
dehydrogenase (LDH) assay122 differs from these by quantifying the number of dead
cells. LDH is a cytosolic enzyme present in viable cells. Following cell death, or
compound-induced death of a cell, the soluble LDH is released into the cell culture
media. Extracellular LDH catalyses the reduction of NADH to NAD+. LDH activity can
be measured via monitoring the absorbance peak for NADH at 340 nm. Alternatively,
the assay could contain a tetrazolium salt (similar to the MTS cells proliferation assay)
which is reduced by NADH to form the strongly coloured dye, formazan.
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2.3.2 Anti-Cancer
Treatment of epithelial cancers, including prostate and breast cancer are limited to
chemotherapies from compounds including taxol, doxorubicin and cis-platin. Contrary
to the cytoprotective actions mentioned in Section 2.3.1, CO has the ability to induce
apoptosis in cancer cells.9,123 Furthermore, administration of CO acts to sensitize
cancerous cells to chemotherapy whilst exhibiting a protective influence over normal
cells against chemotherapeutic toxicity. Furthermore, exposure to CO whilst undergoing
chemotherapy treatment (with either doxorubicin or camptothecin) enhances tumour
cell death compared to the effects of chemotherapy alone. Otterbein and co-workers
attributed this to a disruption of the metabolic state of the cancer cell via targeting
the mitrochondria and modulating its activity (noted by an increased production of
ROS and oxygen consumption), ultimately leading to mitochondrial collapse. By
decreasing the synthetic pathways of nucleotides and amino acids whilst increasing
oxidative metabolism, the cancer cell effectively becomes metabolically exhausted.
This intense mitochondrial oxidative stress results in the complete breakdown of the
cell-cycle and death of the tumour cell.124 Indeed, selective accumulation of CORMs
to tumour cells with targeted CO release offers a promising and novel anti-cancer
treatment. This is especially appealing for cancers which display resistance to traditional
chemotherapy treatment, and could also act to prevent the migration of cancer cells to
other organs.
Exogenously supplied CO (either in the form of gaseous CO or via CORM-2) has been
shown to inhibit pancreatic cancers via the suppression of the intracellular signalling
pathways including phosphatidylinositol-3 kinase (PI3K)/Akt, the downstream pathway
of which has been shown to contribute to cancer neovascularisation.125 Indeed, human
pancreatic cancer cell lines administrated with CORM-2 displayed inhibition of the akt
phosphorylation signalling pathway. To attribute this outcome to CO, proliferation of
pancreatic cancer cells exposed to CO-enriched synthetic air (500 ppm, 24 h) was shown
to be significantly reduced compared to cells exposed to air. Mice carrying human
pancreatic xenografts administrated with CORM-2 or gaseous CO (500 ppm, 24 h)
exhibited reduced tumour volumes, limited tumour neovascularisation and significantly
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enhanced survival rate compared to models administrated with the inactive, iCORM-2
control.126 The observed anti-cancer properties of CO seem to oppose the effects elicited
by NO. Indeed, inducible expression of nitric oxide synthase has been correlated with
microvessel density in human gastric cancer.127
2.3.3 Anti-inflammatory
One of the fundamental therapeutic actions of CO is the inhibition of pro-inflammatory
cytokines and the up-regulation of anti-inflammatory cytokines.5,28,30 Inflammation
can be readily induced following administration of endotoxin, lipopolysaccharides
(LPS). Hubbell and co-workers evaluated the anti-inflammatory activity of the micelle-
protected CORM-3 by monitoring the LPS-induced production of the pro-inflammatory
transcription factor, NF-κB.60 This was achieved via addition of LPS to a cell line
transfected with a reporter plasmid expressing a secreted embryonic alkaline phosphatase
(SEAP) gene. Expression of this gene is influenced by a promotor which responds
to NF-κB. NF-κB activation can therefore be correlated with the amount of secreted
SEAP. Indeed, addition of LPS caused the secretion of SEAP via NF-κB activation,
which was suppressed in the presence of the active CORM species.
Alternatively, inflammation can be monitored via the Enzyme Linked Immuno Sorbent
Assay (ELISA, Figure 42). Administration of LPS to macrophages promotes the
production of pro-inflammatory cytokine, TNF-α. The ELISA assay allowed the
concentration of TNF-α to be determined spectrophotometrically: The cell supernatants
(which contains the TNF-α) are added to wells coated with a TNF-α antibody, known
as the ‘capture antibody’, followed by the addition of an TNF-α antigen, which binds to
the immobilized antibody. Next, a biotinylated monoclonal antibody is added and binds
to the immobilized antibody. Addition of the enzyme, streptavidin-peroxidase binds
to the biotinylated antibody, which acts on a substrate solution to produce a coloured
product. The absorbance intensity is directly proportional to the concentration of TNF-
α, determined by plotting against a standard curve of known cytokine concentration.
In this thesis, the anti-inflammatory effects of the developed photoCORMs systems are
analysed via the ELISA assay.
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Figure 42: Representation of the 4-membered sandwich used in the ELISA assay
2.4 Summary
The development of CORMs from the Schlenk line to clinical applications requires an
analytical insight from a range of physical techniques. To ascertain the fundamental
CO release characteristics of a novel CORM, spectroscopic analysis (predominantly
IR spectroscopy) can be readily employed to yield a qualitative release profile. Once
CORM activity and trigger mechanism has been established, a quantitative evaluation
can be obtained via the myoglobin assay. The myoglobin assay represents the principle
analytical method for quantifying CO release. Although the assay exhibits a number
of pitifuls, the method remains relatively easy to reform, does not require uncommon
spectroscopic equipment, and results in the quantifiable description of a CORM CO
release capability. Progress in the field is becoming ever more dependent on the
development of reliable methods to study CORM behaviour in vitro and in vivo. The
progress of in vitro testing has been promising, with techniques assessing CORM toxicity
and gauging therapeutic activity in a measurable and compatible manner. In this thesis,
the quantitative assessment of photoCORM activity is achieved using the myoglobin
assay to verify CO release, in combination with the ELISA assay to authenticate
anti-inflammatory properties in a rounded evaluation of the developed systems.
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Group 8 Metallocyclic PhotoCORMs
3.1 Introduction
To date, the development of photoCORMs has predominantly focused on neutral and
cationic manganese(I) systems. In particular, the Mascharak group have reported a
number of visible light activated photoCORMs.98–101 These comprise of Mn(CO)3-cores
functionalised with bidentate ligands bearing nitrogen donors and an extended pi systems
(Section 1.6.5).
In his exploration of developing photoCORMs, Mascharak proposed certain design
principles to achieve photolabilisation of CO from low energy irradiation. This included
ligand architectures incorporating a heteroatomic extended conjugation system featuring
low-lying orbitals.89,100 The extended pi-system acts to shift the absorption maxima
of the complex in a bathochromic fashion. Ligands fostering low lying empty pi*
orbitals promote MLCT transitions, which are thought to be a predominate step in the
photodissociation of CO. Furthermore, Zobi and co-workers established substitution of
electron withdrawing groups onto the ligand framework decreases the HOMO–LUMO
gap, thereby facilitating MLCT transitions at lower energies.102
The development of photoCORMs based on manganese is perhaps not surprising as one
of the first complexes observed to release CO via photolysis was Mn2(CO)10 (4, Figure 8).
Indeed, the biological studies performed by Motterlini et al. advocated a promising
59
CHAPTER 3. GROUP 8 METALLOCYCLIC PHOTOCORMS
platform from which the field of Mn-based photoCORMs could advance.7 However,
despite being one of the most utilized transition metals, worries over manganese derived
neurotoxicity persist.107
It is reasonable to propose that CORMs featuring transition metals which occur naturally
in biology possess an edge over those that do not. For instance, iron is essential in
the biology for the majority of life on earth. In the human body iron governs the
uptake of oxygen in red blood cells as part of the haemoglobin molecule. Not only this,
iron is implicated in an array of highly complex processes such as the production of
metalloproteins, development of the immune system and is essential for the cognitive
development of children. Furthermore, the body has evolved sophisticated mechanisms
to excrete iron and maintain a non-toxic, homoeostatic quantity. In the event the levels
of iron in the body fall below the homoeostatic threshold, the body recovers by reducing
the production of haemoglobin. However, it should be stated that an excess of iron can
be dangerous. For example, ROS are readily generated via Fenton chemistry.128
The venture of iron-based CORMs began with the photoactivation of Fe(CO)5 (3,
Figure 8) reported by Motterlini et al.7 However, this simple carbonyl exhibited poor
water solubility and high toxicity. Westerhausen and co-workers reported a water
soluble iron-based photoCORM harbouring two cysteamine ligands (29, Figure 28).
The complex released CO following irradiation of visible light (470 nm).91 Unfortunately,
further chemical enhancements to the complex were limited due to the fact the drugs
sphere bears no organic chromophore to modify. Kodanko and co-workers reported
the water soluble dicationic photoCORM 21 (Figure 20).83 Photo-dissociation of CO
was achieved via irradiation with UV light (365 nm). However, the complex displayed
worrying cytotoxicity (at 10 µm) following CO release due to the ability of Fe(N4Py)2+
to inhibit cellular growth. The photoCORM was further modified via the incorporation
of a short peptide. This could govern the complex tissue delivery, and offers a potential
opportunity to induce cellular death through a combination of CO and Fe(N4Py)2+
release. This type of selectivity and toxicity would be desirable for cancer treatments.
Moving away from photo-induced CO release, Liu and co-workers reported the diiron
hexacarbonyl complex, 12 (Figure 14) which released CO following substitution with
cysteamine.69 Unlike Fe(CO)5, the diiron complex bears two thioglycol ligands fostering
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four hydroxyl groups which renders the complex completely water soluble. Co-drug
assisted release of CO resulted in the formation of a monoiron species which was shown
to release further quantities of CO via oxidation.
Biocompatability issues could also be minimised by designing CORMs based on naturally
occurring complexes. The [Fe]-hydrogenase enzyme harbours an active site which
consists of two cis carbonyl groups and a chelating pyridine-acyl ligand architecture.
The natural system is thought to coordinate to a protein-bound sulfur, whilst the
identify of the sixth ligand remains unclear, although it is thought to be solvent
(47, Figure 43).129 Isolation of the active site was only possible in conditions of low
light, which point to a potentially exploitable platform for photoCORM development.
Previous work in our group reproduced a synthetic model of this active site (Y1Fe,
Figure 43).108,109 This synthetic analogue features a low spin Fe(II) metal centre, bears
cis carbonyl groups and surrogates a pyridine-carbamoyl ring instead of an pyridine-
acyl ring. Furthermore, the complex incorporates an bromide ligand (instead of a
sulfur) trans to one of the CO ligands. This is advantageous: Mascharak demonstrated
complexes fostering halide ligands displayed a red shift in absorption compared to
complexes bearing other ligands.98 Moreover, the bromide provides a platform to further
modify the complex via substitution reactions involving thiolates. The sixth ligand
comprises a labile solvent molecule, which can be reversibly replaced by CO under a
CO atmosphere.
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Figure 43: 47: Fe-hydrogenase enzyme active site (X = solvent, Cys = Cysteine). Y1Fe:
Synthetic analogue. Y2Fe: Modified photoCORM
This iron-based complex adopts all the prerequisite design principles for photoCORM
development: the pyridyl ligand provides a chromophore for light absorption which
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could be extended or chemically modified. The coordination sphere contains a total of
three potentially labile CO equivalents: two metal-bound CO ligands and a third CO
functionality ‘hidden’ in the 5-membered ferracyclic ring. This chapter discusses the
synthesis, structure and photoCORM behaviour of Y1Fe. Building on this, we increased
the conjugation of the ligand architecture to yield Y2Fe and probe the influence on
CO release. In addition, the chemistry of ruthenium analogues complexes is discussed,
including a comparison between the choice of metals (Fe vs Ru) and its impact of visible
light-induced CO labilisation.
3.2 Synthesis of Ferracyclic Complexes
The initial synthesis of Y1Fe was reported by Turrell et al. in 2010.108 Insight into
the formation of this carbonyl complex revealed the intermediate salt comprised a
cationic protonated 2-aminopyridine fraction and a ferracyclic dibromo anion fraction
(X1Fe).109 Therefore we adapted the literature procedure by adding two equivalents
of 2-aminopyridine (Scheme 5). This not only improved the reliability of the reaction,
but also drove the equilibrium towards the formation of the precipitate product, which
resulted in a slightly improved yield of Y1Fe (51 % vs 46 %). This chemistry was
extended via the reaction of Fe(CO)4Br2 with 1-aminoisoquinoline at −40 ◦C to yield
X2Fe and Y2Fe.
[Fe(CO)4Br2] N
Fe
HN
CO
Br
CO
BrO
NH2N
CH2Cl2
NH2N
N
Fe
HN
CO
NCMe
CO
BrOH
MeCN
(2 eq)
X1Fe,  X2Fe Y1Fe,  Y2Fe
Scheme 5: Synthesis of charged intermediate species and neutral ferracyclic photo-
CORMs
The formation of Y1Fe and Y2Fe can be monitored via IR spectroscopy. The IR
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spectra for Y1Fe consists of three bands for a cis dicarbonyl at 2047 cm−1 and closely
positioned signals at 1995 and 1982 cm−1. The three carbonyl bands suggests the
presence of multiple geometric isomers in solution. Attenuated total reflection (ATR)
IR is consistent with a cis dicarbonyl geometry (1984 and 2046 cm−1). Formation of
the five-membered carbomoyl ring is observed with peaks at 1666 and 1621 cm−1. The
solvent molecule is only weakly coordinating, and is reversibly replaced with CO whilst
under a CO atmosphere.108
X-ray crystallography confirms the presence of the carbamoyl functionality, with the two
carbonyl ligands retaining a cis geometry: one carbonyl being trans to the chromophore
nitrogen and the other located trans to the bromide ligand. The carbamoyl CO bond
length (1.227(5)Å in Y2Fe·MeCN) is significantly longer than the carbonyl ligands
(1.127(2)Å and 1.130(5)Å in Y2Fe·MeCN), suggesting the carbamoyl CO bond is
predominately double bond in character whereas the two carbonyls are of triple bond
character.
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Figure 44: ORTEP representation of Y1Fe·MeCN (left) and Y2Fe·MeCN (right)
showing 50 % ellipsoids; non-coordinated MeCN and hydrogen atoms except
for H(2) have been omitted for clarity
In DMSO, Y1Fe exhibits a broad MLCT absorption band centred at 260 nm with a
pronounced tail trailing into the visible region near 500 nm, giving the complex a yellow
appearance. Comparison of the λmax value of Y2Fe reveals a similar profile with a
significant additional absorbance band at 335 nm due to the additional conjugation
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system of the aminopyradyl framework (Figure 45). The extinction coefficient of these
two complexes in the visible region report at 1500–2000m−1 cm−1.
A comparison of the electronic absorbance profiles for the neutral complexes and
charged intermediate species are also shown in Figure 45. The structures of the charged
X1Fe and X2Fe species are shown in Scheme 5. In both cases, the iron centre has an
octahedral geometry with cis carbonyl ligands. The sixth ligand consists of a bromide
ligand, which is replaced by solvent to give the corresponding neutral complex. The
electronic absorption spectra of the charged species displays a hypsochromic shift with
a less-predominant tail in the visible region compared to the neutral species.
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Figure 45: Comparison of the electronic absorption spectra of Y1Fe with X1Fe (left)
and Y2Fe with X2Fe (Right) in DMSO
A number of important parameters must be considered when designing the ligand
architecture. First, despite the red shift influence on absorptivity elicited via an
extended conjugation system, the subsequent increase in hydrophobicity of the complex
results in aqueous solubility issues. Second, to ensure adequate cellular uptake, the
developed CORM should not exceed a molecular size of 500–600 g mol−1. These two
factors ultimately limit the size of the conjugation systems.
An alternative strategy is the addition of heteroatoms onto the conjugation system to
further modulate absorption. To this effect we employed 2-aminopyrimidine, which
harbours a N-donor atom within the ring system. Unfortunately, only the intermediate
salt product (X3Fe, Figure 46) was isolable, with IR evidence of the neutral species
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in solution (2055, 2004, 1992, 1981, 1668 and 1617 cm−1). Similarly, we incorporated
an additional amine functional group ( NH2) onto the ligand architecture in order to
examine any shifts in the absorption spectrum. Addition of 2,6-diaminopyridine to
Fe(CO)4Br2 resulted in the precipitation of a yellow solid (X4Fe, Figure 46). Dissolution
in acetonitrile yielded an IR profile with the expected characteristic peaks (2056, 2000,
1655 and 1640 cm−1). However, characterisation of the neutral species beyond IR was
not unsuccessful.
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Figure 46: Structure of intermediate anionic complexes, X3Fe and X4Fe
Figure 47 shows the profound difference in the absorption spectra for X3Fe and X4Fe
in DMSO. Addition of an amine functional group onto the ligand framework results in a
substantial red shift of the MLCT band compared to ligand systems which incorporate
an N-donor atom into the conjugation system. Anionic product X4Fe exhibits strong
MLCT bands at 259 nm and 340 nm, the latter of which trails into the visible region.
Compare this to X3Fe, which displays absorptivity only in the UV-region (299 nm).
A non-negligible absorbance is observed trailing into the visible, although the molar
extinction coefficient value in this region is minimal.
Interrogation of the UV/Vis spectra for the intermediate salt substituents reveal a
hypsochromic shift of the MLCT band compared to that of the neutral complexes. Fur-
thermore, the intermediate species may participate in stronger backbonding to the CO
ligands, perhaps as a consequence of the anionic charge. For these reasons, we decided
to focus our efforts on the development of the neutral complexes as photoCORMs.
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Figure 47: Electronic absorption spectra of X3Fe (black) and X4Fe (red)
3.3 Quantification of CO Release Behaviour
3.3.1 IR Spectroscopy
The primary method employed to establish photo-induced release of CO from Y1Fe was
IR spectroscopy. A solution of Y1Fe shielded from light is stable for extended periods
of time. Complex Y1Fe exhibits three strong bands for a cis dicarbonyl at 2047 cm−1
and close signals at 1995 and 1982 cm−1, which is indicative of two isomers present in
solution. The carbomoyl stretch is seen at 1666 and 1621 cm−1. Photo-induced CO
release was achieved using a KL5125 fibre optic light source, which included a light
intensity/brightness control (‘low power’ 0.216 W and ‘high power’ 0.840 W). This
lamp produces a broadband of visible light. Steady progress of the photolysis of CO is
shown in Figure 48. A subtle shift is observed as the peak at 2047 cm−1 decreases to a
new wavenumber at 2042 cm−1. Notably, the two distinct peaks at 1995 and 1982 cm−1
merge into a single, averaged peak at 1989 cm−1 following CO release. This suggests
the presence of only one isomer in solution after initial CO loss. Figure 48 displays the
decrease in intensity of the carbonyl peak at 2047 cm−1 vs time.
With regards to Y2Fe, prior to illumination the IR spectra consisted of a distinct
carbonyl band at 2053 cm−1 with two carbonyl signals at 1999 and 1989 cm−1. The
carbamoyl bands are observed at 1662 and 1613 cm−1. Notably, the carbonyl vibrations
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Figure 48: Left: Infrared Spectra of Y1Fe during visible light (‘high power’) triggered
CO release in THF. Data ranges from 0 min (blue, prior to illumination) to
90 min (red), measured at intervals of 10 min. Right: Carbonyl intensity at
2047 cm−1 decrease over time of illumination
of Y2Fe are found at a higher wavenumber than the corresponding peaks of Y1Fe.
Replacement of pyridine for isoquinoline (with more conjugation in the ligand frame)
leads to reduced backbonding to the carbonyl ligands, which consequently weakens the
M CO bond and increases the labilisation of CO. Figure 49 shows CO release triggered
via visible light. Again, loss of CO is characterised with subtle shifts of the vibrational
bands.
Initial CO loss from Y1Fe and Y2Fe is accompanied with the appearance of a new
signals at 2098 and 2017 cm−1, which indicates the formation of a potential intermediate
species. The most obvious explanation is the coordination of a solvent ligand following
the sequential release of CO. However, this intermediate species is short lived, with
the signal intensity rapidly decreasing with subsequent CO release. Furthermore,
precipitation of an insoluble ‘iCORM’ product slowly appeared over the course of
the experiment. Attempts to characterise this by mass spectrometry did not yield
identifiable molecular ions.
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Figure 49: Left: Infrared Spectra of Y2Fe during visible light (‘high power’) triggered
CO release in THF. Data ranges from 0 min (blue, prior to illumination) to
40 min (red), measured at intervals of 10 min. Right: Carbonyl intensity at
2049 cm−1 decrease over time of illumination
3.3.2 Myoglobin Assay
Light-induced CO release from Y1Fe and Y2Fe has been investigated using the myo-
globin assay (Section 2.1.3). The assays were completed following irradiation with a
broadband visible light source. More specifically, the photoCORMs were irradiated at
‘low power’ (0.216 W) and ‘high power’ (0.840 W) visible light. Neither complex released
CO when kept in the dark in the presence of Mb and sodium dithionite. Despite the
extended conjugation system of Y2Fe, the CO release properties of each complex is
markedly similar under the same light conditions (50).
The CO release rates and quantum yield (Section 2.2.1) measurements are summarised
in Table 1. Figure 50 shows the formation of MbCO via photoCORM activity. Both
complexes yielded reproducible results which were verified at three different concen-
trations (10, 20 and 30µm) in independent experiments. The CO release capabilities
of each complexes is dependant on the intensity of light used. Irradiation of ‘low
power’ visible light (dashed lines) were markedly similar for both complexes which
correlates with the near identical quantum yield values obtained. The CO release
properties following illumination with ‘high power’ visible light (solid lines) establish
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Figure 50: Plot of the amount of MbCO formed via CO liberated from Y1Fe (30 µm,
left) and Y2Fe (30µm, right) (Dashed: ‘low power’ (0.216 W) irradiation,
Solid: ‘high power’ (0.840 W) irradiation)
the fundamental preference for employing ligand architectures harbouring larger con-
jugation systems. For instance, two equivalents of CO are liberated from Y2Fe after
80 minutes of illumination, whereas the same equivalents are release from Y1Fe after
120 minutes. Indeed, the apparent rate of CO release is significantly greater in Y2Fe.
This is reflected in the quantum yield measurements, where the light absorbed by Y2Fe
following intensity irradiation exceeded that of Y1Fe.
Table 1: Table showing rates of CO release and quantum yield for Y1Fe and Y2Fe
Complex Average Apparent Rate (µm/min) Quantum Yield
0.216 W 0.840 W 0.216 W 0.840 W
Irradiation Irradiation Irradiation Irradiation
×10−3 ×10−3 ×10−4 ×10−5
Y1Fe 7.7(10) 15.9(6) 1.54 1.39
Y2Fe 7.9(6) 23(4) 1.58 1.49
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3.4 Ruthenium Analogues
A survey of the literature shows ruthenium has been employed in a variety of CORM
systems, although predominately utilized in thermal CORMs. Motterlini et al. reported
the CO release capabilities of the ruthenium-based CORM-2 (5, Figure 8) in 2002.7
However, this complex suffered from poor solubility in aqueous media. Water solubility
was enhanced via the coordination of a glycinate ligand to the ruthenium metal centre,
yielding CORM-3 (6, Figure 8), which is probably the most well-known and widely tested
CORM to date. Despite this, clinical development of CORM-3 has been hindered over
concerns regarding purification and instability in water and human plasma. Moreover,
the complex is thought to undergo a water-gas shift reaction, in which CO is liberated
following attack by water to generate CO2.119
Hubbell and co-workers employed polymeric nanocarriers to capture the ruthenium
carbonyl core in an attempt to modulate the CO-delivery of CORM-3.60 The resulting
micellar-CORM (8, Figure 10) was shown to release CO at a slower rate compared
to the parent complex. Furthermore, CO release from the micelles was demonstrated
to alleviate inflammation in vitro and reduce the cytotoxicity effect elicited from the
Ru(CO)3Cl(amino acidate) moiety.
Enhancement of CO delivery through the chemical modification of CORM-3 was also
embarked upon by Bernardes and co-workers. Exploiting the chemical instability of the
ruthenium carbonyl, Bernardes reports the reaction of CORM-3 hydrolytic decompos-
ition products with proteins via a histidine residue.119 The resulting metalloproteins
displayed spontaneous CO release in aqueous media, and were shown to inhibit in-
flammatory cytokine production. Furthermore, incorporation of the protein albumin
exhibited biodistribution tendencies towards tumour cells in vivo.
In the field of photoCORMs, Schatzchneider and co-workers developed a number of
ruthenium(II) carbonyl complexes featuring polypyridyl ligand architectures (23–25,
Figure 22).85 These complexes exhibit strong MLCT transitions between 299–326 nm and
release CO in response to UV irradiation at 365 nm. Visible light activated ruthenium
photoCORMs were first reported by Mascharak in 2013.100 These complexes fostered
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ligand architectures featuring extending conjugation systems. This section discussion
the synthesis, structures and photoCORM properties of a series of stable Ru(II) carbonyl
complexes, namely Y1Ru, Y2Ru, Y4Ru and Y5Ru (Figure 51).
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Figure 51: Structures of analogous ruthenium carbonyl complexes
3.4.1 Synthesis of Ruthenium Complexes
Unlike Fe(CO)5, Ru(CO)5 is unstable and must be freshly prepared via the method
reported by Baird and co-workers.130 Photoillumination of Ru3(CO)12 (νCO 2061, 2032
and 2012 cm−1) using a UV-lamp under an atmosphere of CO readily yields a colourless
solution of Ru(CO)5 (νCO 2037 and 2002 cm−1). Cooling to −40 ◦C followed by drop-
wise addition of Br2 liquid results in the precipitation of Ru(CO)4Br2 as a yellow
solid.131
The synthetic pathways of the ruthenium complex is analogous to that of the iron
complexes: reaction of Ru(CO)4Br2 with 2-aminopyridine (2 Eq) in dried dichlorometh-
ane resulted the evolution of CO gas and rapid formation of a white precipitate. The
precipitate redissolved in the coordinating solvent, acetonitrile. However, owing to the
stronger metal–ligand bond strength exhibited by the ruthenium complexes, a halide
extracting agent (AgPF6) was required to isolate the neutral complex. Isolation of the
isoquinoline derivative followed an identical reaction pathway. Homogeneous X-ray
quality crystals were isolated upon cooling. Both complexes harbour the anticipated
five-membered metallocyclic ring featuring a carbamoyl functionality, cis carbonyl
ligands, one bromide and one solvent (MeCN) ligand (Figure 52).
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Figure 52: ORTEP representation of Y1Ru·MeCN (left) and Y2Ru·MeCN (right)
showing 50 % ellipsoids; non-coordinated MeCN and hydrogen atoms except
for H(2) have been omitted for clarity
Table 2 shows a comparison of the bond lengths of Y1Fe and Y1Ru. Bond lengths of
the ruthenium complex are typically around 0.1Å longer than for the iron structure.
The bond lengths of the carbamoyl functionality [1.229(3) Å] and [1.238(3) Å] in the
both complexes are longer than the metal bound carbonyl ligands (Y1Fe: [1.136(3) Å]
and [1.086(3) Å], Y1Ru: [1.136(3) Å] and [1.088(3) Å]). This suggests the carbamoyl
functionality is of double bond character whilst the metal bound carbonyl ligands are
triplets. Moreover, in both complexes, the carbonyl ligand trans to the bromide is
shorter than the carbonyl trans to the pyridinyl ligand.
Table 2: Comparison of metrical data for Y1Fe·MeCN and Y1Ru·MeCN
Bond distance/Å
Y1Fe·MeCN Y1Ru·MeCN
M Br 2.4632(5) 2.5613(3)
M C(6) 1.931(2) 2.012(2)
M C(7) 1.782(3) 1.884(3)
M C(8) 1.811(3) 1.909(3)
M N(1) 1.992(2) 2.112(2)
M N(3) 2.022(2) 2.187(2)
C(6) O(1) 1.229(3) 1.238(3)
C(7) O(2) 1.136(3) 1.136(3)
C(8) O(3) 1.086(3) 1.088(3)
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Initial investigations into the CO release capabilities of Y1Ru and Y2Ru focused on
monitoring the carbonyl vibrational peaks via IR spectroscopy in response to irradiation.
A solution of Y1Ru exhibits three strong carbonyl bands; one at 2061 cm−1 and two
closely positioned signals at 1998 and 1990 cm−1. Two carbamoyl peaks are observed
at 1671 and 1622 cm−1. With regards to Y2Ru, the IR profile consists of the same
characteristic peak pattern: three carbonyl peaks at 2061, 2000 and 1991 cm−1 and two
carbamoyl signals at 1667 and 1631 cm−1.
Comparison for the positions of the carbonyl vibrational bands of the iron and ruthenium
complexes reveal the latter reside at a much higher wavenumber (approximately 2047
vs 2061 cm−1). The strengthened carbon-oxygen bonds of the ruthenium carbonyls
suggest a weakened M C bond and increased labilisation of CO. Indeed, the larger 4d
molecular orbitals of the ruthenium metal centre participates in less efficient overlap
with the pi* orbital of the CO ligand, whereas the iron complexes participate in stronger
backdonation due to the more efficient overlap of the 3d molecular orbitals. This is
a distinct advantage of designing ruthenium-based CORMs over iron-based CORMs.
Unfortunately, examination of the UV/Vis spectrum for Y1Ru and Y2Ru reveal that
neither complex display absorbance bands in the visible region (Figure 54). Unsur-
prisingly, visible light triggered CO release experiments were unsuccessful. However,
monitoring the IR bands in response to UV-irradiation results in rapid loss of the
carbonyl bands. Since Y1Ru and Y2Ru do not release CO under irradiation of our
visible light source, we can be confident that the utilised KL5125 fibre optic lamp only
emits wavelengths in the visible region. This acts as a verification tool to authenticate
the activation of the iron based photoCORMs via visible light.
Incorporation of the isoquinoline ligand results in a significant red shift in absorbance,
as well as a greater molar extinction coefficient value compared to the less conjugated,
pyridine ligand. The enhanced stability and robustness of the ruthenium analogues lead
to the successful isolation of the neutral complex Y4Ru, for which only the charged iron
species could be obtained. As incorporation of heteroatoms into the pyridyl conjugation
system appeared to have little influence on the electronic absorption spectra, we
decided not to pursue this ligand architecture any further. Instead, we designed a
ligand framework which combined the extended conjugation system of the isoquinoline
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ligand with the presence of an additional amine substituent. Reaction of sodamide
with o-cyanobenzyl chloride resulted in a variety of aminoheteroaromatic substances
including 1-amino-3-formamidoisoquinoline (48). This was isolated through a series of
water washes, and refluxed with sodium hydroxide to yield 1,3-diaminoisoquinoline (49,
Scheme 6).132
CN
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N
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O N
NH2
NH2NaOH (2M)
EtOH, reflux
Multiple purifications
via water washes
48 49
Scheme 6: Scheme for the synthesis of ligand architecture, 1,3-diaminoisoquinoline132
The structures of Y4Ru andY5Ru were confirmed via X-ray crystallography (Figure 53).
Both complexes bear the characteristic five-membered metallocyclic ring, with bound cis
dicarbonyl ligands. However, the occupation of the sixth ligand (trans to the carbamoyl
linkage) of Y5Ru is unique: the bromide ligand occupies the sixth position, with the
solvent ligand trans to CO. Although the geometry of the complex would be dynamic
in solution, it is thought this distinctive geometry is a consequence of crystal packing.
Further to this, coordination of the ligand architecture differs from that observed for
Y2Fe and Y2Ru.
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Figure 53: ORTEP representation of Y4Ru (left) and Y5Ru·MeCN (right) showing
50 % ellipsoids; hydrogen atoms except for H(2) have been omitted for clarity
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The IR spectra for Y4Ru further confirmed the cis carbonyl geometry is maintained
(2066 and 2003 cm−1). This was also demonstrated in observing the IR spectra for
Y5Ru, with carbonyl signals at 2065 and 2003 cm−1. Although small, based on the
stretching frequencies there is a clear strengthening of the C O bond in Y4Ru and
Y5Ru compared to Y1Ru and Y2Ru. This could be a consequence of reduced back-
donation, implying that the NH2-substituted ligands are poorer electron donors to the
metal. The ability of the ligand to donate to the metal depends on the availability
of electron density in the pyridyl lone pair, and this may be reduced by the inductive
effect of the NH2-substituent.
Examination of the UV/Vis spectrum for Y4Ru showed incorporation of an additional
amino functional group onto the ligand architecture produced a marked increased in
the absorption band at 340 nm. The combination of the extended conjugation system
and presence of an additional donor functional group results in Y5Ru displaying an
absorption band in the visible region of the spectrum. Despite the notable absorbance
peak >400 nm, investigations via IR spectroscopy and myoglobin assay revealed no
liberation of CO following visible light irradiation.
250 300 350 400 450 500 550 600
0
5000
10 000
15 000
20 000
λ/nm
/
m
−1
cm
−1
Y1Ru
Y2Ru
Y4Ru
Y5Ru
Figure 54: Electronic absorption spectra of Y1Ru, Y2Ru, Y4Ru and Y5Ru in DMSO
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3.5 Summary
A synthetic route for the generation of metallocyclic carbonyls based on iron and
ruthenium has been established. Alterations of the ligand conjugation system modulates
the complexes absorption properties. Ligand architectures featuring an additional amine
substituent result in a strong MLCT absorbance shifted towards higher wavelengths.
Isolation of the corresponding anionic intermediate was successful, with IR evidence
of the neutral species in solution. Complexes Y1Fe and Y2Fe participate in visible
light triggered CO release, as demonstrated via IR monitoring and quantified via the
myoglobin assay. The corresponding ruthenium analogues act as UV-active photo-
CORMs. Modification of the ligand framework to incorporate amine substituents was
successful. Synthesis and coordination of new ligand 1,3-diaminoisoquinoline resulted
in a substantial bathochromic shift of the complexes absorption profile.
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Chapter 4
Group 8 Carbonyl Complexes Bearing
Thiolated Saccharides
4.1 Introduction
The generation of organometallic CORMs which satisfies the appropriate pharmaceutical
properties is extremely challenging. Indeed, organometallic carbonyl complexes are
typically reactive towards oxygen and moisture, and as such, are exclusively synthesised
in anaerobic conditions, employing dried solvents and inert atmospheric gases. Such
complexes would not survive aerobic media and are not suitable for biological applica-
tions. There are a small number of exceptions; radiopharmaceutical complexes of the
general formula [M(CO)3L3]+ (where M = 99mTc and Re) exhibit excellent air stability
and water solubility.133 Unfortunately, as none of these complexes release CO, little
information for CORM development can be obtained from them.
According to Motterlini and Otterbein, the clinical development of CO-releasing carbonyl
complexes is dependent on the complex demonstrating a number of pharmaceutical
characteristics. These include appropriate water solubility and stability, sufficient
biocompatibility, low toxicity pre- and post-CO release and rapid excretion of any
‘iCORM’ intermediates.123 Furthermore, the active species should exhibit sufficient
stability to allow administration of the drug (via pill, intravenous or topical application),
survive the circulation system and only become potent at the targeted tissues.
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Through the rational design of the drug sphere it is possible to transform simple carbonyl
complexes from their apparent bio-incompatible origins and develop systems suited
for biological applications. The coordination of specific ancillary ligands tailored to
impart desirable pharmacological properties can modulate traits such as water solubility,
toxicity and biocompatibility. Moreover, CORM conjugates can be developed via
linkages to frameworks including nanoparticles and polymeric cages.134 In terms of
complex stability, a ‘happy middle-ground’ must be found to, on the one hand, ensure
adequate administration and structural integrity in vivo, whilst still being susceptible
to triggered CO release.
Of course, a CORMs structural integrity and CO release behaviour should not change
in the presence of water. Ford and co-workers reported a trianionic tunsten carbonyl
complex (16, Figure 16) which exhibited a slow back reaction in the presence of water.
In this case, water induced CO release was detected via IR and UV/Vis spectroscopy.78
Liao and co-workers experienced similar issues in the development of a α-diketone
CORM (45, Scheme 4), which was deactivated following hydration of the carbonyl
functional groups in the presence of water. To overcome this, the CORM was encaptured
in a protective micelle.104
Water solubility can be conferred to hydrophobic complexes with the aid of nano-
carriers. Nano-carriers are constructed using amphiphilic polymers, where the CORM
is encaptured in a lipophilic interior and water solubility is achieved by a hydrophilic
exterior. This techniques was used by Zheng and Ford to encage a manganese carbonyl
photoCORM bearing two hydrophobic triphenylphosphine ligands. The nanoparticles
utilized here consisted of a up-converter component, which absorbed near-IR irradiation
and re-emitted visible irradiation that could be re-absorbed by the closely embedded
photoCORM.135
A survey of the literature revealed the first CORMs to demonstrate water solubility
include CORM-3 (6, Figure 8) and CORM-A1 (Section 1.6.6).103,136 The water solubility
of 6 is achieved via coordination of the biogenic glycine ligand to the ruthenium metal
centre. On the other hand, CORM-A1 is a sodium boranocarbonate species and does not
contain a transition metal centre. Both complexes contain a carboxylic acid functional
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group which is thought to impart water solubility. Indeed, functional groups which
particulate in hydrogen bonding increase the overall hydrophilicity of the complex.
Conversely, ligand architectures of predominately hydrocarbon character will increase
the complexes hydrophobicity. The strategy of employing biologically-compatible ligands
was also utilized by Liu and co-workers, who reported the diiron hexacarbonyl complex,
12 (Figure 14). Water solubility was achieved via the thioglycol linkages between the
two iron centres which harboured a total of four hydroxyl groups.69 Similarly, the diiron
system 32 (Figure 29) developed by Fan and co-workers employ two bridging linkages,
each consisting of a deprotonated carboxylic acid functional group which confer water
solubility.93
An attractive strategy to impart both biocompatibility and water solubility is the
incorporation of a sugar moiety onto the active CORM species. Sugars play a num-
ber of essential biological roles in the human body, including molecular recognition.
Furthermore, they naturally occur with varying repeating units (monosaccharides, oli-
gosaccharides and polysaccharides) all of which are rich in hydrophilic hydroxyl groups.
Utilizing sugar components could promote drug delivery to specific tissues, as well
as reduce toxicity and influence biodegradation.137 Lynam and co-workers reported
a photoCORM featuring fructopyranose 17, (Figure 17) which rendered the complex
water soluble. Despite being water soluble, the complex suffers from poor stability in
aqueous media, liberating CO at a slow rate in the absence of irradiation.79 Bogdanova
and co-workers developed two photoCORMs which incorporated a vitamin B12 scaffold.
Re-B12CORM (35, Figure 31) suffered from cellular uptake issues which was overcome
in Mn-B12CORM (36, Figure 31), where the carbonyl complex was attached to the
vitamin scaffold via a ribose sugar moiety. The tricarbonyl ruthenium CORM, ALF-492
(2, Figure 3) contains a galactose-derived ligand which significantly enhances the water
solubility and biocompatibility of the complex. Furthermore, the sugar moiety confers
preferential delivery to the liver by interacting with asialoglycoprotein receptors.48
The natural [Fe]-hydrogenase active site (47), which our metallocyclic carbonyl com-
plexes are based on, possesses a thiolate functional group in place of the halide (Fig-
ure 43). Previous work in our group has successfully demonstrated the substitution
of the halide for simple thiolates.108 Coordination of an aliphatic thiolate resulted in
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the generation of a dimeric species, in which the thiolate acts as the bridging linkage.
Monomeric species could be isolated by employing bulky aromatic thiols which prevent
dimerisation (Figure 55). Building on from the bio-inspired photoCORMs discussed in
Chapter 3, this chapter is concerned with enhancing the water solubility and biocom-
patibility of our complexes. The synthesis, structures and CO-release capabilities of
the iron and ruthenium metallocyclic complexes modified with thiolated saccharides is
discussed.
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Figure 55: Previously isolated monomeric and dimeric thiolated species108
4.2 Synthesis of Ferracyclic Complexes bearing Thi-
olated Saccharides
Naturally occurring substances have been shown to have beneficial influences on CORM
behaviour.61,119,133,134 One avenue for promoting biocompatibility and water solubility
is the coordination of saccharide molecules. Furthermore, carbohydrates can act as
biomarkers for molecular recognition, which could play a critical role in drug delivery.
An appropriate candidate is 1-thio-β-d-glucose, which could be reliably synthesised
following the procedure reported by Davis and co-workers (Scheme 7).138
The 1-thio-β-d-glucose could be coordinated to the iron metal centre via substitution of
the halide (Scheme 8). The reaction was completed in dry methanol and follows the same
pathway previously observed for simple thiolates.108 Introduction of the monosaccharide
was accompanied with new IR absorbances (in MeOH) at 2046, 2025 and 1977 cm−1 for
D1Fe and at 2048, 2025 and 1980 cm−1 for D2Fe. Mass spectral analysis produced hits
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Scheme 7: Synthesis of 1-thio-β-d-glucose138
corresponding to a dimeric structure. X-ray quality crystals of D2Fe were obtained
following slow evaporation of the solvent.
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Scheme 8: Synthesis of ferracyclic photoCORMs bearing thiolated saccharide ligands
As shown in Figure 56, two thioglucose molecules acts as bridging linkages between
the two metal centres. Clearly, the ring structure of the sugar is not sufficiently bulky
to prevent dimerisation. The thioglucose derivatives proved to be significantly more
soluble in aqueous media compared to the first generation complexes. D1Fe which bear
the smaller pyridyl ligand framework was shown to be completely soluble in water.
The presence of the extended aromatic system of D2Fe seemed to hinder total water
solubility, requiring small traces (2 %) of DMSO to achieve complete dissolution.
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Figure 56: ORTEP representation of D2Fe·2MeOH·1.5H2O showing 50 % ellipsoids;
solvent molecules and hydrogen atoms bound to carbon have been omitted
for clarity
The electronic absorbance profiles further demonstrate the dimeric nature of the new
complexes; the molar extinction coefficient values appear to be much greater than the
parent complexes. However, on a per metal basis, we find similar molar extinction
coefficients values. D1Fe exhibits a strong MLCT absorbance band at 303 nm which
(like the parent complexes) trails into the visible region of the spectrum. The extended
conjugation system of D2Fe generates MLCT absorption bands at 282 and 288 nm with
an additional absorbance at 337 nm which trails into the visible. Both complexes have
a yellow appearance. The molar extinction coefficients in the visible region appears to
be greater in the dimeric species (>2000m−1 cm−1) compared to the parent complexes
(1500–2000m−1 cm−1). All complexes are stable in DMSO in the absence of light.
However, these complexes break down with loss of CO when expose to visible light
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Figure 57: Comparison of the electronic absorption spectra of D1Fe (left) and D2Fe
(right) in DMSO
4.2.1 Quantification of CO Release
4.2.2 IR Spectroscopy
The IR profile for D1Fe contains carbonyl peaks at 2046, 2025 and 1977 cm−1. The
carbomoyl absorbance is observed at 1674 and 1622 cm−1. The extended conjugation
system of D2Fe gives rise to carbonyl stretches observed at approximately the same
wavenumbers: 2048, 2025, 1980, 1675 and 1622 cm−1. Photo-dissociation of each com-
plex was screened using a broadband visible light source operated at two different powers;
‘low power’ (0.216 W) and ‘high power’ (0.840 W). Figure 58 shows the contrasting
CO-release capability of D2Fe when exposed to each light intensity. Following ‘low
power’ irradiation, steady release of CO was observed over a time course of 60 min. CO
release behaviour was significantly enhanced following ‘high power’ irradiation, where
rapid CO loss was observed within the first 10 min.
Inspection of the dimeric species quantum yield values (Table ??) reveal an approximate
6 fold increase under ‘high power’ conditions compared to the first generation complexes.
This offers an explanation of the marked difference in CO release behaviour observed at
the two different light intensities.
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Figure 58: IR carbonyl intensity at 2037 cm−1 of D2Fe following visible light irradiation
at ‘low power’ (left) and ‘high power’ (right) in DMSO
Table 3: table showing rates of CO release and quantum yield for first generation
complexes Y1Fe and Y2Fe, and second generation D1Fe and D2Fe complexes
Complex Average Apparent Rate (µm/min) Quantum Yield
0.216 W 0.840 W 0.216 W 0.840 W
Irradiation Irradiation Irradiation Irradiation
×10−3 ×10−3 ×10−4 ×10−5
Y1Fe 7.7(10) 15.9(6) 1.54 1.39
Y2Fe 7.9(6) 23(4) 1.58 1.49
D1Fe 17.1(15) 107(6) 1.70 9.31
D2Fe 17.5(4) 111(4) 1.74 9.67
4.2.3 Myoglobin Assay
The CO release behaviour of the thioglucose derivatives was quantified using the
myoglobin assay. For these measurements, dissolution of D1Fe was achieved in pure
water whilst D2Fe required a H2O DMSO (49 : 1) mixture. Visible light-induced CO
release was monitored at ‘low power’ and ‘high power’. Figure 59 displays the marked
difference in response between these two light intensities.
For both complexes, steady liberation of CO is observed following ‘low power’ irradiation.
Increasing the light intensity rapidly accelerates photodissociation of CO. Furthermore,
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Figure 59: Plot of the amount of MbCO formed via CO liberated from D1Fe (30µm,
left) and D2Fe (30µm, right) (Dashed: 0.216 W irradiation Solid: 0.840 W
irradiation)
the assay suggests a change in mechanism: analysis of the myoglobin data of the
monomeric species reveal the rate of MbCO formation can be fitted using a single
exponential function, whereas the dimeric complexes require a two-term exponential
growth (Figure 60). This is indicative of a two-step process in which initial CO loss
occurs rapidly following irradiation of visible light, followed by slower release of a second
CO equivalent. This is suggestive of the formation of an intermediate species, and
possible breakage of the dimeric system following CO release. Unfortunately, we have
been unable to identify or isolate any such intermediates.
Surprisingly, assay data from D1Fe and D2Fe confirmed the release of only one CO
equivalent per metal centre. In contrast, both metal bound CO molecules are liberated
from the parent monomeric complexes, Y1Fe and Y2Fe. In order to understand this
contrasting difference in CO release capability, we employed density functional theory
(DFT). This allows for the prediction of spectroscopic properties from frontier orbital
energies extracted from structures with optimised geometries.
85
CHAPTER 4. THIOLATED SACCHARIDES
0 5 10 15 20
0
1
2
t/min
C
O
m
ol
ec
ul
es
/c
om
pl
ex
Y2Fe
D2Fe
0 80
0
2
Figure 60: Comparative plot of the amount of MbCO formed via CO liberated from
Y2Fe (30µm, black) and D2Fe (30 µm, red) following 0.840 W Irradiation.
Points: experimental data; Lines: exponential fits. Inset shows full time
course for release from Y2Fe
4.3 DFT Calculations
Modern computational processing power means that simulation of molecular properties
is almost routine for many classes of compound. DFT methods in particular offer a
balance between computational complexity and accuracy of results which is useful for
organic and organometallic systems of up to roughly fifty atoms. In particular, geometry
optimisation and the subsequent prediction of ground state properties is now extremely
common in guiding understanding of reactive intermediates.
The disposition of molecular orbitals is automatically available from DFT optimisations
of ground state structure. These calculations make it possible to examine the principal
locations of the frontier orbitals. The nature of the lowest unoccupied molecular orbital
(LUMO) is significant in predicting light-driven CO dissociation. Transfer of electron
density into this anti-bonding orbital will facilitate CO loss where the nodal planes
occur between the metal and carbonyl group(s). Thus DFT calculation of LUMO
data provides insight into the readiness of a system to liberate CO. In systems bearing
multiple carbonyl ligands, DFT can also suggest which groups are most likely to be
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labile.
We employed this strategy in an attempt to rationalise how the substitution of the
thiolate ligand may have altered the metal 3d orbital contribution to the bound CO
ligands. These DFT calculations were based on optimized structured using X-ray
coordinates when possible. Optimized structures showed good agreement in terms
of bond lengths and angles with the respective X-ray structures. Figure 61 shows
the highest occupied molecular orbital (HOMO) and lowest unoccupied molecular
orbital (LUMO) for complex Y1Fe. The calculated electronic transitions within the
range of absorbances experimentally observed to release CO (i.e. ≥400 nm) include
HOMO → LUMO (448 nm), HOMO-1 → LUMO-1 (419 nm) and HOMO → LUMO-1
(407 nm). We have focused on the molecular orbital (MO) electron densities of the
HOMO and LUMO orbitals in order to examine their relative contributions to facilitate
CO loss.
Through DFT we can predict the likely positions of these orbitals and evaluate whether
there is sufficient MO overlap between the metal d orbitals and the orbitals of the
carbonyl to facilitate CO loss. For Y1Fe, the HOMO and LUMO molecular orbitals
are distributed such that there is adequate overlap with both carbonyl ligands.
Figure 61: Simulated HOMO orbitals (left) and LUMO orbitals (right) of complex
Y1Fe
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The DFT calculations performed for D1Fe would be much more computationally
demanding due to simulating the high number of terminal hydroxyl groups. We decided
to model the thiolate substitute as a simple methyl thiolate.
Figure 62: Simulated HOMO orbitals (left) and LUMO orbitals (right) of complex
D1Fe
As shown in Figure 62, the molecular orbital contribution to the carbonyl ligand trans
to the pyridyl architecture is significantly less pronounced compared to that of the
parent complex. These findings correlate with the observed experimental behaviour
that only one metal bound CO (per metal centre) is liberated during photolysis.
This fundamental change in MO contribution is thought to be a direct result of replacing
the halide for thiolate. However, the dimeric nature of the thioglucose derivatives is
also likely to play a critical role in modulating molecular orbital locations. In order to
associate the decreased labicity of the CO ligand with either the introduction of the
thiolate, or the dimeric structure (or indeed both), DFT simulation of a monomeric
structure fostering a thiolate ligand was performed.
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Figure 63: Calculated energy diagram for Y1Fe (left) and D1Fe (right). Most likely
transitions are in accordance with experimental observations.
This entailed DFT calculations on a five coordinate ferracyclic structure analogous to
‘half’ the dimeric structure. As shown in Figure 64, the monomeric thiolate derivative
possesses adequate HOMO/LUMO coverage of both M CO bonds. The data therefore
suggests the dimeric nature is responsible for the lessened CO release capabilities of
D1Fe and D1Fe.
Figure 64: Simulated HOMO orbitals (left) and LUMO orbitals (right) of a five-
coordinate monomeric structure bearing a thiolate ligand
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4.4 Synthesis of Ruthenium Metallocycles Bearing
Thiolated Saccharides
To enhance the water solubility and biocompatibility of our ruthenium carbonyls,
we replicated the introduction of a thiolated saccharide ligand. Treatment of Y1Ru
with 1-thio-β-d-glucose quickly yielded D1Ru. This chemistry was extended for the
remaining ruthenium analogues in the synthesis of D2Ru, D4Ru and D5Ru (Figure 65).
Conveniently, the generation of these ruthenium derivatives could be achieved via
reaction of 1-thio-β-d-glucose with the ruthenium salt intermediate, thereby eliminating
the requirement to obtain the neutral complex following halide extraction.
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Figure 65: Ruthenium metallocycles bearing thiolated saccharides
The IR spectra of D1Ru, D2Ru, D4Ru and D5Ru exhibit a characteristic shift in
carbonyl bands upon thiolate coordination to lower wavenumber. Furthermore, D1Ru
and D2Ru, which consist of the pyridine and more conjugated isoquinoline architectures
each display a carbonyl stretch at 2060–2062 cm−1. Along with this, the spectra
exhibits another carbonyl peak at 2047–2050 cm−1 which features a shoulder absorption.
However, for D4Ru and D5Ru, in which the ligand framework bears an additional
amine group, the two carbonyl bands observed (2060–2062 cm−1 and 1993–1994 cm−1)
did not feature any shoulder absorbances.
Introduction of the monosaccharide yielded a dimeric structure analogous to the iron
structures, which was confirmed via X-ray crystallography (Figure 66). Light yellow
prism shaped crystals of D2Ru were isolated via the slow evaporation of methanol. The
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coordination geometry around the ruthenium centre is distorted octahedral, featuring
cis carbonyl ligands: one trans to the nitrogen atom of the pyridine ligand, and the
other trans to the thiolate bridge.
Table 4 shows a comparison of the iron and ruthenium structure bond lengths. The
metal − ligand bond lengths are uniformly longer in the ruthenium structure.
Table 4: Comparison of metrical data for D2Fe·2MeOH·1.5 H2O and D2Ru·
3MeOH·1.5H2O
Bond distance/Å
D2Fe·2MeOH·1.5H2O D2Ru·3MeOH·1.5H2O
M(1) S(1) 2.372(3) 2.442(2)
M(1) N(1) 2.019(5) 2.126(5)
M(1) C(10) 1.926(5) 2.022(5)
M(1) C(11) 1.786(6) 1.900(6)
M(1) C(12) 1.782(7) 1.900(6)
C(10) O(1) 1.239(6) 1.242(6)
C(11) O(2) 1.136(7) 1.131(7)
C(12) O(3) 1.135(8) 1.128(8)
The electronic absorption spectra for D1Ru, D2Ru, D4Ru and D5Ru are shown in
Figure 67. In DMSO, D1Ru exhibits a MLCT absorption band predominately of UV-
character, with a peak absorbance at 260 nm and a broad energy band at 306 nm, which
trails to 350 nm. The extended pi-system of D2Ru results in a fundamental increase
in the molar extinction coefficient. Furthermore the spectra reveals an additional
peak at 337 nm, which is characteristic of previous complexes fostering this ligand
architecture.
When comparing the absorption spectra between the corresponding iron and ruthenium
carbonyls, of significant importance is the extent to which each absorption extends. For
example, when comparing D2Fe and D2Ru, the absorption band consequence of the
isoquinoline ligand framework resides at 337 nm for both complexes. However, in the
case of the iron derivative, the absorption band trails significantly beyond the UV-region
and well into the visible. In contrast, the respective ruthenium equivalent exhibits
an absorption band which rapidly falls off at approximately 375 nm. Indeed, it is the
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Figure 66: ORTEP representation of D2Ru·3MeOH·1.5H2O showing 50 % ellipsoids;
solvent molecules and hydrogen atoms bound to carbon have been omitted
for clarity
nature of the transition metal centre, as well as the ligand architecture, which dictates
the fundamental photosensitivity of these complexes.
The photosensitivity of the system towards lower energies is enhanced considerably
upon the inclusion of an additional nitrogen donor atom onto the ligand system (D4Ru).
It is clear to see the absorption profile consequence of this modification strategy trumps
that of simply extending conjugation system, at least in terms of extinction coefficients.
However, the ligand framework which harbours both the extended conjugation system
and an additional nitrogen donor group produces the greatest bathochromic shift.
The electronic absorption spectra for D5Ru displays absorption bands at 258 and
314 nm in the UV-region, with a strong absorption band at 388 nm which trails into
the visible.
IR monitoring of D5Ru revealed the complex releases CO upon irradiation with ‘high
power’ and ‘low power’ visible light (Figure 68). This is in contrast to the corresponding
monomeric complex (Y5Ru) which proved to be inert towards visible light.
Visible light activation of D5Ru was confirmed via myoglobin assay (Figure 69). CO
92
CHAPTER 4. THIOLATED SACCHARIDES
250 300 350 400 450 500 550
0
10 000
20 000
30 000
λ/nm
/
m
−1
cm
−1
D1Ru
D2Ru
D4Ru
D5Ru
Figure 67: Electronic absorption spectra of D1Ru, D2Ru, D4Ru and D5Ru in DMSO
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Figure 68: IR carbonyl intensity at 2050 cm−1 of D5Ru following visible light irradiation
at ‘low power’ (0.216 W, left) and ‘high power’ (0.840 W, right) in DMSO
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release behaviour following ‘high power’ irradiation is similar to that observed for
D1Fe and D2Fe; all three complexes released two equivalents of CO within 20 minutes.
However, there is a stark difference in CO release capability upon irradiated using
‘low power’ visible light. Complexes D1Fe and D2Fe successfully released two CO
equivalents over the course of two hours, whereas D5Ru only released approximately
one equivalent.
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Figure 69: Plot of the amount of MbCO formed via CO liberated from D5Ru (30 µm)
(Dashed: ‘low power’ (0.216 W) irradiation, Solid: ‘high power’ (0.840 W)
irradiation)
4.5 Summary
In summary, we have demonstrated that the water solubility of the parent complexes can
be significantly enhanced following coordination of thioglucose. The resulting dimeric
iron carbonyl complexes undergoes CO liberation in response to irradiation with visible
light. In contrast to the monomeric parent complexes, which was shown to liberate
both metal bound CO ligands, the thioglucose derivatives have been observed to only
release one equivalent per metal centre.
Inspection of the molecular orbital contribution via DFT modelling offers an explanation
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for this surprising difference. In the first generation complexes, both CO groups exhibit
significant LUMO contributions which facilitate labilisation by irradiation. In contrast,
DFT calculations reveal the LUMO position in the dimeric structures is localised on
only one of the CO position. The lack of photodissociation of the second CO group is
likely due to the distinct absence of LUMO contribution at the M CO bond. Further
inspection suggests the determining factor is not the substitution of the thiolate for
halide, but a direct result of the dimeric structure.
The CO release behaviour can be modulated via the intensity (or brightness) of the
visible light irradiation. For D1Fe, the rate of CO release is vastly increased in response
to ‘high power’ irradiation, such that generation of MbCO during the myoglobin assay
plateaued after only 20 minute. The same concentration of MbCO required six times
(120 minute) the irradiation time following application of ‘low power’ visible light.
The synthetic route for incorporation of a thiolated sugar moiety has also been estab-
lished for the ruthenium metallocycles. The increased light sensitive of the dimeric
species results in D5Ru releasing CO following visible light activation. This is in
contrast to the corresponding monomeric species, Y5Ru which requires higher energy
UV-irradiation.
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In vitro Anti-Inflammatory Assays
5.1 Introduction
Quantifying CORM activity in terms of rate and equivalents of CO released is well
established. Indeed, IR spectroscopy (Section 2.1.1) can be readily employed to monitor
CO loss over time and the myoglobin assay (Section 2.1.3) can provide quantitative data
on the amount of CO liberated. However, studies detailing CORM activity in vitro are
comparatively rare. This aspect of CORM development is vitally important, as drug
behaviour in biological systems (in vitro and in vivo) could completely contradict results
observed in the chemistry lab. The most common in vitro investigation performed is
cell viability, which accesses the impact of the drug on cell survival (Section 2.3.1). Cell
viability assays have been reported for a number of CORM systems.90,92,93,104
In 2002, Green and co-workers became the first research group to administer carbonyl
complexes capable of mimicking the therapeutic actions of gaseous CO in biological
systems.7 This study evaluated the cytotoxicity and cardiac protection provided by
Mn2(CO)10 (4) and [Ru(CO)3Cl2]2 (5, Figure 8). Complex 4 displayed no detectable
cytotoxicity at concentrations in the range 0–100µmol L−1. Assessments of 5 also
displayed no cytotoxicity across a range of useful concentrations (0–400 µmol L−1), but
did exhibit toxicity issues at very high concentrations (>400µmol L−1) after prolonged
periods of time. Complexes 4 and 5 were shown to alleviate vessel contractility: in
vitro studies using aortic ring models which had been precontracted with phenylephrine
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showed rapid and significant vasodilatory effects following administration of 5. The
therapeutic action of this ruthenium carbonyl was attributed to CO, as addition of
myoglobin (which scavenges free CO) significantly reduced the overall vasodilatation
observed. Infusion of NG-nitro-l-arginine methyl ester (l-NAME) into rats hearts
caused an increase in the coronary perfusion pressure (CPP). Administration of 4
or 5 was shown to alleviate this condition. In the case of 4, light-activated CO
release resulted in a delayed onset of vasoconstriction with significantly lower levels of
CPP. Administration of this carbonyl complex without light activation produced no
vasodilatation effect.
Building upon this work, Motterlini and co-workers evaluated the biological actions of
the first water soluble CORM, CORM-3 (6, Figure 8).58 Cardiac protection by 6 was
demonstrated in models of ischemia-reperfusion injury and cardiac allograft rejection.
Complex 6 was shown to cause vasorelaxation in a concentration dependent manner
using precontracted aortic rings. Moreover, a long-lasting protective effect was observed:
higher concentrations of contracting agent were required to re-contract the aortic rings
after CORM administration.8 Later, Motterlini and co-workers introduced a series of
iron-based CORMs including 52 (Figure 70).35 Cell viability demonstrated no detectable
cytotoxicity issues at concentration range 10–100µmol, with toxicity issues becoming
pronounced at >200 µmol. Vasodilatation was monitored using isolated aortic rings
precontracted with phenylephrine, and anti-inflammatory properties were observed
following administration of the endotoxin, lipopolysaccharide (LPS).
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Br
Fe(CO)3
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Figure 70: Iron-containing CORM reported by Motterlini and co-workers35
Romão and co-workers demonstrated the in vitro and in vivo CO release properties
of a series of molybdenum carbonyl complexes, including the previously reported, fac-
[Mo(CO)3(histidinate)]Na (53, Figure 71).139 This complex was shown to release CO
when exposed to molecular oxygen. However, oxygen activation of the complex also
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led to the formation of ROS, which can result in damage to cellular structures via
oxidative stress. Despite this drawback, 53 has been successfully implicated to bring
about therapeutical actions in a variety of animal models including lowering arterial
blood pressure.140
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Figure 71: Molybdenum tricarbonyl complex reported by Meder and co-workers,139
CORM properties investigated by Romão and co-workers140
Beyond toxicity monitoring, accessing a photoCORMs ability to induce a CO-related
therapeutic action has received much less attention. Mascharak and co-workers mon-
itored the vessel dilatation effect of a series of fac-Mn(CO)3 based photoCORMs. In
this study, light induced vasorelaxation of mouse aortic muscle rings was achieved in a
concentration-dependent manner. No vasorelaxation was observed under dark conditions
or was inhibited in the presence of sGC inhibitor, ODQ.141,142 Bogdanova and co-worker
accessed the cytoprotective influence of 36 (Mn-B12CORM, Figure 31) on fibroblast
cells under hypoxia conditions.96 Following administration with 36, the culture dishes
were either irradiated with white light or kept in the dark. Photoactivation of the
photoCORM was shown to significantly reduce the number of dead cells under hypoxia
conditions compared to cultures kept in the dark. Poole and co-workers evaluated the
anti-microbial activity of the manganese-based photoCORM, 27 (Figure 24) developed
by Schatzschneider and co-workers.87,143 Their findings demonstrated growth inhibition
and a decreased in viability of an antibiotic-resistant uropathogenic strain of E.coli
following administration and illumination of 27 at 365 nm. Administration of the
CORM without light irradiation yielded no therapeutic effects. In this chapter, we
evaluate the biological activities of complexes Y1Fe, Y2Fe, D1Fe, D2Fe and Y1Ru by
analysing their anti-inflammatory properties in vitro. This is achieved by utilizing the
Enzyme Linked Sorbent Assay (ELISA, Section 2.3.3) which quantifies the production
of LPS-stimulated pro-inflammatory cytokine, TNF-α.
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5.2 Accessing Anti-Inflammatory Behaviour
The cytokine Tumour Necrosis Factor (TNF-α) is a pro-inflammatory mediator and has
been implemented in a number of inflammatory processes in several immune-mediated
inflammatory diseases.144 These includes regulatory behaviour in rheumatoid arthritis,145
Crohn’s disease,146 multiple sclerosis147 and uveitis.148 Indeed, raised TNF-α levels in
transgenic mice caused the development of arthritis pathophysiologically similar to
human rheumatoid arthritis.149 Pharmacological inhibition of this cytokine has been
shown to have beneficial effects, including preventing cardiovascular issues including
myocardial infarction.150,151
The biological activities of TNF-α are mediated by two receptors: primary receptor
TNF-R1 (p55) mediates the pro-inflammatory effects of TNF-α, and TNF-R2 (p75),
which belongs to the same family despite being functionally distinct to TNF-R1, is
involved in signalling attributed to TNF-α mediated effects such as skin necrosis and
apoptosis of activated T-cells.152,153
Strategies for reducing the activity of this pro-inflammatory cytokine usually involve
employing biological products to bind to TNF-α, thereby blocking its activity. These
biological products include monoclonal antibodies and fusion proteins.144 Blockage, or
neutralisation of TNF-α causes the suppression of inflammatory cytokines downstream
the signalling pathway, including IL-1 and IL-6.154 Moreover, inflammatory processes
are inhibited via suppression of adhesion molecules that promote leukocyte activation
and migration. O’Connell and co-workers have recently developed a series of flavonoid
metabiolites which have been shown to reduce the secretion of TNF-α.155
However, TNF-α also appears to be involved in signalling pathways which regulate or
limit the severity and duration of the inflammatory response.156 This in vivo behaviour
was shown to operate through the regulation of macrophage, interleukin IL-12. and
suggested complete blockage of TNF-α may cause adverse complications. Indeed, studies
have attributed reactivation of tuberculosis and development of ocular inflammatory
with the inhibition of TNF-α.157
When screening for the therapeutic actions of CO, it is useful to review the beneficial
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roles of HO-1, which acts as the body’s main source of endogenously produced CO. In
particular, HO-1 has been shown to protect the organism from a number of chronic
pathologies of which inflammation is a common condition. Poss and Tonegawa demon-
strated this using HO-1 deficient mice which were shown to exhibit significantly greater
amounts of inflammatory stress compared to the control group.18 Exogenous adminis-
tration of CO has been shown to mimic the protective effects of HO-1 in inhibiting the
production of pro-inflammatory cytokines.5,28–30
The potential anti-inflammatory capability of CORMs can be gauged by monitoring
the drugs influence on the production of pro-inflammatory cytokines following admin-
istration of endotoxin, lipopolysaccharide (LPS). In a study performed by Motterlini
and co-workers, macrophages were treated with LPS to cause the production of TNF-α.
Administration of CORM-3 (6, Figure 8) was shown to significantly reduce the produc-
tion TNF-α. Furthermore, administration of an inactive ‘iCORM’ control was shown to
have no effect on the production of LPS-induced TNF-α. This validates it is indeed CO
which attenuates the anti-inflammatory response.158 Surveying the literature, this type
of anti-inflammatory assay has not be used to evaluate the therapeutic behaviour of
photoCORMs. It has, however, been successfully utilized by Motterlini and co-workers
as a means of establishing the anti-inflammatory properties of 6.158
5.2.1 Protocol
To probe the anti-inflammatory properties of our complexes, we adopted a non-standard
protocol to achieve light activated CO release in vitro. THP-1 cells (0.5× 106 cells/well)
were seeded in a 24-well plate. The cell line was cultured in RPMI 1640 medium,
supplemented with 10 % foetal bovine serum, l-glutamine (2 mm), penicillin (100 U/mL)
and streptomycin (100µg mL−1). Cells cultures were maintained via incubation at 37 ◦C
in a humidified atmosphere with 5 % CO2. Cell passages used were between 5 and
20.
Production of pro-inflammatory cytokine TNF-α was stimulated via addition of LPS
(1.0µg mL−1 final concentration). Bardoxolone methyl (50µm final concentration) was
used as a positive control for an anti-inflammatory response. As further controls, THP-1
100
CHAPTER 5. IN VITRO ANTI-INFLAMMATORY ASSAYS
cells were treated with vehicle (DMSO), and each condition was analysed in the presence
or absence of LPS (referred to as ‘unstimulated’ and ‘stimulated’ samples, respectively).
Furthermore, each condition was analysed in the presence or absence of light, in order to
verify any adverse effects irradiation with visible light might have on the cells cultures.
The 24-well plate was covered in tin-foil with black dye containing wells separating
the light irradiated samples from the dark condition samples (Figure 72, left). Visible
light irradiation of specific wells was achieved by carefully cutting sections into the
tin-foil which would expose only the desired well (Figure 72, right). Irradiation of cells
operated at ‘high intensity’ for a duration of 10 min per well, set at a distance of 5.0 cm
above the cell culture.
Figure 72: THP-1 cells seeded to a 24-well plate, protected from light using tin-foil
(left), light source setup to achieve well-specific irradiation (right)
A prior experiment determined Y1Fe required 30 min incubation period (37 ◦C) to allow
sufficient cellular uptake. Cell samples were treated with the desired CORM to give a
final concentration of 50µm. After the 30 min incubation period, cells in the ‘stimulated’
conditions were administrated with LPS. Cells in the light condition were irradiated with
visible light, followed by an incubation period of 3 h (37 ◦C). Cytokine concentrations
in supernatants was quantified using the human ELISA kit. Briefly, TNF-α standards
and supernatant samples (100 µL) were added to a 96-well plate precoated with an
THP-1 anti-body and incubated for 2 h at room temperature. Plates were washed with
PBS/0.05 % Tween-20 followed by addition of an enzyme-linked secondary anti-body
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(100µL) into each well. After a further incubation period of 1 h, the plate was washed
and substrate solution (100µL) was added to each well. The plate, whilst being shielded
from light, was allowed to develop for 30 min. The reaction was stopped by addition of
H2SO4 (50µL, 1m). Absorbance measured at 450 nm and calibrated to the absorption
readings of the TNF-α standards.
5.3 Cell Viability Assays
Before accessing the therapeutic anti-inflammatory properties of our complexes, pre-
liminary cell viability studies of Y1Fe were carried out159 on HL-60 and THP-1 cell
lines using the MTS assay.121 Cells were treated with Y1Fe at varying concentrations
(1 mm → 1 µm). After an incubation period of 72 h, analysis of cell morphologies
showed cytotoxicity issues at the highest drug concentration only (1 mm), with no
detectable cytotoxicity at concentrations of 100 µm, 10µm and 1 µm. Cell viability data
is summarized in Figure 73, which includes a vehicle control (DMSO).
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Figure 73: Viability of HL-60 and THP-1 cell lines after 72 h incubation with Y1Fe, as
determined by the MTS assay. Absorbance at 490 nm is proportional to the
number of viable cells121
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5.4 Accessing Anti-Inflammatory Properties
The anti-inflammatory role of CO is well-established,5,6,15,29,46 with a number of public-
ations demonstrating CORM intervention into the inflammatory progress.158,160 Due to
the absence of such biological demonstrations with regards to photoCORMs, we decided
to probe whether our systems hindered an LPS-induced inflammatory response in vitro.
Figure 74 shows the amount of TNF-α produced for each experimental condition. The
‘unstimulated’ samples are represented in blue and the ‘stimulated’ samples in red. As
our complexes were administrated in a DMSO solution, we included a DMSO vehicle
control. A positive control for anti-inflammatory activity employed bardoxolone methyl
(abbreviated ‘bardox’) which inhibits the transcription factor (NF-kB) involved in
inflammation.161
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Figure 74: Effect of Y1Fe on LPS-stimulated TNF-α production. Unstimulated and
LPS-stimulated THP-1 cells were exposed to light and dark conditions in
the presence or absence of Y1Fe
Interestingly, production of TNF-α was inhibited most predominately following ad-
ministration of Y1Fe to cells shielded from light (Dark + Y1Fe sample). This in
vitro behaviour contradicted data obtained from IR spectroscopy and Mb assay, which
suggested visible light irradiation was necessary for CO release. Indeed, CORM admin-
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istration followed by light irradiation of the cells with visible light did elicit a small
anti-inflammatory response. However, the ability of Y1Fe to attenuate the LPS-induced
production of TNF-α was significantly greater in the non-irradiated samples.
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Figure 75: Effect of Y2Fe on LPS-stimulated TNF-α production. Unstimulated and
LPS-stimulated THP-1 cells were exposed to light and dark conditions in
the presence or absence of Y2Fe
This unexpected in vitro behaviour was mimicked in Y2Fe. Administration of Y2Fe
followed by cell irradiation resulted in a notable decrease in the production of TNF-α.
However, as shown in Figure 75, TNF-α production was significantly hindered following
addition of Y2Fe to cells kept in the dark (Dark + Y2Fe sample). The amount of
activity elicited by each CORM species can be calculated by dividing the amount of
TNF-α produced following CORM administration from the amount produced in the
corresponding control sample (identical conditions, except no CORM added). From this,
the degree of anti-inflammatory activity can be represented as a percentage. Figure 76
displays a comparative view of the activities of Y1Fe and Y2Fe in both light and dark
conditions.
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Figure 76: Comparison of the anti-inflammatory activities of Y1Fe and Y2Fe to reduce
to the production of pro-inflammatory cytokine, TNF-α
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Figure 77: Effect of D1Fe on LPS-stimulated TNF-α production. Unstimulated and
LPS-stimulated THP-1 cells were exposed to light and dark conditions in
the presence or absence of D1Fe
Having established anti-inflammatory responses produced from Y1Fe and Y2Fe, we
investigated the ability of D1Fe and D2Fe to attenuate LPS-induced TNF-α production
under the same conditions. Disappointingly, despite their significantly enhanced water
solubility, dimerisation of the iron complexes proved to be detrimental to their ability
to neutralise inflammation. As shown in Figure 77, D1Fe displayed no detectable cap-
ability to regulate the production of TNF-α. D2Fe displayed greater anti-inflammatory
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properties to that of D1Fe. However, modulation of inflammation remained poor, as
displayed in Figure 78.
Interestingly, the in vitro properties of the dimeric species appeared to be identical
under both light and dark conditions. This contrasts with the data collected for the
monomeric species, which displayed significantly greater activity in the dark. A number
of explanations can be suggested for the lack of activity demonstrated by D1Fe and
D2Fe, the most obvious cause being poor cellular uptake. Lipinski’s ‘rule of five’,
which is based on a number of experimental and computational investigations, describes
desirable drug characteristics which favour uptake into the cell.162 Firstly, to ensure
sufficient permeation of the cellular membrane, the drug molecule should not have a
molecular weight exceeding 500 g mol−1. Monomeric species Y1Fe and Y2Fe adhere to
this rule, with molecular weights of 353.9 and 404.0 g mol−1, respectively. In contrast,
dimerisation yielded molecular weights of 855.0 and 1046.9 g mol−1 for D1Fe and D2Fe,
respectively. Moreover, functionalisation with the thioglucose ligands resulted in each
CORM harbouring a total of eight hydroxyl groups. Despite imparting water solubility,
drugs containing more than five hydrogen donor groups exhibit poorer permeability of
the membrane lipid bi-layer. Further to this, drugs which exhibit a lipohilicity reading
of logP > 5, and those fostering more than ten hydrogen bond acceptor groups were
found to display impaired permeability of the membrane bi-layer.162
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Figure 78: Effect of D2Fe on LPS-stimulated TNF-α production. Unstimulated and
LPS-stimulated THP-1 cells were exposed to light and dark conditions in
the presence or absence of D2Fe
To further investigate the bioactivities displayed by Y1Fe and Y2Fe in the absence of
light, we decided to probe the anti-inflammatory properties of the ruthenium analogue,
Y1Ru. As discussed in Chapter 2, Y1Ru does not release CO when irradiated with
visible light and requires activation using UV light. As reported in Figure 79, treatment
of Y1Ru to THP-1 caused a marginal decrease to the production of LPS-induced
TNF-α. As expected, visible light stimulation had no bearing on the degree of activity
observed.
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Figure 79: Effect of Y1Ru on LPS-stimulated TNF-α production. Unstimulated and
LPS-stimulated THP-1 cells were exposed to light and dark conditions in
the presence or absence of Y1Ru
Figure 80 displays a comparative view of the activities of Y1Fe, Y2Fe, D1Fe, D2Fe and
Y1Ru in both light and dark conditions. The overall bioactivies are clear: monomeric
species Y1Fe and Y2Fe exhibit ample therapeutic benefit in the absence of light, with
less activity detected following visible light irradiation. In vitro properties of D1Fe,
D2Fe and Y1Ru display minimal inhibition of TNF-α. At this stage, it is clear more
experimental data is required to fully appreciate the underlying factors behind these
variations. However, one may consider several potential factors which could modulate
drug efficiency.
Pre-incubation of CORM species with THP-1 cell cultures to facilitate cellular uptake
was limited to 30 min. The extent of CORM population which successfully entered
the cell may be vastly different between the smaller monomeric and larger dimeric
species. Furthermore, the rate of light triggered CO release from D1Fe and D2Fe was
shown to be appreciably accelerated compared to the monomeric species. Therefore the
distinct lack of anti-inflammatory activities could in fact be a consequence of hindered
cellular uptake coupled with prematurely triggered rapid CO release to the solution
media.
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Figure 80: Comparison of the anti-inflammatory activities of Y1Fe, Y2Fe, D1Fe, D2Fe
and Y1Ru to reduce to the production of pro-inflammatory cytokine, TNF-α
Of course, this does not explain why CORMs harbouring the isoquinoline architecture
(Y2Fe and D2Fe) exhibit a greater anti-inflammatory effect than their smaller, pyridyl
containing counterparts (Y1Fe and D1Fe). However, as stated previously, increased
hydrophobicity of the drug sphere infers betters drug permeability of the cellular
membrane. It is reasonable to speculate that the increased potency of the former
complexes (Y2Fe and D2Fe) may be caused by a higher local concentration inside the
cellular environment.
Perhaps most notable is the contrasting bioactivities of Y1Fe and Y1Ru. The two
complexes display significantly different anti-inflammatory properties. Drug activation
via molecular recognition of the ligand framework seems unlikely. As shown in Table 5,
bond lengths are around 0.1Å longer for ruthenium than for iron, but there is no obvious
link between this elongation and bioactivity. On the other hand, cells utilize a variety
of transition metals for the generation of metalloproteins. Intracellular trafficking of
different metal ions allow the cells to direct usable metals to specific protein sites whilst
managing concentration levels to prevent cytotoxicity issues.163 For example, cellular
uptake of iron is promoted via interaction of the extracellular transferrin protein, with
regulation of iron concentration in the cytoplasm achieved via ferritin, which is an
intracellular protein capable of scavenging and storing free iron. Therefore one might
speculate the dark conditioned activation of our iron complexes may be facilitated via
involvement with iron-specific cellular machinery. This could offer an explanation for
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the superior activity of Y1Fe compared to Y1Ru, for which activation is limited to
interaction with proteins capable of docking ruthenium.
Table 5: Comparison of metrical data for Y1Fe·MeCN and Y1Ru·MeCN
Bond distance/Å
Y1Fe·MeCN Y1Ru·MeCN
M Br 2.4632(5) 2.5613(3)
M C(6) 1.931(2) 2.012(2)
M C(7) 1.782(3) 1.884(3)
M C(8) 1.811(3) 1.909(3)
M N(1) 1.992(2) 2.112(2)
M N(3) 2.022(2) 2.187(2)
5.5 Summary
The field of carbon monoxide releasing molecules is still in its infancy, with the first
reported CORMs reported little over a decade ago.7 Sophisticated detection methods
enable accurate quantification of the rate and equivalents of CO released. However,
for a carbonyl complex to be truly verified as a CORM, its pharmacological properties
must be probed in vitro and in vivo. Surveying the literature revealed the most
commonly employed in vitro CORM characteristic being investigated is cytotoxicity,
with a comparatively smaller number of CORMs demonstrated to elicit a therapeutic
response.
To this effect, we probed the ability of our complexes to inhibit the LPS-induced pro-
duction of the pro-inflammatory cytokine, TNF-α. Surprisingly, the anti-inflammatory
properties of the monomeric iron systems (Y1Fe and Y2Fe) was shown to be most active
in the dark. Inspection of the potency of dimeric species D1Fe and D2Fe revealed a
significant reduction in bioactivity under the same experimental conditions, which could
be a consequence of impeded cellular uptake and non-productive, light triggered CO
release outside the cellular environment. We reasoned the in vitro therapeutic activities
observed in the dark was achieved through interaction with an iron specific protein
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within the cellular environment. This theory was strengthened when administration of
Y1Ru only elicited a minimal response compared to the iron analogues.
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Chapter 6
Iron Carbonyls Bearing a Fluorescein
Linked Ligand Framework
6.1 Introduction
A fundamental requirement for the clinical development of any given CORM is the
ability to impart spatial and temporal control over drug delivery. This property is
of considerable importance due to the fact CO has a high affinity for heamoglobin,
resulting in the formation of carboxyhaemoglobin which ultimately impairs the oxygen
transport ability of the red blood cell. Moreover, larger drug doses would be required
to achieve an effective concentration at the desired tissues if the CORM in question
liberated CO unselectively to healthy and diseased tissues alike.
Many of the current strategies to elicit such spatial and temporal control focus on the
incorporation of specific biogenic ligands onto the CORM drug sphere. The idea being
that incorporation of these targeting ligands would have a high affinity for receptor
sites located predominantly on diseased tissues. Of course, such a CORM would only
be active at these specific tissues, and the therapeutic delivery of CO to a different site
would require the incorporation of a completely different targeting ligand. Alternatively,
enzyme-triggered CORMs (ET-CORMs) release CO in response to a specific enzymatic
interaction. ET-CORMs, such as the acyloxybutadiene iron tricarbonyl complexes
(Section 1.6.3) undergo enzymatic cleavage of the ester functionality, which facilitates
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the liberation of CO.65
Selective drug delivery can also be managed via conjugation of the metal carbonyl motif
with peptides or macromolecular structures including micelles and nanoparticles.134 The
first example of a CORM modified to include a peptide was reported by Schatzschneider
and co-workers.76 The Mn(CO)3-core functionalised with an attached peptide (14,
Figure 15) exhibited preferential targeting of cancer cells. This was achieved via the
specific amino acid sequence of the attached peptide, which in this case resembled part
of the sequence found in the tumour suppressor protein p53. In a later study, Schatz-
schneider and co-workers reported a UV-activated ruthenium photoCORM modified
with peptide nucleic acid (23, Figure 22).85 The attached peptide acted as a delivery
vector which enhanced cellular uptake and provided a means to facilitate site-specific
CO delivery.
An alternative strategy involves the application of a non-invasive external stimulus
to initiate CO release. The advantage of employing photoCORMs (which release CO
only in response to irradiation with light) is that delivery of CO to specific tissues
can be achieved without modifying the drug sphere with specific bio-targeting ligands.
Instead, the photoCORM remains thermally stable until intentionally activated via the
application of light to the targeted tissue.
However, photodissociation of CO generally requires energy in the near-UV (350–400 nm)
region to break the M CO bond. This is a major flaw with this strategy, as near-UV
irradiation causes skin damage and can increase the likelihood of developing skin cancer.
Furthermore, the depth of transmission through biological tissues at this wavelength
range is poor, which potentially limits the activation of the drug. Most desirable would
be a CORM which is activated by longer wavelengths of light. For mammalian tissues,
irradiation in the near-IR region (800–1100 nm) is most favourable due to the extensive
depth of tissue penetration (up to 10 cm)70 whilst being of lower enough energy to
eliminate the risk of photodamage to the skin.
The development of such photoCORMs have largely focused on shifting the absorption
maxima in a bathochromic fashion via extending the pi-system of the ligand architecture,
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or incorporating additional nitrogen donor atoms. However, two new and relatively
unexplored alternative approaches have recently emerged: the incorporation of an
organic dye onto the metal centre to act as a photosensitizer for CO release, and use of
a dye-derivatived chromophore capable of undergoing two-photon excitations to initiate
CO loss.61
The development of suitable photosensitizers presents a number of challenges. Firstly,
the chromophore must be easily synthesised and display appropriate pharmaceutical
characteristics such as biocompatibility and low toxicity. Furthermore, the light absorb-
ing component should be relatively small in size as to not hinder cellular uptake. Most
importantly, the designed compound should improve the light harvesting ability of the
CORM by absorbing longer wavelengths of light.
Of course, the strategies of drug sphere modification and use of an external trigger
can be combined, as was the case of the manganese photoCORM-conjugate developed
by Zheng and Ford.135 The hydrophobic photoCORM (54, Figure 81) was encaged
in a water-soluble nanocarrier capable of up-conversion from near-IR to visible. The
manganese photoCORM was shown to release approximately two equivalents of CO
upon irradiation with visible (470 nm) light. Examination of the absorption maxima of
the complex revealed a strong band at 400 nm, which trailed into the visible region just
beyond 500 nm. Therefore, an effective up-converter would absorb near-IR light and
exhibit re-emission bands which overlapped with the absorbance bands of the metal
carbonyl. Following incorporation of the manganese carbonyl into the nanoparticle, CO
release was achieved via irradiation with 980 nm light.
N
N
PPh3
PPh3
OC
OC
Mn
54
Figure 81: Hydrophobic manganese-based photoCORM developed by Zheng and Ford135
This ‘combination strategy’ was also explored in the development of selective cancer
treatments. Traditionally, chemotherapy involves highly toxic drugs being distributed
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to healthy and cancerous cells, with the selectivity for cancer cells being exclusively
dependent on their increased rates of proliferation compared to healthy cells. To
increase the selective toxicity of anti-cancer drugs, an attractive solution is to employ
macromolecular carriers which selectively accumulate in tumour tissues due to the
enhanced permeability and retention (EPR) effect. This strategy was utilized by
Kunz and co-workers who coordinated fac-Mn(CO)3 fragments to methacrylate or
methacrylamide polymer backbones (20, Figure 19).81 Labilisation of CO was triggered
in response to irradiation at 365 nm.
The application of photosensitizers has been successful employed in the development of
photosensitive nitric oxide (NO) releasing molecules. The Ford group have designed
a pendant chromophore attached to an iron/sulfur/nitrosyl cluster (55, Figure 82)164
which is able to sensitize NO release via a two-photon excitation process. This antenna is
able to absorb wavelengths in the near-IR region and trigger NO loss through frequency
up-conversion and the re-emission of irradiation in the visible region. More specifically,
photochemical production of NO was achieved following excitation at 800 nm, which
resulted frequency up-conversion and re-emission of irradiation between 480–700 nm.
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Figure 82: Iron/sulfur/nitrosyl cluster featuring two fluorescein moieties164
Taking inspiration from this work, we aimed to improve the light harvesting ability of
our complexes at longer wavelengths through the incorporation of a dye-derivatized
chromophore. This chapter explores two linking strategies, namely click chemistry and
generation of an thiolated fluorescein chromophore.
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6.2 Principle of Two-Photon Excitation
Absorption of electromagnetic radiation initiates the promotion of an electron from a
lower energy state to one of higher energy. The molecule rapidly relaxes back to the
lower energy state during which energy is released in the form of luminescence. The
absorption and emission of light is illustrated using the Jablonski diagram (Figure 83).
The lowest energy level is known as the ground state (S0), with higher energy (or excited)
states being referred to as S1, S2, . . . , Sn. Each electronic energy level comprises a
number of vibrational states (illustrated as 0, 1, 2, etc.), within which there are also
much smaller rotational energy states (omitted for clarity).
Upon absorption of radiation and population of a higher energy vibrational state,
the molecule rapidly relaxes to the lowest possible vibrational state via non-radiative
transitions in a process known as internal conversion. This process occurs rapidly
and is complete before emission starts. At this point, two types of luminescence
can occur: fluorescence, the relaxation of an electron from a singlet excited state,
and phosphorescence, a forbidden transition from a triplet state (T1). The electron
promoted into a singlet excited state has a spin opposite to the ground state electron.
These two electrons form a pair. Florescence does not require a change in electron
spin and is therefore a quantum mechanically ‘allowed’ transition. Contrast this to
phosphorescence, where inter-system crossing from a singlet excited state to a triplet
excited state involves a change in electron spin. The paired electrons in the ground
and triplet states have the same orientation. Therefore phosphorescence transitions are
formally ‘not allowed’ and consequently have much lower emission rates compared to
fluorescence.
In a standard single photon absorption, the energy gap between the ground and excited
state is equal to or less than the energy of the photon absorbed. Energy transfer to
the excited state occurs, followed by fluorescence as the molecule relaxes back to the
ground state. The energy of the fluorescence emission (hν ′) will be slightly lower than
the energy of the photon absorbed due to relaxation to the lowest vibrational energy
level; this is known as the Stokes’ shift. Two photon absorption (TPA) is the absorption
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Figure 83: Jablonski diagrams depicting a single-photon absorption (left) and a two
photon absorption (right)
of two photons which collectively promote an electron to an excited state. This leads
to fluorescence emission with an energy of 2hν ′. This is a type of anti-Stokes emission,
in which the fluorescence emission is significantly higher in energy compared to the
energy of each photon absorbed. Inspection of the electronic absorption spectra for
a two-photon excitation would display absorption bands at longer wavelengths and
emission bands at shorter wavelengths. The probability of absorbing two photons
simultaneous is given by the molecules cross-section (δ). This is unsurprisingly small,
but can be systematically increased through increasing the pi-conjugation system with
donor and acceptor atoms at the centre and ends of the molecule. The most obvious
advantage of TPA is the ability to access excited states using photons of only half the
required energy. This is especially beneficial for drug delivery where longer wavelengths
of light cause less photochemical damage.165
Unlike single photon absorption, which depends linearly on the intensity of the excitation
radiation, the intensity of a TPA increases with the square of the intensity of the
excitation light. Consequently, TPA usually employ intense and focused pulsed lasers
in order to generate large irradiances. There are a number of applications which utilize
TPA, including fluorescence imagining and photodynamic therapy.166
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6.3 Linking Strategies
To maximise the efficacy with which the emitted visible light (generated via near-IR
irradiation) activates the photoCORMs, the up-converter system should be covalently
bonded to the carbonyl complex to ensure close proximity and optimal re-absorption
by the active species. In critiquing the best pathway to secure the two-photon up-
converter, we trialled two anchoring strategies. One of these approaches, namely
click chemistry, involved attaching the fluorescein chromophore to the pyridyl ligand
framework. However, prior to our attempts to develop such a chromophore system, we
explored the synthesis of a simplified ‘model ligand’ in order to verify a synthetic route.
The second route involved the synthesis of a thiolated fluorescein derivative which
should mimic the coordination chemistry described in Chapter 4. Each strategy utilized
2-iodoethyl fluorescein ester (56, Figure 84) as the starting material. Like 56, simplified
ligand 57 was synthesised via a Steglich esterification using dicyclohexylcarbodiimide
(DCC) and 4-N,N -dimethylaminopyridine (DMAP).
OHO O
O
O I
O
O I
56 57
Figure 84: Starting materials fluorescein-2-iodoethyl ester (56) and benzyl-2-iodoethyl
ester (57)
6.3.1 Click Chemistry
Click chemistry was originally defined by Sharpless in 2001, who initially developed
the technique to be used in the field of drug discovery.167 The CuI-catalysed Huisgen
1,3-dipolar cycloaddition offers a quick and simple means to connect azides and terminal
alkynes.168 This is achieve through the formation of a 1,2,3-triazole five membered
ring. The procedure is highly regiospecific, exclusively forming only 1,4-substituted
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products.169,170 Moreover, high yields are typically obtained as a result of the large
thermodynamic driving force attributed to the formation of C N bonds. Reactivity
between the azide and terminal alkyne usually requires a catalyst. There are exceptions
in which a catalyst is not required: electron deficient alkynes are efficiently reactive
enough for the reaction to proceed at ambient condition.171 Otherwise, an CuI catalyst
is used to initiate the reaction. Most commonly, the CuI catalyst is generated through
the reduction of CuSO4·5H2O with sodium ascorbate. This in situ approach was
adopted due to the reactions enhanced water and oxygen tolerance. Contrast this to
addition of a copper halide catalyst in which the reaction would require the use of dried
organic solvents and an inert atmospheric gas.
We initially explored the pathway of click chemistry in an attempt to isolated model
ligand, 60 (Scheme 9). NMR spectroscopy revealed complete disappearance of the
starting material alkyne peak at 3.06 ppm. However, because the chemical environment
for each starting material remained largely unchanged throughout the reaction (excluding
loss of alkyne and formation of the triazole ring which contains a single proton), little
diagnostic information could be derived for the NMR spectra. Identification of this
ligand was confirmed through the observed molecular ion peak at 310.1299 ([M + H]+).
Reaction of Fe(CO)4Br2 with 60 in dried dichloromethane overnight resulted in the
formation of a dark yellow precipitate. Dissolution in acetonitrile yielded the expected
ferracyclic complex bearing the click-anchored model ligand. ATR IR spectroscopy
revealed new peaks at 2047, 1991, 1724 and 1621 cm−1. The desired product as confirmed
via observation of a molecular ion peak at 487.0640 ([M − Br]+).
Following the successful generation of 60 and incorporation onto the iron metal centre,
we attempted to replicate this chemistry in the production of 62 (Scheme 10). The
2-iodoethyl fluorescein ester starting material (56) was synthesised following a modified
procedure reported by Ford and co-workers.174 Reaction with sodium azide yielded the
corresponding azide (61) via nucleophilic substitution.
The proton NMR profiles for 56 and 61 (shown in Figure 85) exhibit identical splitting
patterns for the fluorophore fragment. The most notable change occurs in the signals
for the pendant alkyl arm. The gap between these two triplet signals was significantly
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CuSO4 5H2O,
Ascorbic Acid,
H2O / tBuOH (2:1)
Si(CH3)3
60
NH2N
I
HCCSi(CH3)3,
CuI, PPh3,
PdCl2(PPh3)2
57 59
58
Scheme 9: Schematic for the synthesis of the desired model ligand (60) via click chem-
istry. Molecules 58 and 59 were generated using literature methods172,173
less in 61 (3.23 and 4.10 ppm) compared to 56 (2.99 and 4.24 ppm). Subjecting this
azide (61) to click conditions in the presence of alkyne (58) did lead to the loss of the
terminal alkyne signal. However, mass spectrometry failed to identify the molecular
ion.
OHO O
O
O
OHO O
O
O N3
OHO O
O
O I
NaN3
NH2N
CuSO4 5H2O,
Ascorbic Acid,
H2O / tBuOH (2:1)
N
N
N
N
H2N
56 61 62
58
Scheme 10: Schematic for the synthesis of 62
Proton NMR spectroscopy showed loss of signal intensities corresponding to the tricyclic
fluorenyl ring (Scheme 10, shown in red) with good agreement with the rest of the
molecule (shown in blue). This may suggest cleavage of the C C bond in the fluorophore,
or may be indicative of an attack on this unit, most probably at the ketyl functionality.
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2.53.03.54.04.55.05.56.06.57.07.58.08.5
f1 (ppm)
1.361.570.661.411.311.530.892.061.00
2.982.993.004.234.244.255.306.776.776.796.796.856.866.956.977.267.327.337.697.697.757.758.288.298.308.30
2.53.03.54.04.55.05.56.06.57.07.58.08.5
f1 (ppm)
1.701.821.721.721.951.052.521.00
2.572.612.652.742.972.983.223.233.243.263.433.563.623.643.663.673.724.094.104.114.204.236.726.746.816.896.917.267.307.327.677.697.727.748.248.26
3.03.54.04.55.05.56.06.57.07.58.08.5
f1 (ppm)
1.941.221.811.821.511.461.021.621.291.711.171.001.98
2.523.183.193.344.454.464.474.594.604.615.776.156.536.556.746.757.477.497.777.777.787.797.877.878.158.158.178.35
Figure 85: Above: proton NMR spectrum of 56 in CDCl3. Middle: proton NMR spec-
trum of 61 in CDCl3. Bottom: proton NMR spectrum of 62 in D6 DMSO
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6.3.2 Thiolated Fluorescein
The second strategy employed was the generation of a fluorescein thiolate which could
coordinate directly to the metal centre through substitution of the halide. Although
this approach would prevent the addition of the water-solubilising thioglucose ligand,
the synthesis is more straightforward and easier to manufacture compare to the click
chemistry. This strategy is therefore ideal to be used as a quick means to evaluate the
effectiveness of attaching a two-photon up-converter to the photoCORM species.
The iodo-derivatized fluorescein precursor (56) was synthesised via a modified literature
method.174 The pendant alkyl halide arm was attached to the fluorescein molecule via
formation of an ester linkage at the carboxylic acid functional group. The Steglich
esterification reaction utilized DCC to which the carboxylic acid functionality of the
fluorescein was able to attack, forming an O-acyl-urea intermediate. This was followed
by attack of DMAP, which formed a reactive amide which could be attacked by the
2-iodoethanol alcohol group to form 56.
OHO
O
OH
O DCC,tBuOH,
DMAP,
2-Iodoethanol
OHO
O
O
O
I
OHO
O
O
O
S NH2I
NH2
S
H2N NH2
OHO
O
O
O
SH
Na2S2O5
56
6364
Scheme 11: Schematic for the synthesis of 64
The alkyl halide of 56 undergoes a nucleophilic substitution reaction with thiourea to
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form the alkylisothiouronium salt, 63. Generation of the desired thiol (64) product
can be achieved through hydrolysis of the intermediate alkylisothiouronium salt species.
Typically, NaOH is employed, however, the fluorophore consists of an ester functionality,
which would readily hydrolyse under such conditions. Instead, the reaction utilized
the milder reducing agent, Na2S2O5. Notably, hydrolysis required vigorous stirring and
reflux conditions over 24 h. T.L.C analysis (CH2Cl2 CH3OH (9 : 1)) showed complete
consumption of the alkylisothiouronium salt (Rf = 0.0) with the formation of two closely
positioned bands at Rf = 0.60 and 0.68. Mass spectra analysis revealed the band at Rf
= 0.68 contained a molecular ion peak corresponding to the desired product (393.0797,
[M + H]+), whilst the remaining peak (Rf = 0.60) showed evidence of the formation
of the disulphide species (783.1347, [M + H]+). The UV/Vis spectrum of fluorescein
changes depending on the pH and solvent. This is because fluorescein can exist in a
number of protic forms, each with a different absorption spectrum.164 Inspection of
the UV/Vis spectrum of fluorescein in DMSO reveal three distinct peaks in the visible
region at 435, 462 and 491 nm with significantly reduced molar extinction coefficients.
As shown in Figure 86, the chromophore absorptivity remains essentially unchanged
through reaction of 56 to 64.
300 400 500 600
0
10 000
20 000
30 000
40 000
50 000
λ/nm
/
m
−1
cm
−1
56
64
Figure 86: Electronic absorption spectra of 56 and 64 in DMSO
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6.4 Summary
In summary, we explored avenues to enhance the near-IR light harvesting ability of
our metallocyclic carbonyl complexes by coordinating a two-photon up-converter onto
the drugs sphere. Two anchoring strategies were investigated. First, we explored click
chemistry as a means of attaching a fluorescein-derivatized dye onto the pyridyl ligand
architecture. Before embarking on the generation of the ‘clicked’ fluorescein ligand,
we probed the synthetic procedure using a simplified model ligand. Generation of the
model azide and linkage to the pyridyl ligand framework was successful under click
conditions. Employing the same chemistry with the fluorescein-derivatized starting
material successfully yielded the intermediate azide species, 61. However, attachment
to the 2-aminopyridine ligand framework via formation of a 1,2,3-triazole ring proved
to be unsuccessful.
For our second approach, we devised to syntheses a thiolated fluorophore as an alternative
method to attach the fluorescein molecule. This strategy mimics the coordination
chemistry displayed in Chapter 4 and offers a readily accessible means to validate the
principle behind combining a two-photon up-converter with our systems. Reaction of
56 with thiourea yielded 63, which was subsequently hydrolysed to obtain the desired
product, 64.
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Conclusion and Future Directions
7.1 Conclusion
This research adds to the body of knowledge surrounding the development of novel
carbonyl complexes capable of acting as therapeutic agents through the delivery of CO.
Metallocyclic carbonyl complexes based on iron and ruthenium have been successfully
identified and characterised. Research focused on the visible light induced CO release
capabilities of the ferracyclic complexes, which were verified via infra-red spectroscopy
and the myoglobin assay. UV/Vis spectroscopic analysis showed absorption profiles
shifted towards the red with an increasing degree of conjugation in the ligand framework.
Not only this, incorporation of a nitrogen donor group onto the architecture further
enhanced the light sensitivity of the complex.
Reaction of these first generation carbonyls with thioglucose yielded dimeric species
with significantly enhanced water solubility. Quantification of CO release revealed a
dramatic change in CO release behaviour between the monomeric and dimeric species,
including a change in mechanism. Indeed, Y1Fe and Y2Fe exhibited steady release of
two equivalence of CO over 120 min. Complexes D1Fe and D2Fe, however, displayed
rapid loss of the first equivalent of CO, followed by much slower liberation of a second
equivalent. Notably, D1Fe and D2Fe only liberate half of the available metal bound
carbonyl ligands present. DFT calculations attribute this to insufficient HOMO–LUMO
contribution consequence of the dimeric geometry. The heightened photosensitivity of
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the dimeric species is perhaps most exemplified when comparing D5Ru to monomeric
analogue, Y5Ru, where the former displays visible light activated CO release and the
latter does not.
The ability of these complexes to act as therapeutic agents was accessed. LPS-induced
inflammation of THP-1 cells was alleviated following addition of Y1Fe and Y2Fe, with
the most observable inhibition of TNF-α exhibited in cells kept in the dark. This
surprising finding contradicted the photoCORM activities verified using the myoglobin
assay, and we speculate the anti-inflammation response is a consequence of CO loss
initiated in vitro. Complexes D1Fe and D2Fe produced minimal anti-inflammatory
influence, possibly due to poor cellular uptake. The distinct lack of bioactivity imparted
by Y1Ru suggest the intracellular CO loss is triggered via interaction with an iron
specific enzyme or cellular machinery.
7.2 Future Avenues
Further to our demonstrations of in vitro anti-inflammatory behaviour, investigations
into additional inflammatory markers should be carried out. This includes monitoring
any changes in the immune responses elicited by pro-inflammatory cytokines IL-1 and
IL-6 following CORM administration, as well as examining any up-regulatory activity
of anti-inflammatory cytokines such as IL-10. Also, future in vitro investigations should
allow extended incubation times to probe the cellular uptake capabilities of D1Fe
and D2Fe. Synthetic efforts should be made to isolate a monomeric species featuring a
bulky thio-saccharide derivative. Such a species should display sufficient water solubility
whilst being small enough to efficiently cross the cellular membrane.
Further to this, in order to verify that the achieved anti-inflammatory responses operate
via a CO signalling pathway, the following investigatory efforts should be made. First,
cell lines should be administrated with gaseous CO and a direct comparison in activity
made. Indeed, there have been many studies which establish the therapeutic benefit
of gaseous CO on inflammation. However, in the contexts of this research, this direct
comparison would authenticate the bioactivities of our complexes as CORMs, rather
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than eliciting activity independent of CO. This can be combined with investigations
into the levels of CO produced in vitro following CORM administration. This can be
achieved via the detection method reported by Tschugguel and co-workers, in which
CO present in the cell supernatant was reacted with haemoglobin. The amount of
carboxyhaemoglobin produced can be determined by spectrophotometric analysis, which
in turn provides an accurate quantification of the concentration of CO.175 This method
adopts the same detection principles used in the myogobin assay, except it allows for an
exact determination CO generated in vitro. Alternatively, administration of a suitable
‘iCORM’ would allow the therapeutic response to be attributed to CO.
There have been numerous studies implicating the involvement of various CO target
sites and signalling pathways. It would therefore be beneficial to inspect the extent of
activity in the presence of specific pathway activators or inhibitors. As summarised in
Figure 2, there is convincing evidence that CO mediates its therapeutic effects via the
soluble gyanylyl cyclase (sGC) system and involvement with MAPK proteins (not to
mention others). In order to investigate whether the anti-inflammatory effects observed
operate through either of these pathways, in vitro investigations exclusively modulating
each pathway should be carried out. For example, to ascertain any involvement of
sGC, the scope of TNF-α inhibition may be markedly increased in the presence of sGC
activator, YC-1 (1, Figure 1) or notably decreased in the presence of sGC inhibitor,
ODQ.
Further research will be required to determine the exact in vitro activation mechan-
ism which facilitated the anti-inflammatory response from the monomeric ferracyclic
complexes kept in the dark. As the corresponding ruthenium carbonyl produced signi-
ficantly lower activity, we speculate intracellular CO loss was initiated via interaction
with an iron-specific protein. Motterlini and co-workers mention the unusual case of
[Fe(bpy)(SPh)2(CO)2] which has been shown to cause vasodilation despite failing to
generate MbCO in the presence of myoglobin. This is suggestive of an intracellular
CO release mechanism initiated via complex involvement with biological machinery.26
However, one must be careful when assigning this therapeutic effect to the actions of
CO. Indeed, bipyridine (including derivatives) has also been shown to restore vascular
disorders.176,177 Unfortunately, no further details on the study of [Fe(bpy)(SPh)2(CO)2]
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as a therapeutic agent have been given.
Despite the impressive ability of Y1Fe and Y2Fe to alleviate inflammation, the selective
activation of these complexes is lost in vitro. The development of CORMs which facilitate
spatial and temporal control over CO delivery is vitally important. Modification of our
ruthenium complexes with the light-sensitizing chromophores discussed in Chapter 6
could provide an avenue to develop light directed CO release.
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Chapter 8
Experimental
8.1 General
All reactions were conducted under a dry nitrogen atmosphere using standard Schlenk
techniques. Starting materials were purchased from Aldrich or Alfa Aesar and were used
without further purification. All glassware and solvents were pre-dried and degassed
prior to use. The appropriate drying agents were used for solvent drying: CH2Cl2
(CaH2), tetrahydrofuran (Na/(C6H5)2CO) and acetonitrile (CaH2). FT-IR spectra were
recorded using a Perkin-Elmer SpectrumBX instrument. NMR spectra were recorded
on a Bruker AvanceIII 500 operating at 500 MHz, at ambient temperature (ca 21 ◦C).
Chemical shifts are given in parts per million (δ) and quoted relative to the residual
solvent peak. UV-visible spectra were recorded using an Agilent Technologies Cary 60
in disposable 1 cm plastic cuvettes. Elemental analysis was carried out at London
Metropolitan University. Mass Spectrometry was carried out at the National Mass
Spectrometry Facility at the Swansea University. The preparations of Fe(CO)4Br2,108
Ru(CO)4Br2,130,131 1-thio-β-d-glucose,138 58172 and 59173 were carried out following
literature procedures.
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8.2 Synthesis
8.2.1 Complex Y1Fe
N
Fe
HN
O CO
NCMe
Br
CO
The synthesis was carried out using a modified procedure to that reported in the
literature.108 To a solution of [Fe(CO)4Br2] (0.78 g, 2.36 mmol) in CH2Cl2 (60 mL) was
added 2-aminopyridine (0.46 g, 4.9 mmol). The solution was left to react for 2 h. Gas
was evolved and a yellow precipitate formed over time. Once precipitation was complete,
the supernatant was removed via decantation. The yellow product was recrystallized
from acetonitrile affording brown crystals (0.46 g, 51 %). M.p. 108 ◦C. Found C 36.37, H
2.67, N 14.16 %; C9H8BrFeN3O3·C2H2N requires C 36.49, H 2.81, N 14.14 %. UV/Vis
(DMSO) λmax 277 (1.65× 104) nm (m−1 cm−1). νmax (MeCN) 2051, 1997, 1987, 1668,
1621 cm−1. m/z (Orbitrap) 375.9 [M + Na]+.
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8.2.2 Complex Y2Fe
N
Fe
HN
O CO
NCMe
Br
CO
[Fe(CO)4Br2] (0.29 g, 0.77 mmol) was dissolved in CH2Cl2 (30 mL) and cooled to −40 ◦C.
1-Aminoisoquinoline (0.19 g, 1.82 mmol) in CH2Cl2 (20 mL) was added drop-wise (pro-
tected from light), and the resulting solution allowed to warm to −10 ◦C. The solution
was allowed to react at room temperature for a further hour. The solution was decan-
ted to leave a yellow precipitate. Recrystallisation from acetonitrile (25 mL) yielded
[FeBr(C10H7N2O)(CO)2(MeCN)] (0.37 g, 48 %). X-ray quality crytals were obtained
from the same solvent. Decomposes at 155 ◦C. Found C 41.40, H 2.34, N 10.16 %;
C14H10BrFeN3O3 requires C 41.62, H 2.49, N 10.40 %. UV/Vis (DMSO) λmax 283
(1.68 × 104), 349 (5.59 × 103) nm (m−1 cm−1). νmax (MeCN) 2053, 1999, 1989, 1662,
1613 cm−1.
8.2.3 Complex X3Fe
N
N
Fe
HN
O CO
Br
Br
CO
N
NH2N
H
To a solution of [Fe(CO)4Br2] (100 mg, 0.28 mmol) in CH2Cl2 (50 mL) was added 2-
aminopyrimidine (26 mg, 0.27 mmol). After 3 h, an orange/yellow precipitate forms,
which was collected via decantation of the supernatant. The yellow product was
recrystallized from acetonitrile affording brown crystals (0.17 g, 41 %). Found C 27.19,
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H 2.00, N 17.30 %; C11H9Br2FeN6O3 requires C 27.02, H 1.86, N 17.19. UV/Vis (DMSO)
λmax 297 (1.35 × 104) nm (m−1 cm−1). νmax (CH2Cl2) 2058, 2009, 1989, 1661, 1635,
1625 cm−1.
8.2.4 Complex X4Fe
N
Fe
HN
O CO
Br
Br
CO
NH2N
H
NH2
NH2
[Fe(CO)4Br2] (0.12 g, 0.31 mmol) was dissolved in CH2Cl2 (30 mL) with the exclusion
of light. Upon cooling to −40 ◦C, 2,6-diaminopyridine (74 mg, 0.67 mmol) dissolved in
CH2Cl2 (20 mL) was added drop-wise. The reaction was allowed to warm naturally to
room temperature. After 2 h a yellow precipitate formed, the supernatant was decanted
and the solid dried under vacuum (0.17 g, 55 %). UV/Vis (DMSO) λmax 341 (2.52×104),
259 (2.68× 104) nm (m−1 cm−1). νmax (ATR) 2036, 1972, 1632, 1552 cm−1.
8.2.5 Complex Y1Ru
N
Ru
HN
O CO
NCMe
Br
CO
To a solution of [Ru(CO)4Br2] (49.7 mg, 0.13 mmol) in CH2Cl2 (10 mL) was added
2-aminopyridine (27.4 mg, 0.29 mmol). Gas was evolved and a white precipitate formed
almost immediately. Once precipitation was complete, the supernatant was removed
via decantation. The white product was redissolved in acetonitrile. Addition of
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one equivalent of AgPF6 under stirring resulted in the formation of AgBr precipita-
tion. Filtration and cooling of the solution yields colourless X-ray quality crystals of
[RuBr(C6H5N2O)(CO)2(MeCN)] (35.7 mg, 49 %). M.p. 167 ◦C. Found C 30.23, H 1.99,
N 10.44 %; C10H8BrN3O3Ru requires C 30.09, H 2.02, N 10.53 %. UV/Vis (DMSO)
λmax 298 (6.74× 103), 262 (1.26× 104) nm (m−1 cm−1). νmax (THF) 2055, 1987, 1672,
1621 cm−1. m/z (Orbitrap) 319.9 [M+].
8.2.6 Complex Y2Ru
N
Ru
HN
O CO
NCMe
Br
CO
A solution of [Ru(CO)4Br2] (53.8 mg, 0.14 mmol) and 1-aminoisoquinoline (48.0 mg,
0.33 mmol, 2 eq) in CH2Cl2 (10 mL) was stirred for 30 min, after which time a pale
precipitate appeared. The supernatant was decanted and the precipitate dried under
vacuum. Addition of MeCN (12 mL) and one equivalent of AgPF6, followed by separation
via filtration and recrystallisation yielded [RuBr(C10H7N2O)(CO)2(MeCN)] as colourless
needles (37.3 mg, 58 %). Decomposes 202 ◦C. Found C 37.25, H 2.12, N 9.27 %;
C14H10BrN3O3Ru requires C 37.45, H 2.24, N 9.35 %. UV/Vis (DMSO) λmax 268
(1.87× 104), 341 (9.85× 103) nm (m−1 cm−1). νmax (THF) 2046, 1990, 1967, 1668, 1649,
1618 cm−1. m/z (Orbitrap) 369.9 [M+].
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8.2.7 Complex Y4Ru
N
Ru
HN
O CO
NCMe
Br
CO NH2
[Ru(CO)4Br2] (77.7 mg, 0.21 mmol) was dissolved in CH2Cl2 (10 mmol) to which 2,6-
diaminopyridine (51.0 mg, 0.47 mmol, 2 eq) was added. After 30 min a yellow pre-
cipitate formed. The solution was decanted and the precipitate dried under va-
cuum. The precipitate was redissolved in MeCN (10 mL) containing one equivalent
of AgPF6. Following filtration, recrystallisation yielded colourless needle-like crystals
of [RuBr(C6H7N3O)(CO)2(MeCN)] (44.0 mg, 52 %). Decomposes at 185 ◦C. Found C
28.91, H 2.28, N 13.57 %; C10H9BrN4O3Ru requires C 29.00, H 2.19, N 13.53 %. UV/Vis
(DMSO) λmax 264 (1.33 × 104), 343 (1.54 × 104) nm (m−1 cm−1). νmax (MeCN) 2065,
2002, 1656, 1644, 1617 cm−1. m/z (Orbitrap) 334.9 [M+].
8.2.8 1,3-Diaminoquinoline (49)
N
NH2
NH2
This synthesis was carried out using a literature protocol.132 A solution of o-cyanobenzyl
chloride (8.23 g, 57.9 mmol) in deoxygenated formamide (80 mL) was heated to 55 ◦C.
Upon cooling to 15 ◦C, an ice-cold solution of sodamide (6.2 g, 159 mol) in deoxygenated
formamide (100 mL) was added in portions of 10 mL with stirring under nitrogen. After
2 h a yellow precipitate was separated. Distilled water (300 mL) was added to the
reaction filtrate and allowed to stir 1.5 h. An orange solid was separated from the
filtrate, which was made turbid by another portion of water (300 mL) following 2 h
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of stirring. A dark orange solid was separated and dried. This orange solid (1.84 g,
9.83 mmol, 17 %) was dissolved in ethanol (90 mL) and heated under reflux with sodium
hydroxide (2m, 360 mL) for 1 h. Evaporation resulted in the precipitation of a yellow
powder which was washed with ice-cold water. 1,3-Diaminoquinoline (1.03 g, 11 %) was
isolated as a yellow solid. M.p. 173–175 ◦C. Found C 67.73, H 5.77, N 26.32 %; C9H9N3
requires C 67.90, H 5.70, N 26.40 %. UV/Vis (DMSO) λmax 260 (7.81 × 103), 308
(1.01× 104), 390 (4.33× 103) nm (m−1 cm−1). 1H NMR (500 MHz, DMSO) δ: 5.26 (2H,
s), 5.84 (1H, s), 6.44 (2H, s), 6.91 (1H, ddd, J = 1.4, 6.6, 8.2 Hz), 7.24 (1H, m), 7.28 (1H,
m), 7.89 (1H, d, J = 8.5 Hz). 13C NMR (126 MHz, DMSO) δ: 87.00, 111.38, 119.32,
123.87, 124.46, 129.46, 140.50, 155.01, 156.97. m/z (Orbitrap) 160.0867 [M+]
8.2.9 Complex Y5Ru
N
Ru
HN
O CO
NCMe
Br
CO NH2
A solution of [Ru(CO)4Br2] (0.09 g, 0.24 mmol) was dissolved in CH2Cl2 (20 mL) and
1,3-diaminoquinoline (86 mg, 0.54 mmol) was added. After stirring for 1.5 h a white
precipitate appear. The supernatant was removed and the precipitate dried under
vacuum. The precipitate was redissolved in MeCN (10 mL) containing one equivalent
of AgPF6. The resultant AgBr was filtered off and the remaining solvent removed
under vacuum to product a yellow crystalline solid (39 mg, 35 %). M.p. 194 ◦C. Found
C 36.04, H 2.23, N 11.94 %; C14H11BrN4O3Ru requires C 36.22, H 2.39, N 12.07
%. UV/Vis (DMSO) λmax 258 (1.60 × 104), 308 (1.48 × 104), 401 (4.58 × 103) nm
(m−1 cm−1). νmax (MeCN) 2066, 2001, 1666, 1642 and 1628 cm−1. m/z (Orbitrap)
486.8938 [M + Na]+
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8.2.10 Complex D1Fe
N
Fe
HN
O
S
OC
S Fe
N
CO
NH
O
CO
O
OH
OH
OH
OH
CO O
HO
HO
HO OH
To a solution of Y1Fe (37.2 mg, 0.11 mmol) in MeOH (10 mL) was added one equivalent
of 1-thio-β-d-glucose from a stock solution of known concentration. The reaction was
allowed to stir for 1 h. The solvent was removed under vacuum yielding a yellow solid
(48.0 mg, 51 %). M.p. 95 ◦C. Found C 38.87, H 3.68, N 6.37 %; C28H32Fe2N4O16S2
requires C 39.27, H 3.77, N 6.54 %. UV/Vis (DMSO) λmax 301 (4.12 × 104) nm
(m−1 cm−1). νmax (MeOH) 2046, 2025, 1977, 1674 and 1622 cm−1. m/z (Orbitrap) 857.0
[M+].
8.2.11 Complex D2Fe
N
Fe
HN
O
S
OC
S Fe
N
CO
NH
O
CO
O
OH
OH
OH
OH
CO O
HO
HO
HO OH
A solution of Y2Fe (5.0 mg, 0.0124 mmol) was dissolved in MeOH (10 mL) and one
equivalent of 1-thio-β-d-glucose was added from a stock solution of known concentration.
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The reaction was allowed to stir for 1 h. The product was recrystallized from methanol
affording yellow prisms (3.7 mg, 31 %). M.p. 136 ◦C. UV/Vis (DMSO) λmax 280
(3.23 × 104), 289 (3.24 × 104), 335 (1.94 × 104) nm (m−1 cm−1). νmax (MeOH) 2048,
2025, 1980, 1675, 1622 cm−1. m/z (Orbitrap) 979.0 [M+]
8.2.12 Complex D1Ru
N
Ru
HN
O
S
OC
S Ru
N
CO
NH
O
CO
O
OH
OH
OH
OH
CO O
HO
HO
HO OH
Complex Y1Ru (11.7 mg, 0.03 mmol) was dissolved in methanol (10 mL) and one equi-
valent of 1-thio-β-d-glucose was added from a stock solution. The reaction was allowed
to stir at room temperature for 1.5 h, afterwhich time the solvent was removed un-
der vacuum. The desired product was obtained as a white powder (10.9 mg, 40 %).
M.p. 194 ◦C. UV/Vis (DMSO) λmax 261 (1.38 × 104) nm (m−1 cm−1). νmax (MeOH)
2061, 1987, 1675, 1622 cm−1. m/z (Orbitrap) 948.9 [M+]
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8.2.13 Complex D2Ru
N
Ru
HN
O
S
OC
S Ru
N
CO
NH
O
CO
O
OH
OH
OH
OH
CO O
HO
HO
HO OH
A solution of Y2Ru (3.81 mg, 0.027 mmol) in methanol (5 mL) containing one equivalent
of 1-thio-β-d-glucose was stirred at room temperature for 1.5 h. Slow evaporation of the
solvent produced colourless X-ray quality crystals (2.20 mg, 26 %). Found C 40.92, H
3.33, N 5.29 %; C36H36N4O16Ru2S2 requires C 41.3, H 3.47, N 5.35 %. UV/Vis (DMSO)
λmax 259 (3.15× 104), 338 (1.10× 104) nm (m−1 cm−1). νmax (MeOH) 2059, 2042, 1981,
1658, 1630, 1595 cm−1. m/z (Orbitrap) 1048.9 [M+]
8.2.14 Complex D4Ru
N
Ru
HN
O
S
OC
S Ru
N
CO
NH
O
CO
O
OH
OH
OH
OH
CO O
HO
HO
HO OH
NH2
H2N
To a solution of [Ru(CO)4Br2] (0.11 g, 0.29 mmol) dissolved in CH2Cl2 (10 mL) was
added 2,6-diaminopyridine (60.0 mg, 0.6 mmol) drop-wise at −40 ◦C. The solution was
left to react until it reached room temperature. Once a white precipitation was complete,
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the supernatant was removed via decantation. The white precipitation was dissolved
in methanol (10 mL) and one equivalent of 1-thio-β-d-glucose was added from a stock
solution of known concentration. The solution was allowed to react for 1.5 h, afterwhich
the solvent was removed to give a white solid (50 mg, 18 %). Found C 34.18, H 3.31,
N 8.43 %; C29H34N5O16Ru2S2 requires C 34.43, H 3.51, N 8.60 %. UV/Vis (DMSO)
λmax 258 (1.63× 104), 342 (1.82× 104) nm (m−1 cm−1). νmax (MeOH) 2060, 1993, 1672,
1635, 1622 cm−1. m/z (Orbitrap) 977.9 [M+]
8.2.15 Complex D5Ru
N
Ru
HN
O
S
OC
S Ru
N
CO
NH
O
CO
O
OH
OH
OH
OH
CO O
HO
HO
HO OH
NH2
NH2
Complex Y5Ru (12.05 mg, 0.026 mmol) in methanol (10 mL) containing one equivalent
of 1-thio-β-d-glucose was stirred for 1.5 h, after which the solvent was removed under
vacuum to produce an yellow solid (17 mg, 61 %). Found C 39.14, H 3.46, N 7.56
%; C36H38N6O16Ru2S2 requires C 40.15, H 3.56, N 7.8 %. UV/Vis (DMSO) λmax 258
(3.16 × 104), 314 (2.62 × 104), 388 (6.97 × 103) nm (m−1 cm−1). νmax (MeOH) 2060,
1991, 1635 and 1622 cm−1. m/z (Orbitrap) 1077.9 [M + H]+
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8.2.16 2-Iodoethylbenzoate (57)
O
I
O
Benzoic acid (1.01 g, 8.27 mmol) was dissolved in dry THF (100 mL) under an inert
atmosphere. 1-Hydroxybenztriazole (1.11 g, 8.19 mmol) and 4-(dimethylamino)pyridine
(0.11 g, 0.88 mmol) were added. The solution was cooled in an ice bath to 0 ◦C, followed
by slow addition of 1,3-dicyclocarbodiimide (1.68 g, 8.14 mmol). After stirring for 10 min
2-iodoethanol (0.6 mL, 7.7 mmol) was added drop-wise. The reaction was stirred in an
ice bath under an inert atmosphere for 3 h, after which the ice bath was removed and
the solution allowed to stir for 16 h. The solvent was removed at reduced pressure. The
resulting residue was purified (1.74 g, 76 %) via column chromatography silica gel using
EtOAc Hex (1 : 9) as the elutent mixture. The desired product gave a band at Rf
= 0.78. 1H NMR (500 MHz, CDCl3) δ: 3.43 (2H, t, J = 6.8 Hz, CH2I), 4.57 (2H, t,
J = 6.8 Hz, OCH2), 7.45 (2H, m, m-H), 7.58 (1H, tt, J = 7.4, 1.3 Hz, p-H), 8.08 (2H,
dd, 1H, tt, J = 8.5, 1.26 Hz, o-H).
8.2.17 2-[4-(6-Aminopyridin-3-yl)-1H -1,2,3-triazol-1-yl]ethyl
benzoate (60)
N
NN
O
O
N
NH2
A mixture of 2-amino-5-ethynylpyridine (0.26 g, 2.20 mmol) and 2-azidoethyl benzoate
(0.43 g, 2.25 mmol) was dissolved in tert-butanol (5 mL) and H2O (2.5 mL). CuSO4·
5H2O (5.5 mg, 0.02 mmol, 1 mol %) and l-ascorbic acid (2.0 mg, 0.11 mmol, 5 mol %)
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were added. The reaction was stirred overnight under N2. T.L.C. (hexane EtOAc
(4 : 1)) confirmed product formation (Rf = 0.15). The mixture was extracted with
CH2Cl2 (3 × 10 mL), the combined organic phases washed with H2O (3 × 10 mL) and
dried over MgSO4. The desired product was isolated as a residue after evaporation of
the solvent in vacuo (0.13 g, 20 %). νmax (CH2Cl2) 1016, 1026, 1072, 1098, 1113, 1266,
1721, 2105, 2338, 2361, 2856, 2928, 2963 and 3403 cm−1. 1H NMR (500 MHz, CDCl3)
δ: 3.54 (2H, t, J = 5.0 Hz, CH2), 4.43 (2H, t, J = 5.0 Hz, CH2), 6.52 (1H, br s, NH2),
7.32–7.37 (2H, m), 7.45–7.49 (2H, m), 7.70 (1H, s), 7.81 (1H, d, J = 8.44 Hz), 7.88 (1H,
d, J = 7.74 Hz), 7.96 (2H, d, J = 7.78 Hz) m/z (Orbitrap) 310.1 [M + H]+.
8.2.18 2-Iodoethyl fluorescein (56)
OHO O
O
O I
The synthesis was carried out using a modified procedure to that reported in the
literature.174 Fluorescein (0.676 g, 2.0 mmol) was dissolved in dry THF (50 mL) under an
inert atmosphere. 1-Hydroxybenztriazole (0.289 g, 2.0 mmol) and 4-(dimethylamino)pyridine
(31 mg, 0.22 mmol) were added. The solution was cooled in an ice bath to 0 ◦C, followed
by slow addition of 1,3-dicyclocarbodiimide (0.383 g, 2.0 mmol). After stirring for 10 min
2-iodoethanol (0.2 mL, 2 mmol) was added drop-wise. The reaction was stirred in an
ice bath under an inert atmosphere for 3 h, after which the ice bath was removed and
the solution allowed to stir overnight. The solvent was removed at reduced pressure
and the resulting solid taken up in ice-cold chloroform and filtered. After removal of
the solvent in vacuo, the product was purified via column chromatography silica gel
using CH2Cl2 CH3OH (9 : 1) as the elutent mixture. The desired product gave an
orange band (Rf = 0.4). The desired product was collected as a red crystalline solid
(0.279 g, 28 %). M.p. 167 ◦C. Found C 54.41, H 3.12 %; C22H15IO5 requires C 54.34, H
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3.11 %. UV/Vis (DMSO) λmax 231 (4.53× 104), 460 (2.21× 104), 489 (2.16× 104) nm
(m−1 cm−1). 1H NMR (500 MHz, CD3OD) δ: 3.13 (2H, t, J = 6.1 Hz, CH2), 4.28 (2H,
t, J = 6.1 Hz, CH2), 6.72 (2H, dd, J = 9.3, 2.2 Hz), 6.78–6.75 (2H, m), 7.05 (2H, d,
J = 9.3 Hz), 7.45 (1H, dd, J = 7.6, 1.3 Hz), 7.81 (1H, td, J = 7.7, 1.3 Hz), 7.88 (1H, td,
J = 7.5, 1.4 Hz), 8.36 (1H, dd, J = 7.9, 1.4 Hz). 13C NMR (126 MHz, MeOD) δ: −1.44,
65.70, 102.96, 115.16, 129.87, 130.49, 130.64, 131.04, 132.85, 134.05, 155.14, 157.81,
164.76. m/z (Orbitrap) 487.003 [M+].
8.2.19 2-Azidoethyl fluorescein (61)
OHO O
O
O N3
To a solution of 56 (0.27 g, 0.56 mmol) dissolved in DMSO (3.5 mL) was added one
equivalent of NaN3 (43 mg, 0.66 mmol) dissolved in DMSO (0.5m, 1.5 mL). The mixture
was allowed to stir for 16 h. The reaction was quenched by addition of distilled water
(5 mL). The aqueous phase was separated and washed with CH2Cl2 (2 ×5 mL). The
combined organic phases were washed with brine and dried over MgSO4. The desired
product was isolated following filtration and solvent removal in vacuo to give an orange
residue (0.23 g, 100 %). 1H NMR (500 MHz, CD3OD) δ: 3.24 (2H, t, J = 5.0 Hz, CH2),
4.11 (2H, t, J = 5.0 Hz, CH2), 6.74 (2H, dd, J = 9.2, 2.1 Hz), 6.82 (2H, s), 6.91 (2H, d,
J = 9.1 Hz), 7.35–7.30 (1H, m), 7.68 (1H, td, J = 7.7, 1.3 Hz), 7.75 (1H, td, J = 7.5,
1.4 Hz), 8.26 (1H, dd, J = 7.9, 1.3 Hz). 13C NMR (126 MHz, CDCl3) δ: 0.95, 40.87,
49.31, 63.52, 103.79, 114.98, 121.98, 129.65, 129.77, 130.11, 130.46, 131.24, 132.86,
134.56, 153.61, 157.41, 164.81.
142
CHAPTER 8. EXPERIMENTAL
8.2.20 2-Thiouroniumethyl fluorescein iodide (63)
OHO O
O
O S
NH2
NH2I
Compound 56 (0.129 g, 0.27 mmol) and thiourea (29.65 mg, 0.39 mmol, 1.5 Eq) were dis-
solved in methanol (5 mL) and heated under reflux. After 24 h, T.L.C. (CH2Cl2 MeOH
(9 : 1)) showed a majority product at Rf = 0.0, with some starting material remaining
(Rf = 0.4). The solvent was removed at reduced pressure. The product was isolated by
washing with Et2O, which dissolved the starting material but not the product, which
was isolated as a red solid (0.103 g, 70 %). M.p. 198–200 ◦C. Found C 48.72, H 3.41,
N 5.07 %; C22H15IO5 requires C 49.12, H 3.41, N 4.98 %. UV/Vis (DMSO) λmax 235
(1.23× 104), 506 (1.70× 104) nm (m−1 cm−1). 1H NMR (500 MHz, CD3OD) δ: 3.11 (2H,
dd, J = 6.2, 5.1 Hz, CH2), 4.24 (2H, dd, J = 6.2, 5.1 Hz, CH2), 6.53 (1H, d, J = 2.2 Hz),
6.55 (3H, d, J = 0.9 Hz), 6.87 (2H, dt, J = 9.7, 1.2 Hz), 7.44–7.38 (1H, m), 7.75 (1H, td,
J = 7.7, 1.3 Hz), 7.83 (1H, td, J = 7.5, 1.4 Hz), 8.28–8.22 (1H, m). 13C NMR (126 MHz,
CD3OD) δ: 30.83, 63.48, 104.68, 113.60, 124.17, 130.94, 131.49, 131.91, 132.14, 134.16,
159.86, 181.44. m/z (Orbitrap) 435.1007 [M+].
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8.2.21 2-Thioethyl Fluorescein (64)
OHO O
O
O SH
Compound 63 (24 mg, 0.04 mmol) was dissolved in CH2Cl2 (2 mL). Sodium metabisulfite
(9 mg, 0.05 mmol) was dissolved in distilled water (1 mL). The solutions were combined
and refluxed (110 ◦C) under nitrogen with vigorous stirring for 16 h. Reaction completion
was indicated by T.L.C. (CH2Cl2–MeOH 9:1), with complete disappearance of the
starting material (Rf = 0.0) and formation of new peaks at Rf = 0.6 and 0.68. After
removing from heat, the solution phases were separated. The aqueous layer was washed
with CH2Cl2 (2 ×5 mL) and dried over MgSO4. The solvent was removed via rotary
evaporation, and the product purified via column chromatography silica gel using
CH2Cl2–MeOH (9 : 1) as the elutent mixture. The desired product gave an orange band
(Rf = 0.68). The solvent was removed via rotary evaporation, the resulting product was
collected as a red powder (32 mg, 76 %). M.p. 178–179 ◦C. Found C 64.18, H 3.59 %;
C22H16O5S·H2O requires C 64.38 , H 4.42 %. UV/Vis (DMSO) λmax 232 (3.33× 104),
459 (2.10× 104), 488 (1.90× 104) nm (m−1 cm−1). 1H NMR (500 MHz, MeOD) δ 2.43
(2H, t, J = 6.4 Hz, CH2), 4.09 (2H, t, J = 6.4 Hz, CH2), 6.71 (2H, dd, J = 9.2, 2.2 Hz),
6.77–6.75 (2H, m), 7.04 (2H, d, J = 9.3 Hz), 7.45 (1H, dd, J = 7.5, 1.3 Hz), 7.80 (1H,
td, J = 7.7, 1.4 Hz), 7.87 (1H, td, J = 7.5, 1.4 Hz), 8.33 (1H, dd, J = 7.9, 1.3 Hz).
[CARBON]. m/z (Orbitrap) 392.07 [M+].
8.3 X-Ray Crystallography
For each sample, crystals were suspended in oil and one was mounted on a glass
fibre and fixed in the cold nitrogen stream of the diffractometer. Data were col-
lected using Mo-Kα (λ = 0.710 73Å) radiation using either and Oxford Diffraction
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Xcalibur-3 CCD diffractometer equipped with a graphite monochromator (Y1Ru·
MeCN, Y5Ru·MeCN, D2Fe·2MeOH·1.5H2O) or a Rigaku FR-E++ equipped with
molybdenum rotating anode equipped with confocal mirrors (Y2Ru·MeCN, Y4Ru,
Y2Fe·MeCN, D2Ru·3MeOH·1.5H2O). Data were processed using CrysAlisPro178
(Y1Ru·MeCN, Y5Ru·MeCN, D2Fe·2MeOH·1.5H2O)178 or CrystalClear-SM Ex-
pert (Y2Ru·MeCN, Y4Ru, Y2Fe·MeCN, D2Ru·3MeOH·1.5H2O).179 Structures
were determined dual space methods in SHELXT-2014180 and refined by full-matrix
least-squares methods on F 2 in SHELXL-2014.181 Non-hydrogen atoms were refined
with anisotropic thermal parameters. Hydrogen atoms bound to carbon were included
in idealized positions and their Uiso values were set to ride on the Ueq values of the
parent atom. In Y1Ru·MeCN, Y4Ru, Y5Ru·MeCN and Y2Fe·MeCN hydrogen
atoms bound to nitrogen were located in the Fourier difference map and were re-
fined with the caramoyl N H distance restrained to 0.84(2)Å and, where present,
the amine N H distances restrained to 0.88(2)Å. In Y2Fe·MeCN one C O dis-
tance was restrained to 1.150(2)Å. In Y2Ru·MeCN, D2Fe·2MeOH·1.5H2O and
D2Ru·3MeOH·1.5H2O the hydrogen atoms bound to nitrogen and oxygen could
not be located reliably in this way and were therefore included using a riding model.
Complex Y4Ru was refined as a two component twin with final occupancy of the major
part of 0.952(7).
Data for D2Fe·2MeOH·1.5H2O were refined as a two-component inversion twin.
For the two water atoms no hydrogen atoms were included in the model. A disordered
solvent region in D2Fe·2MeOH·1.5H2O containing approximately one molecule of
MeOH could not be modelled successfully and was handled using SQUEEZE.182
One methanol molecule in D2Ru·3MeOH·1.5H2O was disordered over two positions
with the carbon atom in a common position. The thermal parameters of the two oxygen
atoms were constrained to the same value, whilst the carbon atom was constrained
to the same position and thermal parameters in both molecules. At the end of the
refinement the occupancy of the major position was 0.522(17).
Data collection parameters are summarised in Tables 6 and 7.
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8.4 Myoglobin Assay
Stock solutions of horse heart myoglobin (approx. 130 mg in 4 mL) and sodium thionite
(roughly 200 fold excess) were prepared in phosphate buffered saline (PBS, 0.01m,
pH = 7.4). For the reference spectrum of deoxy-myoglobin, a disposable cuvette was
filled with myoglobin solution (500 µL), sodium thionite (100 µL) and PBS (400 µL).
For the reference spectrum of carboxy-myoglobin, gaseous CO was passed through
to saturate the solution before a UV/Vis spectrum was obtained. For the putative
CORMS, the metal complex was dissolved in DMSO to a known concentration before
transfer a cuvette (10µL). To this cuvette were added stock solutions of myoglobin
(500 µL), and sodium thionite (100µL), along with PBS (390 µL). A UV/Vis spectrum
was run, followed by irradiation of visible light. The cuvette was removed from the
light source before running the UV/Vis spectrum. This procedure was repeated as
appropriate.
8.5 Quantum Yield Measurements
All quantum yields were carried out using a liquid phase potassium ferrioxalate ac-
tinometer. The actinometer was prepared in complete darkness by mixing FeCl3
(24.4 g, 150 mmol) in water (100 mL) with K2C2O4 (76.0 g, 457 mmol) in water (300 mL)
together and allowing to stir for 1.5 h, after which a green precipitate forms. The
supernatant was removed and the precipitate recrystallised from hot water three times.
The actinometer stock solution was prepared by dissolving the K3[Fe(C2O4)3] precipitate
(8.94 g, 18.2 mmol) in distilled water (800 mL) followed by addition of sulfuric acid
(1.0m, 100 mL) and making up to 1 L with distilled water. The irradiation was done
in a darkroom using a red photographic safelight. The light intensity in a photochem-
ical reaction is determined by irradiating the ferrioxalate solution and monitoring the
subsequent changed in absorbance at 510 nm. For each actinometeric measurement a
cuvette was charged with 1 mL (V1) of ferrioxalate solution. The cuvette was placed at
a specified distance away from the light source and irradiated for a set period of time.
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After the allocated irradiation time (t), the solution was well mixed and an aliquot
volume (0.5 mL, V2) was added to a volumetric flask (10 mL, V3) A buffer solution (half
of V2, 0.25 mL) and phenanthroline solution (0.3 % by weight, 2 mL) was added. The
solution was made up to the mark with distilled water (7.25 mL). The solution was
mixed and allowed to develop for 1 h. The absorbance was measured at 510 nm using
distilled water as a reference.
8.6 Anti-Inflammatory Assays
8.6.1 TNF Assay
The human monocytic cell line, THP-1, was obtained from the European Collection of
Cell Cultures (Health Protected Agency, Salisbury, UK). The THP-1 cells were cultured
in RPMI 1640 medium, supplemented with 10 % foetal bovine serum, l-glutamine
(2 mm), penicillin (100 U/mL) and streptomycin (100 µg mL−1). Cells cultures were
maintained via incubation at 37 ◦C in a humidified atmosphere with 5 % CO2. Cells
used were between passages 5 and 20.
THP-1 cells (0.5 × 106 cells/well, 0.5 mL) were seeded in a 24-well plate as shown
above. Water containing organic food dye (1 mL) was added to wells (A3, A4, B3,
C3, D3, D4) to capture any scattered light from penetrating the dark conditioned
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wells. DMSO (1.0 µL) was added to vehicle control wells D5 and D6. Bardoxolone
methyl (50µm final concentration) was added to positive anti-inflammatory control
wells B4 and C4. CORM was dissolved in DMSO to give a 50 mm stock solution.
Administration of CORM (1.0µL) resulted in a final CORM concentration of 50 µm in
the cellular solution. After CORM administration to wells C1 and C5, the 24-well plate
was incubated at 37 ◦C for 10 min. CORM addition to wells C2 and C6 was followed by
further incubation (37 ◦C) for 20 min. A total of 30 min was allowed for CORM cellular
uptake before stimulation with LPS (1.0 µg mL−1 final concentration). 30 min after
CORM addition to well C1, LPS was added to well C4 followed by ‘high power’ visible
light irradiation of well C1 for 10 min (distance between well and light source = 5 cm).
Administration of LPS to wells C2, A6, B6, C6 and D6 was followed by successive
irradiations (10 min) of wells C2 (30 min after CORM addition) and B1. LPS was added
to well B2 prior to irradiation (10 min). The 24-well plate was incubated for 3 h. The
samples were centrifuged (2000 rpm, 5 min) and sample supernatants were collected.
Cytokine concentration quantified via ELISA kit. Each TNF assay was completed three
times.
8.6.2 TNF ELISA
‘Coating buffer’ consisting of NaHCO3 (0.72 g, 8.6 mmol) and Na2CO3 (0.16 g, 1.5 mmol)
dissolved in millipore water (100 mL) was made to pH 9.5 with small additions of
NaOH (5m). A 1/250 dilution of capture antibody was made up with the coating
buffer, of which 100µL was added to each well of a 96-well Nunc-Immuno polystyrene
Maxisorp ELISA flat bottom plate. The plate was sealed and incubated overnight at
4 ◦C. Phosphate-buffered saline (PBS) wash was made up by dissolving NaCl (8.0 g,
146 mmol), Na2HPO4 (0.11 g, 0.80 mmol), KCl (0.20 g, 2.68 mmol) and KH2PO4 (0.2 g,
1.47 mmol) in millipore water (1 L) and made up to pH 7.0 using NaOH (5m). The
coating buffer was removed from the wells using a multi-channel pipette and the plate
was washed three times using the PBS wash with Tween-20 (450µL) added. After
each wash, the plate was inverted and blotted onto absorbent paper to remove residual
buffer. Into each well was added assay dilutant (200 µL), which consisted of a PBS
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and foetal bovine serum (FBS) (9 : 1). The plate was sealed and left at RT for 1 h.
The TNF assay samples were prepared, with the samples containing LPS diluted 1/3.
Standards are also prepared via serial dilutions: concentrations of human TNF at 500,
250, 125, 62.5, 31.2, 15.6 and 7.8 pg mL−1. Assay diluent served as the zero standard.
The assay diluent was removed from each well, and the plate was washed three times
using the PBS-Tween-20 wash. After each wash, the plate was inverted and blotted
onto absorbent paper to remove residual buffer. A standard or TNF assay sample
(100µL) was pipetted into selected wells. The plate was sealed and left at RT for 2 h.
The standard/TNF assay samples were removed via pipette, and the plate was washed
five times using the PBS-Tween-20 wash. After each wash, the plate was inverted and
blotted onto absorbent paper to remove residual buffer. Working detector (100µL)
solution (1/250 dilution of detection antibody + 1/250 dilution of SAv-HRP reagent)
was added to each well. The plate was sealed and incubated at RT for 1 h. The plate
was aspirated and washed using the PBS-Tween-20 mixture seven times, with each wash
allowing the wells to soak for 45 s. After each wash, the plate was inverted and blotted
onto absorbent paper to remove residual buffer. The substrate solution was made up by
mixing reagent A and reagent B (1:1) into a light-protected vial. Protected from light,
the substrate solution (100µL) was added to each well. The plate was sealed, covered
in tin foil and left at RT for 30 min. Addition of a stop solution (H2SO4, 1m, 50µL)
to each well caused a colour change from blue to yellow (colouration dependent on
concentration of human TNF). Absorbance measurement at 450 nm were recorded, with
subtraction of the absorbance at 570 nm which acted as a wavelength correction.
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8.7 Density Functional Theory Calculations
All calculations were performed using the Gaussian 09183 computational package. Geo-
metry optimisation and frequency calculations have been carried out using the Tao–
Perdew–Staroverov–Scuseria184 functional. Bromine, iron and sulfur atoms were de-
scribed by the Hay and Wadt LANL2DZ185,186 basis set with effective core potential.
All other atoms employ the all-electron 6-31++G** basis set. Structures were geometry
optimised in the gas phase with the default convergence criteria and confirmed as
minima through frequency calculations.
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